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ACTIONABLE BIOLOGY AND PROGNOSTIC BIOMARKERS IN BREAST CANCER 











Women of African descent are disproportionately affected by breast cancer relative to European 
women. Africans and African-Americans are more likely to acquire aggressive breast cancer 
phenotypes such as triple negative breast cancer (TNBC), which lacks expression of 
pharmacologically-targetable targets such as estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 (HER2). Given breast cancer patients of African 
descent are predominantly triple negative, they are often refractory to hormone and HER2-
targeted systemic therapies in the clinic, underlying their more aggressive disease course and 
poorer prognosis relative to women of other ethnic backgrounds. My work seeks to identify 
actionable biomarkers in patients of African descent, who are predominantly triple-negative and 
thus lack targeted treatment options and robust risk-predictive biomarkers. Herein, I present a 
three-pronged approach to examine inherent differences in tumor biology among racially-distinct 
 
 
breast tumors. I have examined surrogates of intratumor heterogeneity (mitotic propensity and 
centrosome amplification), the tumor immune microenvironment (tumor-infiltrating 
lymphocytes), and drivers of cell proliferation (human epidermal growth factor receptor family) 
among racially-distinct breast cancer patients and their potential as risk-prognostic biomarkers 
and alternative therapeutic targets. These facets of aggressive tumor biology have been linked to 
the acquisition of aggressive cellular phenotypes and drug resistance/relapse in breast cancer 
suggesting racial disparities in these biomarkers could perhaps be underlying the divergence in 
mortality rates. Furthermore, these key aspects of aggressive tumor biology (drivers of 
intratumor heterogeneity, tumor-infiltrating lymphocytes, and drivers of cell proliferation) can be 
evaluated in clinical samples using techniques such as immunohistochemistry and H&E staining 
as well as therapeutically targeted through rationally-designed agents such as putative 
centrosome declustering agents, immunotherapeutic intervention, monoclonal antibodies, and 
receptor agonists. Hence, my work suggests clinically-facile risk-prognostic and actionable 
biomarkers for patients of African descent, which may aid in reducing the global racial disparity 
in breast cancer. Furthermore, this work has broader clinical implications by extending 
prognostic biomarkers and actionable targets for aggressive breast cancer patients, irrespective of 
ethnicity, as well as paves the path for alternative avenues of addressing the global racially 
disparate burden in breast cancer such as metabolic, epigenetic, and proteomic approaches. 
Moreover, our work may further encourage the implementation of personalized treatment in the 
clinic based on each patient’s distinct tumor molecular profile.    
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1 INTRODUCTION  
1.1 The racially disparate burden in breast cancer  
At least 1 in 8 women in the United States (US) will acquire breast cancer (BC) in their 
lifetime(1). BC reigns as the number one form of invasive cancer diagnosed among women in 
the United States (US) and ranks second place, behind lung cancer, among the leading causes of 
death from cancer among women today(1). Women of African descent are disproportionately 
afflicted and affected by BC compared to women of European descent in the US. African-
American (2) women exhibit significantly higher BC incidence rates than European-American 
(3) women before the age of 40(4). However, among all ages, AA women are more likely to die 
from BC than EA, Hispanic, and Native American women with death rates as much as 60% 
higher in some states such as Louisiana and Mississippi(4, 5). Furthermore, AA women tend to 
be diagnosed and die from BC at a much younger age compared to their EA counterparts(4). 
Moreover, BC patients of African ancestry experience a more aggressive clinical disease course 
as AAs exhibit lower proportions of localized BC and higher proportions of regional and distant-
stage BC than EAs and other ethnic groups(4). Hence, AAs are more likely to be diagnosed with 
advanced staged BC than EAs among BC patients(6, 7).  The prevalence of more aggressive BC 
subtypes is higher among AA compared to EA patients. Estrogen receptor-negative, 
progesterone receptor (PR)-negative, and triple negative BC (TNBC) have been reported to be 
more prevalent among AA compared to EA patients(8). TNBC, defined by a lack of ER, PR, and 
human epidermal growth factor receptor 2 (HER2), was recently reported to be twice as high 
among AA (24 per 100,000) compared to EA (12 per 100,000) women leaving AA patients with 
a lack of pharmacologically-targetable treatment options(4). Racial disparity in clinical outcomes 
persists within BC subtypes. Chen and colleagues observed that AA women exhibit a 40-70% 
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higher risk of developing stage IV disease than EA women across all BC subtypes(9).  Among 
luminal-A like and luminal-B like BC patients, AAs were found to exhibit a 76% and 56% 
higher mortality rates than EAs, respectively(9). Black women were reported to exhibit 
significantly worse overall survival (OS) and progression-free survival (PFS) than white women 
among ER-positive BC patients(10). Although controversial, some studies have reported a more 
aggressive disease course and a poorer prognosis in AAs compared to EAs among TNBC 
patients(11-13).  
Distinctions in inherent tumor biology have been suspected to underlie the racial 
disparate burden in BC. Thus, cancer health disparity research has largely focused on identifying 
pharmacologically-targetable biomarkers differentially-expressed among racially-distinct BC 
patients or strongly associated with African ancestry that can enhance risk-prognostication and 
reduce the disproportionately higher mortality rates observed among patients of African descent. 
However, many of the targeted therapeutics rationally designed for these biomarkers may 
perform well in preclinical studies but often perform dismally once they reach advanced clinical 
trials or elicit a significant response in only a small percentage of BC patients(14). One of the 
primary factors underlying this poor performance is the high interpatient and intratumoral 
heterogeneity rampant among the BC landscape, which interferes with the efficacy of these 
targeted agents(14-17). These novel agents are also often accompanied by toxic, harmful side 
effects that exacerbate the patient’s previously compromised health(18-20). Moreover, validating 
detection methods with high specificity and sensitivity, identifying appropriate cut-offs, lack of 
robust drug response biomarkers, limited understanding of drug mechanism of action, lack of 
pharmokinetic/pharmocodynamic studies, high costs of drug development, interobserver 
discordance, and variability in tissue fixation, sample procuring methods, antibodies, 
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immunohistochemical (IHC) staining methods, and resources all present significant challenges in 
successfully integrating targeted therapeutics into the clinic(14, 19-28). Furthermore, the time 
consuming, costly, and inefficient preclinical and clinical trial process presents further 
challenges in clinical implementation. Thus, AA BC patients are left with limited effective 
treatment options.  
1.2 Triple negative breast cancer   
The clinical management of TNBC continues to confound clinicians. Accounting for a 
small subset (10-20%) of all BC cases, TNBC patients experience notably lower survival rates 
than non-TNBC patients(11, 29, 30). The defining feature of this subtype is its lack of ER, PR, 
and HER2 overexpression(31); therefore, the only treatment options for TNBC are conventional 
chemotherapy, surgery and radiation therapy. TNBC is notorious for its extensive interpatient 
heterogeneity and intratumoral heterogeneity (32) that collude to produce poor clinical 
outcomes(33). In fact, TNBC is renowned for its aggressive clinical disease course and its higher 
prevalence among women of younger age and African descent(29, 34-36). Higher visceral and 
cerebral metastasis and local relapse rates typify their clinical course(37, 38). Furthermore, 
TNBC tumors display more unfavorable clinico-pathological features upon presentation such as 
larger tumor size, higher nuclear grade, higher stage, higher mitotic index, higher Ki67 
proliferation index, and lymph node involvement compared to other breast cancer subtypes(34, 
39, 40). These tumors also possess a higher likelihood of exhibiting distant recurrence within the 
first five years of diagnosis(34). These statistics have highlighted the need for finding new 
treatment modalities to improve TNBC outcomes. However, these efforts have been met with a 
stalemate in the clinic owing to the heterogeneous nature of the disease. Neoadjuvant 
chemotherapy is the first-line treatment choice for TNBCs due to their relatively higher 
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chemosensitivity and pathological complete response (pCR) rates compared to non-TNBC 
patients(35). Despite reportedly higher pCR rates, TNBC patients tend to experience 
significantly reduced progression-free survival (PFS) and lower overall survival (OS) within 3 
years post-treatment compared to non-TNBC patients(41). This contradiction, often termed by 
clinicians and researchers as “the triple-negative paradox”, may in part be explained by the small 
percentage of TNBC patients that actually fall into the pCR group(34, 41). Only 30% of TNBC 
patients that undergo anthracycline and taxane-based cytotoxic chemotherapy prior to surgery 
achieve pCR and experience improved DFS rates(42). In addition, among patients with residual 
disease, TNBC patients experience higher relapse and death rates than non-TNBC patients 
within the first three years of follow-up(43-45). This outcome may partially be reflected by the 
high administration of adjuvant endocrine therapy for patients with luminal tumors. Thus, there 
is an urgent need for alternative targeted treatment options for this subset of BC patients. Despite 
a surge of preclinical and clinical studies investigating promising therapeutic targets for TNBC 
patients over the past decades, as of date, none have been approved.   
1.2.1 Heterogeneous landscape of triple negative breast cancer 
Perhaps the most groundbreaking attempt to subcatergorize TNBCs according to 
common molecular features was undertaken by Lehmann and colleagues(46). Lehmann and his 
colleagues analyzed gene expression profiles of human TNBC tumor samples and conducted 
consensus clustering on the most differentially expressed genes to segment the subtype into 
seven unique clusters sharing common gene expression profiles. Six stable clusters and one 
unstable cluster was classified by Lehmann et. al as seven distinct TNBC subtypes characterized 
by shared gene ontologies and unique enriched canonical pathways. These seven molecular 
TNBC subtypes were labeled basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory, 
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mesenchymal (M), mesenchymal stem-like (MSL), luminal androgen receptor (LAR), and 
unstable (UNS). The basal-like 1 (BL1) and basal-like 2 (BL2) subtypes stratify the intrinsic 
basal-like BC molecular subtype. These subgroups of basal-like BCs were found to be enriched 
in components of the cell cycle, DNA replication pathways, DNA damage response, and exhibit 
upregulation of genes associated with proliferation such as Ki67. The BL2 subtype is particularly 
enriched in growth factor receptor expression such as EGFR, Insulin-like growth factor (IGFR), 
and hepatocyte growth factor (MET). The IM subgroup is enriched for gene ontologies involved 
in fundamental signaling immune pathways such as T cell and B cell receptor signaling, natural 
killer cell pathway, and cytokine signaling. Additionally, this group has been observed to display 
increased antigen processing and presentation (46). The M and MSL subtypes are both enriched 
in genes that regulate cell motility, extracellular matrix receptor interaction, and cell 
differentiation including enhanced Wnt/β-catenin and TGF-β signaling. However, the MSL 
subtype differentiates itself from the M subtype with increased expression of genes in pathways 
that promote growth factor (i.e. EGFR, platelet-derived growth factor (PDGF)), calcium, and 
extracellular signal-regulated kinase signaling. In addition, MSL exhibits high activity of genes 
involved in angiogenesis and epithelial-mesenchymal transition. Perhaps the most distinguishing 
feature of the MSL subtype from the M subtype is a reduced expression levels of markers 
associated with cell proliferation along with elevated expression of stem cell and mesenchymal 
stem cell genes. Although ER negative, LAR subtype gene expression analysis revealed 
enhanced androgen and estrogen metabolic pathways. Particularly, increased expression of 
androgen receptor and its downstream targets was observed and further supported by enhanced 
nuclear AR immunohistochemical staining. Additionally, hierarchical clustering revealed that the 
LAR subtype exhibit a luminal-like gene signature making them resemble luminal ER positive 
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breast cancer. Lehmann and colleagues also uncovered subtype-specific sensitivities among the 
TNBCs to conventional therapeutic agents(46). They identified TNBC cell lines that share 
homogenous gene ontologies with each of the major TNBC subtypes through conducting gene 
expression profiling and clustering analysis. Their work yielded a comprehensive panel of TNBC 
cell lines representative of the six identified molecular TNBC subtypes. They utilized the panel 
to analyze differential drug response between the subtypes to traditional therapeutic agents 
administered in clinics. Cell viability assays revealed that the cell lines characterized as basal-
like displayed significantly higher sensitivity to cisplatin compared to mesenchymal- and LAR-
like lines likely due to their enrichment in DNA damage response markers. As one may suspect, 
the AR-dependent LAR-like cell lines displayed significantly higher sensitivity to the AR 
antagonist, bicalutamide, than the basal-like lines. These results suggest that the increased AR 
signaling present in LAR tumors permit this subgroup of TNBC patients to be selectively 
susceptible to anti-androgen targeted therapy. This clinically translatable information is valuable 
and warrants further investigation to discriminate TNBC subtypes according to their favorable 
therapeutic response to guide clinical decision-making.  
Androgen receptor is expressed in approximately 10-43% of TNBCs depending on the 
cutoff of positivity used and thus, has emerged as a promising therapeutic target for TNBC 
patients(47). AR knockdown and inhibition with enzalutamide among AR-expressing TNBCs 
has resulted in reduced proliferation, migration, invasion and increased apoptosis in vitro and in 
vivo(48-50). Traina and colleagues also observed that enzalutamide elicited a clinical benefit rate 
(CBR) of 25% at 24 weeks and a median progression-free survival (PFS) of 14.7 weeks among 
advanced AR-positive TNBC patients in a nonrandomized phase II clinical trial as opposed to 
patients exhibiting less AR expression, who exhibited a CBR of only 20% at 24 weeks and a 
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median PFS of 12.6 weeks (unpublished data). Another phase II clinical trial using the AR 
antagonist, bicalutamide, elicited a CBR rate of 19% at 24 weeks and a median PFS of 12 weeks 
among AR-positive TNBC patients(51). However, the remaining roughly 67-90% of TNBCs 
lack AR expression deeming the disease a “quadruple threat” and is often referred to as 
quadruple negative breast cancer (QNBC). Thus, this subgroup of TNBCs are more immune to 
novel AR-targeted therapeutic agents compared to AR-expressing TNBCs and some studies have 
reported a worse prognosis among QNBCs compared to TNBCs(52-57). Hence, some QNBCs 
exhibit even more of a dire need for alternative therapeutic options and risk-predictive 
biomarkers than AR-positive TNBCs. TNBC has been a hot topic of cutting-edge research over 
the past decade in which a plethora of ongoing preclinical and clinical trials have yielded 
promising biomarkers and therapeutic targets. However, recent evidence suggests genetic 
differences between TNBC and QNBC tumors and although the prognostic role of AR in TNBC 
remains controversial, many studies have revealed that a lack of AR expression confers a more 
aggressive disease course. However, leading-edge research on alternative biomarkers and 
treatment strategies for QNBC patients remain scarce. Thus, there is an urgent need for increased 
preclinical and clinical QNBC research to uncover novel actionable molecular targets for this 
unique group of TNBC patients.  
1.2.2 The racially disparate burden in triple negative breast cancer 
Intriguingly, racial disparities exist within the inherently aggressive TNBC subtype. As 
previously mentioned, pre-menopausal African-American (2) women are overwhelmingly more 
afflicted with TNBC compared to women of other ethnicities, which is primarily underlying their 
substantially lower survival rates and poorer clinical outcomes(41, 58). Moreover, studies show 
higher incidence rates and earlier age of onset of TNBC in native African women compared to 
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AA women(12, 59). Moreover, accumulating evidence suggests that even among TNBCs, AAs 
experience poorer clinical outcomes such as lower OS and PFS than EAs owing to more 
unfavorable clinico-pathological features such as larger tumor size, higher proliferation, more 
extensive lymph node involvement, and presentation at a younger age(12, 13, 60). In addition, 
ITH was recently found to be greater in AA compared to European-American (3) TNBC 
tumors(61). Further evidence has uncovered that AA TNBCs harbor more aggressive TNBC 
subtypes such as BL1 and MSL while EA TNBCs harbor more favorable TNBC subtypes such 
as LAR(60, 61). Interestingly, Gasparini and colleagues observed that loss of AR was more 
prevalent among AA compared to EA TNBC patients as well as associated with more 
unfavorable clinico-pathological features and a poorer prognosis(62). Furthermore, Davis et. al 
discovered that AR loss was more associated with AA compared to EA TNBC tumors(63). 
These findings are consistent with reports of a greater prevalence of basal-like TNBC, which 
lacks AR expression and reduced sensitivity to AR antagonists, among AA compared to EA 
TNBCs (46). These unsettling statistics necessitate further investigation into the potential 
molecular drivers underpinning disparities in tumor biology between AA and EA TNBCs.  
Several studies are addressing inherent biological differences between AA and EA 
TNBCs. A comparative analysis revealed higher Ki-67 and c-Kit expression and lower CK5, 
CK8, CK19, CD44 and AR expression in AA than EA TNBC patients(60). Linder et al., 
transcriptionally profiled AA and EA TNBC samples and observed increased loss of BRCA1 
expression and upregulation of IGFR and VEGF in AA compared to EA tumors(64). The group 
also found higher IGF-1 and VEGF activity and tumor vascularization in AAs compared to EAs 
among TNBC tumors. Gene-expression studies have uncovered considerably more upregulation 
of Wnt-β-catenin signaling in TNBC patients of African descent compared to TNBC patients of 
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European descent(12). Nalwoga et al., detected notably more enrichment of aldehyde 
dehydrogenase 1 (ALDH1), a cell surface marker associated with cancer stem cells, in TNBC 
tumors of African origin compared to TNBC tumors of non-African origin(65). Therapies 
targeting the previously mentioned inherent molecular differences distinguishing AA from EA 
TNBCs, such as PARP, IGFR, VEGF, and Wnt inhibitors, may potentially aid in attenuating the 
ethnic disparity in TNBC. However, these rationally-designed agents have yet been shown to 
perform robustly in TNBC patients or have been approved for targeted TNBC treatment. Thus, 
further investigation is warranted to uncover robust therapeutic targets and risk-prognostic and/or 
predictive biomarkers for AA TNBC patients.  
1.3 Intratumoral heterogeneity 
ITH has indisputably become one of the chief culprits underlying challenges in 
successfully treating and managing BC. Wang and colleagues claim that “no two cancer cells 
within the same cancer have the same genome”(66). Thus, BC cells are able to resist or become 
immune to conventional treatment strategies, such as chemotherapy, as well as rationally 
designed novel targeted therapies. Thus, intratumor diversity may underlie therapeutic resistance, 
metastasis, and relapse, which all characterize BC aggressiveness(67). Keenan and colleagues 
reported that AAs exhibit greater intratumor heterogeneity than EAs among both BC and TNBC 
tumors, which may be underlying the racial disparate burden in these diseases(61).  Hence, it 
may be worthy to investigate disparities in drivers of ITH between AA and EA breast tumors or 
target the “root” of racial disparities in BC as a promising alternative strategy to alleviating the 
burden. Centrosome amplification (CA) and mitotic propensity (MP) have been considered to be 
two key drivers of ITH as they collectively foster chromosomal instability (CIN), which 
promotes ITH(67). Herein, my research proposes to investigate differences in these two drivers 
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of ITH between AA and EA BCs to rationalize the racial disparate burden in BC and uncover 
their potential as robust prognostic biomarkers and/or therapeutic targets in AA BC patients.  
1.3.1 Centrosome amplification: Driver of intramoral heterogeneity 
The centrosome is the microtubule-organizing center of the cell and plays a key role in 
cell shape, cell polarity, cell motility, cell adhesion, organelle transport, and assembly of the 
mitotic spindle to ensure normal bipolar cell or genome division(68, 69).  Normal cells harbor 1-
2 centrosomes depending on the phase of the cell cycle it is in. However, cancer cells typically 
exhibit CA or an increase in the number (numerical CA) or size (structural CA) of centrosomes 
which can sporadically occur as a result of dyregulation of the centrosome duplication pathway, 
de novo centrosome biogenesis, and/or cytokinesis failure(70).  Thus, supernumerary 
centrosomes can compromise mitotic fidelity and interfere with proper segregation of 
chromosomes into daughter cells. As a result, aneuploidy or chromosomal instability arises 
which can pave the path for the generation of clonal diversity and aggressive karyotypes(71, 72). 
Centrosomal aberrations have been shown to positively correlate with ploidy and chromosomal 
instability(71, 72). Cells burdened with extra centrosomes often cluster their centrosomes at 
opposite poles of the cell to form a “pseudo biopolar spindle” in lieu of a lethal multi-polar 
spindle in order to ensure cell survival and allow genomically unstable cells to successfully 
replicate and thrive(73). Centrosome clustering has been significantly associated with worse OS 
and recurrence-free survival (RFS)(71). Excess centrosomes can also interfere with cell polarity 
and thus, enhance cell migration and progression(74, 75). Thus, CA has been linked to breast 
tumorigenesis and aggressiveness. Approximately, 80% of breast carcinomas have been reported 
to display CA(72). Centrosomal aberrations in breast tumors have been significantly associated 
with high grade and stage, lymph node metastasis, TNBC phenotype, and poor clinical outcomes 
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such as overall survival (OS) and progression-free survival (PFS) (71, 72, 76, 77).  As previously 
mentioned, these aggressive characteristics are associated with BC patients of African ancestry. 
Thus, it may be worthy to investigate differences in centrosomal profiles between AA and EA 
breast tumors as a suspect in the racial disparate burden in BC. Establishing differences in the 
incidence and severity of CA between AA and EA TNBC patients may provide compelling 
evidence for rationalizing differences in tumor progression and the divergence in clinical 
outcomes between the ethnic groups. Furthermore, uncovering this inherent tumor biological 
disparity between the racially-distinct patients may establish CA as a novel racial disparity 
biomarker in BC and a promising target for therapeutic intervention. CA is a cancer-cell specific 
trait that distinguishes them from normal, healthy cells. Thus, targeting CA offers a minimally 
cytotoxic therapeutic strategy that selectivity targets cancer cells burdened with severe 
centrosomal aberrations. Conveniently, there are already rationally designed drugs that 
selectively kill cancer cells harboring CA and are currently under clinical evaluation as 
promising anti-cancer therapeutics. These novel agents include putative centrosome declustering 
drugs such as griseofulvin and noscapine, commercially available HSET inhibitors such as 
CW069 and AZ82, and poly-ADP ribose polymerase inhibitors such as GF-15(2, 78-81). 
Furthermore, non-invasive methods that can detect centrosomal status (i.e. fine-needle aspirate 
cytology, immunohistochemistry) may demonstrate feasibility in the clinic for selecting patients 
that will exhibit susceptibility to these agents(77, 82). Validating associations between the 
severity level of CA with tumor growth, metastasis, and chemoresistance in preclinical and 
clinical BC models may illuminate upstream or downstream targets of CA that may be driving 
more aggressive BCs and variances in tumor progression between racially-distinct patients. 
Moreover, this elucidation may lay the groundwork for future studies to investigate differences 
12 
 
in molecular signaling pathways preceding the onset of CA or the mechanisms extra centrosomes 
exploit to drive more aggressive tumor behavior in AA compared to EA TNBC patients. 
Furthermore, CA exists in precancerous lesions and has been demonstrated to act as a precursor 
to breast tumorigenesis(83). Thus, evaluating centrosomal profiles among early-stage AA BC 
patients may serve as a risk-predictive biomarker for aggressive disease.     
1.3.2 Mitotic propensity: Engine of intratumoral heterogeneity 
MP, or turnover rate of proliferating cells in a tumor, is another important component 
fueling ITH(67).  Tumors with a high propensity are more prone to erroneous mitoses and 
consequently chromosomal instability. As a result, increased clonal diversity and the generation 
of aggressive cellular phenotypes can arise. Indices routinely utilized in the clinic to measure 
tumor proliferation include mitotic index (MI) and Ki-67 proliferation index (84). MI and KI 
have proven to be useful as autonomous indices in the clinic as a high MI and KI among early 
stage tumors have been reported to be synonymous with a poor patient prognosis in BC(85, 86).  
However, both indices are gleaned from separate fields and thus the precise propensity of a 
tumor cell to double among the proliferating cell population remains elusive. MI is deduced by 
computing the quantity of mitotic (M phase) cells per 10 high-powered microscopic fields 
whereas, KI is determined as the percentage of positive Ki-67 nuclear stained proliferating (G1, 
S, G2, and M phases) carcinoma cells in low-powered microscopic fields. A higher MI and KI 
have been reported among AA compared to EA breast tumors(87). Furthermore, extraneous 
factors often interfere with accurately quantitating mitotic figures in patient tumor samples and a 
lack of consensus on an appropriate cut-off and discrepancies in Ki-67 immunohistochemical 
(IHC) staining still persists(32, 88, 89). Thus, our group recently proposed a novel metric that 
rationalized the inconsistencies and limitations of MI and KI as autonomous prognosticators. The 
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metric cleverly integrates MI and KI onto the same measurement scale to ascertain the frequency 
of mitotic cells among Ki-67 positive cycling cells or mitotic propensity, termed mitosis: 
proliferation (M:P ratio). Hence, our metric provides an additional layer of risk-predictive 
information than MI and KI alone. My research proposes to investigate differences in M:P ratio 
or cycling kinetics between AA and EA breast tumors to (i) rationalize their differences in ITH 
and metastatic propensity and (ii) determine if M:P ratio can enhance risk-prognostication for 
AA BC patients at risk for faster tumor kinetic progression.   
1.4 Tumor immune microenvironment 
Accumulating evidence suggest that the interplay between the breast tumor and its 
microenvironment plays a critical role in tumor progression and therapeutic responses. The 
breast microenvironment provides a supportive niche for tumor growth and is composed of the 
extracellular matrix, stromal cells, fibroblasts, adipocytes, endothelial cells, and immune 
cells(90).  Immune cells infiltrate the tumor upon neoplastic transformation to elicit an 
antitumoral or protumoral inflammatory response. Primarily lymphocytes, macrophages, mast 
cells, and neutrophils comprise the inflammatory defense army that infiltrate the incipient tumor 
to mount an attack or facilitate tumor progression(91). Thus, these inflammatory cells harbor 
dual roles in BC initiation and progression by secreting cytokines, growth factors, chemokines, 
oxygen intermediates to stimulate proliferation, apoptotic prevention or promotion factors, 
morphogenesis factors, and inducing mutagenic changes that promote DNA damage in tumor 
cells(91). Tumor associated macrophages (TAMs), neutrophils, T, and B lymphocytes harbor 
both pro-tumorigenic and tumoricidal properties however, natural killer (NK) lymphocytes are 
the only tumor infiltrating immune cells that harbor solely anti-tumorigenic properties. Tumor 
infiltrating lymphocytes (TILs) have been recognized as a bonified biomarker of the anti-tumoral 
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immune response, have been proven to harbor both prognostic and predictive value in BC and 
TNBC, and have become one of the primary targets of cancer immunotherapy today. Thus, TILs 
will be the primary focus of my dissertation.      
1.4.1 Tumor infiltrating lymphocytes: Critical mediators of the antitumoral immune 
response 
TILs are white blood cells or T, B, and NK lymphocytes that migrate to the tumor stroma 
or within the tumor upon neoplastic transformation to eradicate tumor cells and control tumor 
progression. In BC, TILs primarily consists of T cells (~75%) and specifically CD8+ cytotoxic T 
cells, CD4+ helper T cells, and CD4+ regulatory T cells (T regs)(92, 93). Cytotoxic T 
lymphocytes kill tumor cells by inducing apoptosis. T cells express T cell receptors (TCRs) that 
recognize neoantigens on cancer cells and induce programmed cell death by (i) releasing the 
cytotoxin perforin to inject granzymes into the cytoplasm and trigger the caspase cascade 
pathway through their serine protease function and by (ii) expressing their surface protein, FAS 
ligand, which can bind to Fas on the cancer cell and recruit the death-induced signaling complex 
and Fas-associated death domain to activate the caspase cascade reaction. TILs are associated 
with more aggressive BC such as high grade, high stage, high Ki-67, lymph node metastasis, and 
younger age at diagnosis(93). Furthermore, TIL infiltration is significantly more observed in 
TNBC compared to non-TNBCs(92). Particularly, CD8+ T lymphocytes inversely correlates 
with ER and PR expression and their density is significantly higher in TNBCs compared to non-
TNBCs(94, 95).  However, a presence of TILs have been associated with a significantly better 
prognosis in BC and TNBC. TILs have been shown to be an independent predictor of improved 
pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) in both BC 
and TNBC as well as better OS and disease-free survival (DFS) among non-NAC treated TNBC 
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patients(96, 97). High TIL levels have also been significantly associated with improved overall 
survival (OS), increased metastasis-free survival (MFS), and reduced distance recurrence in 
TNBC(96). Hence, the presence of TILs plays a critical role in disease course and survival 
outcomes among BC and TNBC patients.     
1.4.2 Racial disparities in the tumor microenvironment: Suspect in the racially disparate 
burden in BC  
Emerging evidence suggest disparities in the breast tumor immune microenvironment 
exists between AA and EA breast tumors, which has been suspected to be contributing to the 
racial disparate burden in BC. Tumor stromal genes such as PSPHL, CXCL10, and CXCL11 
have been reported to be significantly higher in AA compared to EA BC patients(98). Multiple 
groups have revealed significantly higher levels of pro-inflammatory cytokines such as resistin, 
leptin, interleukin 6 (IL-6) as well as the resistin receptor, CAP1, in AA compared to EA 
patients(99-103). Martin and colleagues also observed significantly higher expression levels of 
vascular endothelial growth factor (VEGF) and syndecan-1 (known inducers of angiogenesis) in 
AA compared to EA BC patients(98). In addition, Martin et. al observed greater microvessel 
density in AA compared to EA BC patients(98). TAMs have also been reported by several 
groups to be significantly higher in AA compared to EA BC patients(98, 104, 105).  Tripathi and 
colleagues also discovered an enriched immune gene signature in the T and B cell response 
pathways among AA QNBC tumors suggesting increased anti-tumor immunity among AA 
QNBC patients (unpublished data). Hence, this evidence suggests disparities between AAs and 
EAs exists in the breast tumor microenvironment, which may be underlying the racial disparity 
in BC. However, the role of racial disparities in the tumor microenvironment in the racial 
disparate burden in BC, and especially in TNBC, remains poorly explored. Particularly, racial 
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disparities in TIL levels between AA and EA breast tumors remain elusive. In this dissertation, I 
investigate differences in TILs between AA and EA TNBC patients and their potential as robust 
risk-prognostic/predictive biomarker and therapeutic target for AA patients at risk for a poorer 
prognosis.   
1.5 Tumor cell proliferation 
Aggressive BC is often characterized by what it lacks such as the absence of the hormone 
and growth receptors, ER, PR, AR, and HER2 that promote BC proliferation and consequently a 
lack of risk-prognostic and targeted treatment options.  Furthermore, as previously discussed, BC 
patients of African descent tend to lack expression of these tumor proliferation markers, 
exempting them from being eligible to receive conventional treatments targeting these 
biomarkers, which is a major underlying factor in their observed disparate clinical outcomes 
compared to patients of other ethnicities. Hence, it may be advantageous to investigate the role 
of other growth receptors in aggressive BC subtypes that lack expression of these traditional 
proliferation biomarkers such as TNBC and QNBC among AA BC patients as alternative risk-
prognostic and/or targeted treatment options.  
1.5.1 Human epidermal growth factor receptor family 
The human epidermal growth factor receptor (EGFR) family consists of four structurally 
related tyrosine kinase receptors (EGFR/HER1, HER2, HER3, and HER4) that collectively 
stimulate growth factor signaling pathways that play critical roles in cell proliferation, growth, 
survival, and differentiation, such the PI3 kinase, Ras-Raf-MAPK, JNK, and PLCg 
pathways(106-108). Aberrant expression of these receptors can also promote loss of cell 
adhesion and polarity and initiate invasion and angiogenesis and has been associated with human 
malignancies(109-111). Activation of these receptors and their signaling pathway via ligand 
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binding is mediated through hetero- or homo- dimerization of these receptors followed by 
subsequent phosphorylation of tyrosine residues on the intracellular tyrosine kinase 
domain(112). HER2 preferentially dimerizes with EGFR(113). HER2 is overexpressed in 
approximately 20-25% of all BCs and is a well-established predictive biomarker and therapeutic 
target in BC(107). However, owing to the lack of HER2 amplification in TNBCs and QNBCs it 
may be advantageous to investigate other members of the EGFR family as viable risk-predictive 
biomarkers or therapeutic targets for TNBC patients and patients of African ancestry. In this 
dissertation, I will investigate the role of the other three EGFR family members (EGFR, HER3, 
and HER4) in the global racial disparate burden and their potential as risk-prognostic/predictive 
biomarkers and/or therapeutic targets among ethnically-distinct TNBC patient populations.  
1.5.1.1 EGFR 
EGFR is overexpressed in at least 50% of TNBCs, which is notably higher compared to 
other BC subtypes(107). Ligands for EGFR include EGF, ampiregulin, transforming growth 
factor (TGF)-α, betacellulin, heparin-binding EGF, and epiregulin(114). EGFR expression is 
significantly more associated with young age, lower hormone receptor expression levels, high 
grade, high proliferation, genomic instability, and lymphocytic infiltration(115, 116). EGFR has 
expression has also correlated with higher risk of relapse among adjuvant treated BC 
patients(116). Moreover, high EGFR copy number, immunoreactivity and expression have been 
shown to be independent prognostic indicators of poorer overall survival (OS) and disease-free 
survival (DFS) in TNBC, suggesting EGFR to be a potentially targetable and risk-prognostic 
biomarker in TNBC (117-120). Researchers at Caris Research Institute recently reported that 
EGFR IHC expression was higher among AR-negative compared to AR-positive TNBCs 
suggesting increased cellular growth and proliferation in QNBCs compared to TNBCs as well. 
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Anti-EGFR agents such as tyrosine kinase inhibitors (i.e. gefitinib and erlotinib) and anti-EGFR 
monoclonal antibodies (i.e. cetuximab) are currently being tested in TNBC patients in phase I/II 
clinical trials as monotherapy and in combination with chemotherapy and have elicited improved 
response in some patients(121). Thus, EGFR may serve as a promising risk-prognostic 
biomarker and therapeutic target for TNBC and QNBC patients as well as patients of African 
ancestry who exhibit a high prevalence of these diseases. 
1.5.1.2 HER3 
HER3 is unique in that it is the only receptor in the family that is catalytically inactive 
and requires dimerization with other members in order to be active(122). The receptor 
heterodimerizes with EGFR to stimulate the PI3K signaling pathway(122). Its overexpression 
has been reported in approximately 20-30% of invasive breast carcinomas(123). Yamaguchi and 
colleagues recently observed that HER3 signaling promotes upregulation or programmed cell 
death ligand 1 (PD-L1) which plays a critical role in suppression of anti-tumor immunity 
(unpublished data). HER3 has also been reported to limit patient sensitivity to EGFR-targeted 
agents such as cetuximab by increasing EGFR-HER3 heterodimerization and activating 
downstream signaling pathways in BC(124). Reports on the prognostic role of HER3 in BC 
remain conflicted however, it has been associated with poorer overall survival (OS) and DFS in 
TNBC according to one study (122, 125). Our group also recently reported that combined 
EGFR-HER3 score predicts worse BC-specific survival (BCSS) and increased distant metastasis 
after adjusting for age and stage among TNBC patients (unpublished data). A high EGFR-HER3 
score among chemotherapy-treated patients in this cohort was associated with high IHC 
expression of luminal cytokeratins, DNA damage response proteins, and P-cadherin. Hence, it 




HER4 is detected in less than half of BCs and generally characterized by antiproliferative 
and pro-apoptotic activity(126). This EGFR family member has been reported to be 
downregulated in 18-75% of BCs and upregulated in 7-29% of cases(127).  It is also unique in 
that it is the only member of the family that exist in four juxtamembrane (JM) and cytoplasmic 
(CYT) isoforms (JM-a/CYT1, JM-a/CYT2, JM-b/CYT1, and JM-b/CYT2) due to alternative 
mRNA splicing and one of these isoforms (JM-a) can be cleaved by tumor necrosis factor 
(TNF)-α converting enzyme (TACE) and γ-secretase and released into the cytoplasm as a soluble 
HER4 intracellular domain (4ICD) that can translocate to the nucleus(128-130). Ligands for 
HER4 include the neuregulins, epiregulin, betacellulin, and heparin-binding EGF(114). The 
receptor displays a diverse range of roles including modulating cell proliferation, cell cycle 
arrest, and pro-apoptotic pathways(131, 132).  The 4ICD of HER4 promotes proliferation of ER-
α positive BC cells and apoptosis of BC cells through the cell-killing BH3 domain(133). Thus, 
HER4 is often associated with a favorable prognosis in BC and specifically prolonged event-free 
survival and OS among TNBCs(122, 134, 135). However, Kim et. al recently reported that high 
HER4 levels are significantly associated with poor 5-year disease relapse free survival in 
TNBC(84). HER4 has been reported to positively correlate with ER-positive BC and be 
associated with less recurrence and mortality among ER-positive patients(131, 136). 
Upregulation of HER4 gene expression has even been shown to predict response to neoadjuvant 
chemotherapy (NAC) in BC(137). In addition, HER4 has been associated with low proliferative 
indices, cell growth inhibition, and low histological grade as well as been observed to antagonize 
the influence of HER2 on clinical outcome(127). HER4 mRNA expression levels were found to 
be significantly lower among AR-negative compared to AR-positive TNBC cases(62). Hence, 
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lack of HER4 expression may be a marker of aggressive BC and serve as a novel prognostic 
biomarker this patient population.  
1.5.1.4 Retinoic acid receptor-α 
Retinoic acid (RA), a derivative of retinol of vitamin A, influence cell growth, 
differentiation, and death through binding to members of the retinoic acid receptor (124) 
subfamily comprised of RARa, RARb, and RARg, which belong to the nuclear receptor 
superfamily of transcription factors(138). RARs heterodimerize to members of the retinoic X 
receptor (RXR) subfamily to initiate RA-mediated signaling. RAR is activated by both all-trans 
and 9-cis RA, whereas RXR can only be activated by 9-cis RA(139). The RAR-RXR dimer 
translocates to the nucleus and regulates transcription of target genes by binding to specific RA 
response elements (RAREs) on the gene promoter. Unlike the EGFR family, RA signaling 
through RARs has been reported to elicit differentiation as well as antiproliferative, pro-
apoptotic, and anti-oxidant activity(138). Thus, aberrant RA signaling has been linked to breast 
tumorigenesis and RA and its derivatives (retinoids) are often exploited as potential 
chemotherapeutic or chemopreventative agents. However, ER-negative BCs and TNBCs have 
been reported to express lower levels of RARa compared to non-TNBCs which may reflect their 
enhanced proliferative activity(140). The role of RARa in TNBC and particularly in the racially 
disparate burden remains elusive. Hence, my dissertation work explores the potential role of this 
biomarker as a driver of the racial disparity in TNBC incidence and mortality between patients of 
African and European descent.  
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2 DISTINCTIONS IN BREAST TUMOR RECURRENCE PATTERNS POST-
THERAPY AMONG RACIALLY-DISTINCT POPULATIONS 
2.1 Abstract 
Clinical studies have revealed a higher risk of breast tumor recurrence in African-American 
(2) patients compared to European-American (EA) patients, contributing to the alarming inequality 
in clinical outcomes among the ethnic groups. However, distinctions in recurrence patterns upon 
receiving hormone, radiation, and/or chemotherapy between the races remain poorly characterized. 
We compared patterns and rates (per 1000 cancer patients per 1 year) of recurrence following each 
form of treatment between AA (n=1850) and EA breast cancer patients (n=7931) from a cohort of 
patients (n=10504) treated between 2005-2015 at Northside Hospital in Atlanta, GA. Among 
patients who received any combination of adjuvant therapy, AA displayed higher overall rates of 
recurrence than EA (p=0.015; HR: 1.699; CI: 1.108-2.606). Furthermore, recurrence rates were 
higher in AA than EA among stage I (p=0.031; HR: 1.736; CI: 1.052-2.864) and T1 classified 
patients (p=0.003; HR: 2.009; CI: 1.263-3.197). Interestingly, among patients who received 
neoadjuvant chemotherapy, AA displayed higher rates of local recurrence than EA (p=0.024; HR: 
7.134; CI: 1.295-39.313). Our analysis revealed higher incidence rates of recurrence in AA 
compared to EA among patients that received any combination of adjuvant therapy. Moreover, our 
data demonstrates an increased risk of tumor recurrence in AA than EA among patients diagnosed 
with minimally invasive disease. This is the first clinical study to suggest that neoadjuvant 
chemotherapy improves breast cancer recurrence rates and patterns in AA.  
2.2 Introduction 
The significant divide in breast cancer mortality between African-American (2) and 
European-American (EA) patients remains a challenge for clinicians. Despite a similar number of 
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reported incidences of breast cancer among AA and EA women, AAs experience notably higher 
severity in clinical outcomes and exhibit a 40% higher death rate than EAs among premenopausal 
and menopausal breast cancer patients (1-3). Recurrent breast cancer has impeded successful 
management of the disease for decades and is one of the primary factors for this racial division in 
prognosis (4). Statistics demonstrate that approximately 40% of all breast cancer survivors will 
experience a recurrence episode during their lifetime, which has been suggested to play a principal 
role in breast cancer mortality (4, 5). Clinical studies have revealed a higher risk of recurrence in 
AA compared to EA, presumably contributing to the inequality in clinical outcomes among the 
ethnic groups (1). This statistic has provided an impetus for clinicians to devise and implement 
robust prognosticative measures to preclude recurrence in AA breast cancer patients. However, 
distinctions in recurrence rates and patterns following various forms of treatment between the races 
have not been thoroughly evaluated. This warrants more investigation to potentially attenuate the 
observed racial disparity in recurrence in the clinic. Hence, we conducted a large institutional study 
based in Atlanta, Georgia, in which we analyzed rates and patterns of tumor recurrence post 
hormone, radiation, and chemotherapy among AA and EA breast cancer patients. This 
retrospective clinical study uncovered previously unrecognized distinctions in recurrence patterns 
following each conventional form of treatment among racially distinct breast populations and may 
impart valuable clinical insight into preclusive measures for mitigating the ethnic disparity in 
breast tumor recurrence.  
2.3 Results 
2.3.1 Clinico-pathological characteristics of patients 
The demographics, breast clinico-pathological characteristics, therapies administered and 
patterns of recurrence among the patients in the cohort are illustrated in Fig 1. From this cohort of 
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10,504 NH patients, 225 were recorded as having experienced a recurrence episode and 6,009 were 
determined as displaying no breast tumor recurrence. The remaining patients did not have recorded 
data indicating presence of recurrence or lack thereof. Among patients displaying recurrence, 
higher risk of recurrence was more prevalent among younger patients (p<0.0001) (Fig 1A). Among 
patients with no missing recurrence data, approximately 61% of patients who experienced 
recurrence were under the age of 48, compared to only 39% who did not experience any recurrence. 
Among breast clinico-pathological characteristics, recurrence was significantly more associated 
with higher nuclear grade, NGH grade, stage, as well as T, N, and M classifications (p<0.0001) 
(Fig 1B). Moreover, recurrence was weakly associated with lymph node metastasis with roughly 
35% of patients with recurrence displaying a positive nodal status compared to only 15% of non-
recurrence patients (p=0.121). Regarding treatment, there were statistical significant differences 
in the distribution of recurrence and non-recurrence patients who were administered neoadjuvant 
and adjuvant chemotherapy, hormone therapy, and a combination of adjuvant therapies (p<0.0001) 
(Fig 1C). There was a weak statistical significant difference between the proportion of recurrence 
and non-recurrence patients that received radiation therapy (p=0.065). Please visit Supplementary 
Table 1 for details. 
2.3.2 Clinico-pathological characteristics among racially distinct patients  
Among the NH patients exhibiting recurrence, the demographics, breast clinico-
pathological features, and therapies administered were compared between AA (n=49) and EA 
(n=166) as shown in Fig 2. Regarding patient demographic characteristics, a test of hypothesis for 
population differences revealed a weak statistical significant difference in age at diagnosis between 
the races (p=0.145) (Fig 2A). Approximately 51% of AA were diagnosed under the age of 48, 
compared to only 35% of EA. No significant differences in either clinico-pathological 
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characteristics or treatments between the races were observed, likely owing to a significant 
reduction in patient numbers after stratification of recurrence patients by race (Fig 2B, C). Please 
visit Supplementary Table 2 for details.  
2.3.3 Recurrence patterns among racially distinct patients  
Recurrence rates and patterns, expressed in terms of incidence rates, were compared 
broadly between AA and EA patients (Table 1); the analysis indicated that AA exhibited higher 
overall tumor recurrence rates than EA (p=0.002; HR: 1.676; CI: 1.210-2.323). AA also displayed 
higher rates of distant recurrence than EA (p=0.023; HR: 1.699; CI: 1.075-2.684); however, these 
differences did not remain statistically significant after controlling for age, grade, and stage, likely 
owing to low patient numbers. Additionally, AA experienced higher rates of single tumor 
recurrence episodes than EA (p=0.003; HR: 1.758; CI: 1.208-2.557) and higher rates of distant 
recurrence to a single site than EA breast cancer patients (p=0.012; HR: 1.742; CI: 1.130-2.684), 
although statistical significance was not maintained after adjusting for age, grade, and stage.  
2.3.4 Recurrence patterns among racially distinct patients following each form of treatment 
Incidence rates and patterns of recurrence were compared between AA and EA after they 
received hormone, radiation, chemotherapy, and/or any combination of adjuvant therapy (Table 
2). AA exhibited unadjusted higher rates of recurrence (p=0.041; HR: 1.612; CI: 1.021-2.545) and 
a trend towards higher incidence of distant tumor recurrence than EA post radiation therapy 
(p=0.065; HR: 1.732; CI: 0.967-3.100). However, statistical significance was lost after controlling 
for age, grade, and stage. The same trend of higher overall and distant recurrent was observed 
among recurrent patients who received hormone therapy and any combination of adjuvant 
therapies. Among patients who underwent hormone therapy, AA displayed stronger overall 
tendencies than EA to suffer from recurrence (p=0.112; HR: 1.541; CI: 0.906-2.623) and distant 
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recurrence (p=0.123; HR: 1.692; CI: 0.868-3.301). Following any combination of adjuvant 
therapy, AA displayed higher recurrence rates than EA after adjusting for age, grade, and stage 
(p=0.015; HR: 1.699; CI: 1.108-2.606). Moreover, AA displayed higher rates of distant recurrence 
than EA (p=0.003; HR: 2.164; 1.290-3.629) before adjusting for age, grade, and stage, as well as 
stronger tendencies toward regional recurrence (p=0.104; HR: 2.043; CI: 0.863-4.837) after 
receiving any combination of adjuvant therapy.  
Quite interestingly however, among patients with recurrence that received neoadjuvant 
chemotherapy, this trend was reversed. AA displayed lower tendencies toward recurrence than EA 
patients; however, statistical significance was unable to be achieved owing to a low number of 
patients (n=40) recorded as receiving neoadjuvant chemotherapy and exhibiting recurrence. 
Furthermore, AA displayed lower tendencies toward regional and distant tumor recurrence 
(p=0.112; HR: 0.310; CI: 0.073-1.315) than EA patients. Moreover, AA displayed higher rates of 
local recurrence than EA after controlling for age, grade, and stage (p=0.024; HR: 7.134; CI: 
1.295-39.313). These results suggest that aggressive recurrence rates and patterns may be 
attenuated in AA patients who received neoadjuvant chemotherapy. Additional studies with larger 
numbers of patients with recurrence that received neoadjuvant chemotherapy could further clarify 
the significance of this trend. 
2.3.5 Recurrence rates among racially distinct breast cancer patients in different stages 
Overall incidence rates of recurrence were compared between AA and EA in both early (I–
II) and late stage (III-IV) breast cancer patients (Table 3). Our data revealed that AA displayed 
higher recurrence rates than EA among stage I patients (p=0.001; HR: 2.165; CI: 1.348-3.476), 
even after adjusting for age, grade, and stage (p=0.031; HR: 1.736; CI: 1.052-2.864). Among early 
stage (I-II) patients, AA also exhibited higher recurrence rates than EA (p=0.002; HR: 1.793; CI: 
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1.252-2.567), although statistical significance was only weakly maintained after controlling for 
age, grade, and stage (p=0.131; HR: 1.339; CI: 0.917-1.956). Furthermore, AA displayed higher 
recurrence rates than EA among T1 classified patients, irrespective of age, grade, and stage 
(p=0.003; HR: 2.009; CI: 1.263-3.197). Moreover, unadjusted models reveal that AA displayed 
higher rates of recurrence than EA among N0 (p=0.005; HR: 1.777; CI: 1.186-2.661) and M0 
(p=0.002; HR: 1.682; CI: 1.210-2.338) classified patients. However, rates of recurrence were not 
significantly higher in AA as compared to EA among late stage patients. Thus, these results suggest 
that AA are at higher risk than EA for tumor recurrence among patients with non-invasive or 
minimally invasive breast cancer. 
2.3.6 Survival outcomes among racially distinct patients displaying recurrence 
Survival duration after initial recorded recurrence was compared between the racial groups 
(Fig 3). AA exhibited a non-statistically significant trend toward shorter survival time than EA 
after experiencing their first episode of recurrence (p=0.231) (Fig 3A). The average time until 
death was compared between EA and AA patients who experienced distant recurrences (Fig 3B). 
Interestingly, AA and EA patients exhibiting distant recurrence were comprised of similar 
percentages of alive patients, however AA (n=26) died considerably sooner than EA (n=80) 
(p=0.015). More precisely, AA patients who experienced distant recurrences died approximately 
one year earlier than EA distant recurrent patients. However patient numbers were too low to 
control for variables of age, grade, and stage.  
2.4 Discussion 
This clinical study is the first extensive investigation into the rates and patterns of tumor 
recurrence in breast cancer patients following conventional treatments among racially distinct 
populations. Our study has revealed notable distinctions in recurrence patterns among EA and AA 
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patients. First, AA displayed considerably higher rates of recurrence than EA (Table 1 and 2). 
Second, we observed higher severity in recurrence patterns displayed by AA for whom we 
discerned stronger trends in AA of tumor recurrence to regional and distant sites (Table 1 and 2). 
This trend was evident after patients received radiation, hormone, and any combination of adjuvant 
therapies. Overall, these observed trends were quite significant since local recurrence tends to elicit 
a more favorable clinical prognosis compared to distant recurrence, while the latter trends type 
precedes a poorer clinical prognosis. Triple negative breast cancer (TNBC) patients have been 
shown to display an increased risk for recurrence and particularly for recurrence to distant sites, 
while non-TNBC patients exhibit higher trends of recurrence to local sites (1,8). These findings 
parallel our observations of an increased risk of overall and especially distant recurrence in AA, 
as well as an increased risk of local recurrences in EA. This tendency reflects the well-reported 
higher incidence of TNBC phenotypes in AA patients and a higher prevalence of non-TNBC 
subtypes in EA patients (8,9). Furthermore, we observed a trend of a higher number of recurrence 
episodes in AA compared to EA. Additionally, we discerned stronger inclinations of distant 
recurrence to multiple organs in AA compared to EA. These observed aggressive recurrence 
patterns reveal that AA patients exhibit an increased prospect of a poor clinical prognosis, 
theoretically contributing to their higher mortality rates than EA patients. Recurrence rates were 
also found to be higher in AA than EA among early stage, minimally invasive breast cancer 
patients (Table 3). This data presents an intriguing paradox as advanced stage upon diagnosis is 
typically associated with increased risk for recurrence (10-13). Thus, these findings suggest that 
AA patients of all clinical stages should be closely evaluated for the prospect of tumor recurrence. 
Neoadjuvant chemotherapy seemed to reverse these observed recurrence trends (Table 2). Among 
patients who received neoadjuvant chemotherapy, AA displayed a lower rate of recurrence than 
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EA; however due to a low number of recorded patients that received neoadjuvant chemotherapy, 
statistical significance was diminished. In addition, higher incidences of aggressive recurrence 
patterns in AA were notably attenuated after these patients underwent neoadjuvant chemotherapy. 
This data suggest preoperative chemotherapy may reduce the severity of recurrence rates and 
patterns in AA patients. This study suggests that neoadjuvant chemotherapy should be 
recommended for AA patients who are at higher risk for developing recurrence. A recent clinical 
study reported that in fact, neoadjuvant chemotherapy is administered more frequently to AA than 
EA patients likely as a result of their higher prevalence of advanced stage, grade, and triple 
negative receptor status upon presentation (14). Owing to their robust prognostic value, the extent 
of lymph node involvement and tumor size warrant stringent evaluation upon diagnosis and serve 
as principal prognostic factors in assessing breast cancer recurrence proclivities in AA patients (1). 
Established supplementary prognostic factors often considered by clinicians, such as higher stage 
and grade upon initial diagnosis, lymphatic and vascular invasion, premenopausal status, and a 
TNBC phenotype, also merit thorough scrutiny for AA breast cancer patients (9,10-13,15-17). 
Hence, rigorous supervision of the prospect of recurrence is conceivably compulsory to palliate 
the elevated risk of recurrent breast cancer demonstrated by AA patients.  
Although prior clinical studies have exposed disparities in recurrence risk among EA and 
AA, this study is one of the first to uncover distinctions in rates and patterns of tumor recurrences 
following conventional forms of breast cancer treatments among the racial groups, and thus 
highlights the need for further investigation and surveillance. Our comprehensive analysis has also 
illuminated previously unrecognized differences in the rates and patterns of recurrence post-
chemotherapy among racially distinct populations by suggesting that AA respond better to 
neoadjuvant chemotherapy. Additionally, no study has yet elucidated the significantly higher risk 
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for recurrence among early stage AA patients. Overall, this study further advocates that race should 
be considered among the potential decisive risk factors in the clinic for recurrence. Awareness of 
the higher rate of recurrence in AA may compel clinicians to consider race as a critical factor in 
evaluating the prospect of the cancer returning after patients enter remission, and allow this factor 
to play a major role in treatment decisions. Hereinafter, enriched comprehensive screening 
programs and tailored treatment plans may be imperative to impede augmented risk of tumor 
recurrence and aggressive recurrence patterns in AA patients that may be reinforcing their poor 
clinical outcomes.  
2.5 Methods 
2.5.1 Study cohort 
In this study, a large cohort of breast cancer patients treated at Northside Hospital (NH) 
in Atlanta, Georgia from 2005 to 2015, were examined. We received approval and permission by 
the institutional review board at Northside Hospital to access patient clinico-pathological 
information used in this study and have a written human subjects assurance on file. The 
demographics and clinico-pathological characteristics of each patient were recorded to generate a 
database of 10,504 patients. Patient demographic information recorded in the database included 
age at time of diagnosis and ethnicity. Age at diagnosis among patients was divided into three 
subgroups, comprised of patients below the age of 48 (premenopausal), over the age of 55 
(postmenopausal), and in between (perimenopausal), to precisely describe menopausal status. 
The races of patients in the database were primarily comprised of African-Americans (2) and 
European-Americans (EA). The “unknown/others” subcategory denote patients of all other 
ethnicities (excluding AA and EA) and patients lacking race information. Breast tumor 
characteristics that were recorded for each patient consisted of nuclear grade, Nottingham (NGH) 
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grade, stage, nodal status, T (primary tumor), N (lymph node metastasis) and M (distant 
metastasis) classifications. American Joint Committee on Cancer (AJCC)/Union for International 
Cancer Control (UICC) TNM Classification and Stage groupings for breast carcinoma will be 
used in this article. All patient treatments were recorded, including chemotherapy, hormone, and 
radiation therapy. Patients that underwent chemotherapy were subcategorized into neoadjuvant 
and adjuvant depending on the timing of treatment. Additionally, any combination of hormone, 
radiation, and chemotherapy that patients received was labeled as a combination of adjuvant 
therapies. Follow up data was collected to determine breast cancer recurrence episodes, as well 
as the site of recurrence, such as local, regional or distant sites. Local recurrences comprise 
recurrence of the tumor in the primary site. Regional recurrence encompasses recurrence of the 
breast cancer in adjacent lymph nodes. Distant recurrences involve metastatic breast cancer in 
remote organs such as distant lymph nodes, bone, liver or others. 
2.5.2 Follow-up 
Both follow-up of patients and initial diagnosis occurred between the years of 2005 and 
2015. Initial diagnosis dates as well as treatment start and completion dates for any therapies were 
documented. Dates of last contact for all patients were recorded. Survival status (alive/dead) was 
reported for each patient along with survival time. Dates of first recurrence were noted. February 
19, 2015 was the final follow-up for the last patient seen.  
2.5.3 Statistical analysis  
A significance level of 0.05 and 95% confidence intervals were selected for all analyses. 
Sample sizes were based on the available patients that comprised each category in the NH database 
and not power analysis. Chi-square tests were performed to examine significant differences in 
clinico-pathological characteristics, therapy administration, and recurrence characteristics 
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between recurrence and non-recurrence patients as well as between AA and EA breast cancer 
patients. Recurrence rates were calculated as per 1000 person-years. Test statistics were computed 
using MATLAB (MATLAB and Statistics Toolbox Release 2015a, The MathWorks, Inc., Natick, 
Massachusetts, United States) program and 1-tailed univariate p-values were reported. One-tailed 
analysis was preferred over two-tailed for this particular study to adequately reflect the 
presumption that treatment is expected to improve patient outcome. Multivariate Cox proportional 
hazard models were computed to determine significant differences in recurrence rates and patterns 
between the racial groups (6, 7). These statistical models were additionally modified to control for 
variables of age, grade, and stage. The Kaplan Meier analysis was conducted in SAS 9.4 program 
to estimate survival function for AA and EA with recurrent disease over a 10-year period. A log-
rank test was conducted to evaluate significance level for between-race differences in survival. 
Finally, a t-test was used to compare mean time from first recorded recurrence event until death 
among patients with distant recurrence.  
2.6 Tables and Figures 






  EA AA p value; HR (95% CI) 
p value; HR (95% 
CI) 
  n IR n IR Unadjusted Model Adjusted Model 
Overall 166 13.44 49 21.77 0.002; 1.676 (1.210, 2.323) 
0.319; 1.192 (0.844, 
1.683) 
Recurrence site  
Local 48 3.89 12 5.33 0.373; 1.349 (0.698, 2.606) 
0.665; 0.857 (0.428, 
1.718) 
Regional 27 2.19 10 4.44 0.188; 1.701 (0.772, 3.747) 
0.151; 1.749 (0.815, 
3.752) 
Distant 84 6.8 27 12 0.023; 1.699 (1.075, 2.684) 
0.280; 1.299 (0.809, 
2.085) 
Number of recurrences 
Single 131 10.6 41 18.21 0.003; 1.758 (1.208, 2.557) 
0.218; 1.287 (0.861, 
1.923) 
Multiple 35 2.83 8 3.55 0.754; 1.139 (0.505, 2.573) 
0.315; 0.652 (0.283, 
1.503) 
Distant recurrence  
Single site 73 5.91 24 10.66 0.012; 1.742 (1.130, 2.684) 
0.451; 1.220 (0.728, 
2.043) 
Multiple sites 11 0.89 3 1.33 0.492; 1.566 (0.436, 5.625) 
0.617; 0.672 (0.142, 
3.187)  
Abbreviation: IR, incidence rate (1000 person-years). 
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).  




Table 2.2 Recurrence rates and patterns after receiving any form of treatment among racially 




  EA AA p value; HR (95% CI) 
p value; HR (95% 
CI) 
Treatment n IR n IR Unadjusted model Adjusted model 
Chemotherapy 
Overall 85 22.73 23 26.66 0.466; 1.181 (0.755, 1.846) 
0.807; 0.943 (0.587, 
1.514) 
Local 13 3.48 7 7.46 0.125; 2.053 (0.818, 5.151) 
0.394; 1.548 (0.567, 
4.226) 
Regional 20 5.35 6 6.4 0.594; 1.284 (0.512, 3.219) 
0.749; 1.169 (0.450, 
3.041) 




Overall 32 28.95 6 19.77 0.373; 0.673 (0.281, 1.609) 
0.409; 0.690 (0.286, 
1.664) 
Local 2 1.81 4 13.18 0.026; 6.857 (1.256, 37.447) 
0.024; 7.134 (1.295, 
39.313) 
Regional 7 6.33 0 0 N/A N/A 
Distant 23 20.81 2 6.59 0.112; 0.310 (0.073, 1.315) 
0.136; 0.332 (0.078, 
1.417) 
Adjuvant chemotherapy 
Overall 57 20.96 18 26.16 0.405; 1.253 (0.737, 2.130) 
0.891; 1.039 (0.603, 
1.788) 
Local 12 4.41 3 4.36 0.865; 0.897 (0.255, 3.153) 
0.500; 0.645 (0.181, 
2.303) 
Regional 15 5.52 6 8.72 0.333; 1.598 (0.619, 4.125) 
0.843; 1.102 (0.421, 
2.885) 
Distant 30 11.03 9 13.08 0.664; 1.179 (0.561, 2.480) 
0.100; 1.000 (0.463, 
2.159) 
Hormone therapy 
Overall 69 10.45 17 15.94 0.112; 1.541 (0.906, 2.623) 
0.949; 1.020 (0.568, 
1.830) 
Local 15 2.27 2 1.87 0.676; 0.731 (0.169, 3.172) 
0.290; 0.332 (0.043, 
2.558) 
Regional 14 2.12 4 3.75 0.369; 1.654 (0.552, 4.959) 
0.580; 1.380 (0.442, 
4.305) 
Distant 40 6.06 11 10.31 0.123; 1.692 (0.868, 3.301) 
0.482; 1.307 (0.619, 
2.757) 
Radiation therapy 
Overall 79 12.62 23 19.34 0.041; 1.612 (1.021, 2.545) 
0.986; 1.004 (0.609, 
1.658) 
Local 22 3.52 6 5.04 0.450; 1.414 (0.575, 3.475) 
0.689; 0.816 (0.302, 
2.205) 
Regional 10 1.6 3 2.52 0.532; 1.503 (0.419, 5.392) 
0.736; 1.264 (0.324, 
4.490) 
Distant 47 7.51 15 12.61 0.065; 1.732 (0.967, 3.100) 
0.810; 1.083 (0.568, 
2.063) 
Adjuvant radiation, hormone, and chemotherapy 
Overall 101 11.94 30 19.63 
0.013; 1.678 (1.115, 
2.524) 
0.015; 1.699 (1.108, 
2.606) 
Local 31 3.66 3 1.96 
0.279; 0.520 (0.159, 
1.698) 
0.145; 0.405 (0.121, 
1.364) 
Regional 19 2.25 7 4.58 
0.104; 2.043 (0.863, 
4.837) 
0.558; 1.310 (0.531, 
3.230) 
Distant 51 6.03 20 13.09 
0.003; 2.164 (1.290, 
3.629) 
0.101; 1.607 (0.912, 
2.833) 
Abbreviation: IR, incidence rate (1000 person-years). 
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).  













  EA AA p value; HR (95% CI) 
p value; HR (95% 
CI) 
  n IR n IR Unadjusted Model Adjusted Model 
Grouped stage 
Early (I-II) 130 11.14 39 19.08 
0.002; 1.793 (1.252, 
2.567) 
0.131; 1.339 (0.917, 
1.956)  
Late (III-IV) 31 55.17 9 50.65 
0.857; 0.934 (0.445, 
1.962) 
0.637; 0.823 (0.366, 
1.850) 
Individual Stage 
I 70 7.76 23 15.84 
0.001; 2.165 (1.348, 
3.476) 
0.031; 1.736 (1.052, 
2.864) 
II 60 22.67 16 27.02 
0.447; 1.239 (0.713, 
2.154) 
0.823; 0.936 (0.523, 
1.674) 
III 25 48.01 7 45.01 
0.902; 0.949 (0.410, 
2.195) 
0.590; 0.774 (0.306, 
1.959) 
IV 6 145.8 2 90.29 
0.822; 0.832 (0.167, 
4.152) 
0.967; 0.964 (0.168, 
5.518) 
TNM Staging 
T             
T0 2 130.83 0 N/A  N/A N/A 
T1 67 9.75 28 25.63 
<0.0001; 2.776 
(1.781, 4.326) 
0.003; 2.009 (1.263, 
3.197) 
T2 54 28.48 11 22.3 
0.504; 0.801 (0.419, 
1.534) 
0.215; 0.647 (0.325, 
1.287) 
T3 12 49.67 1 13.31 
0.215; 0.275 (0.035, 
2.115) 
0.161; 0.228 (0.029, 
1.796) 
T4 9 106.73 4 121.36 
0.680; 1.282 (0.394, 
4.173) 
0.983; 1.015 (0.241, 
4.270) 
N             
N0 101 9.81 31 16.89 
0.005; 1.777 (1.186, 
2.661) 
0.211; 1.319 (0.854, 
2.037) 
N1 44 27.05 12 39.2 
0.201; 1.518 (0.801, 
2.877) 
0.828; 1.079 (0.545, 
2.136) 
N2 13 46.45 4 53.23 
0.744; 1.207 (0.391, 
3.719) 
0.965; 0.970 (0.258, 
3.646) 
N3 5 55.06 1 43.27 
0.742; 0.697 (0.081, 
5.970) 
0.974; 0.962 (0.095, 
9.711) 
M             
M0 157 12.82 46 20.8 
0.002; 1.682 (1.210, 
2.338) 
0.288; 1.210 (0.851, 
1.721) 
M1 6 145.8 2 90.29 
0.822; 0.832 (0.167, 
4.152) 
0.967; 0.964 (0.168, 
5.518) 
Abbreviation: IR, incidence rate (1000 person-years). 
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).  




Figure 2.1 NH demographics, breast clinico-pathological characteristics, and treatment 
compared between patients with or without tumor recurrence.  
(A) The numbers and percentages of patients displaying demographic and (B) breast clinico-
pathological characteristics were compared for patients with (n=225) and without recurrence 
(n=6009). (C) The numbers and percentages of recurrence for both recurrence and non-recurrence 
patients that underwent each form of conventional breast cancer treatment were also compared. 
Significant differences were observed between recurrence and non-recurrence patients displaying 
all clinico-pathological characteristics (p<0.0001), with the exception of nodal status (p=0.012). 
Significant differences were also observed between recurrence and non-recurrence patients 
receiving each form of treatment (p<0.0001), except for radiation therapy (p=0.065). A chi-square 
statistical analysis was used to generate p-values in order to determine significant differences in 
the proportion of patients exhibiting or not exhibiting recurrence in each category. For example, 
regarding grade, a p value of 0.02 represents a significant difference for the distribution of 
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recurrence and non-recurrence patients across all grades. Please refer to Supplementary Table 1 
for details. 
 
Figure 2.2 NH demographics, breast, clinico-pathological and treatment compared between 
AA and EA with tumor recurrence.  
(A) The demographic and (B) clinico-pathological characteristics of AA (n=49) and EA (n=166) 
patients with recurrence in the NH cohort were compared. (C) Treatment administration was also 
compared between AA and EA recurrent breast cancer patients. A chi-square statistical analysis 
was used to generate p-values in order to determine significant differences in the proportion of AA 
and EA patients exhibiting each characteristic and undergoing each form of treatment. No 














Figure 2.3 AA exhibit lower survival duration than EA among recurrent breast cancer 
patients. 
(A) Survival time from first recurrence episode until death was compared between AA and 
EA breast cancer patients. Log-rank analysis was conducted to determine statistical 
differences between the racial groups. AA exhibited a non-significant lower survival time 
than EA (p=0.231). (B) The mean time (days) until death was compared between AA and 
EA breast cancer patients displaying distant recurrence. AA died notably sooner than EA 
patients (p=0.015). A t-test was performed to determine significant differences between the 
racial groups.  
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3 A NOVEL METRIC ILLUMINATES DISTINCTIONS IN CYCLING KINETICS 
AMONG RACIALLY-DISTINCT BREAST TUMORS 
3.1 Abstract 
Breast tumors in African-Americans (AAs) exhibit higher recurrence rates and faster 
kinetic progression to metastasis than those in European-Americans (EAs). This results in a stark 
ethnic disparity in breast cancer outcomes. Hence, enhancing understanding of cell cycle kinetics 
within breast tumors may illuminate motives underpinning racial differences in metastatic 
propensities. Current clinico-pathological prognostic markers that evaluate cell proliferation in 
breast carcinomas include mitotic index (MI) and Ki-67 index (KI). However, as autonomous 
prognosticators measured on distinct scales, MI and KI lack the ability to convey the proportion 
of mitotic cells among cycling cells, undermining their prognostic value. We performed a three-
color immunofluorescence staining on paraffin-embedded AA (n=81) and EA (n=124) breast 
tumor tissue specimens from Northside Hospital to integrate mitotic cells and cycling cells into 
the same measurement scale. Phospho-histone H3 was used as a mitotic marker and Ki-67 as a 
cell proliferation marker. Stained samples were examined with confocal microscopy to determine 
the proportion of mitotic cells to Ki-67 positive cycling cells to yield a Mitosis: Proliferation 
(M:P ratio). We observed higher M:P ratio in AA compared to EA breast tumor tissue specimens 
(p=0.002). We also observed higher M:P ratio in AA compared to grade-matched and stage-
matched EA patients. AA displayed significantly higher M:P ratio than EA among early stage 
breast tumors (p=0.015). Furthermore, among the clinico-pathological parameters, age, race, 
grade, stage, and receptor status, multivariate analysis revealed that race was the only variable 
that exhibited a significant confounding influence on M:P ratio (p=0.042).  Conclusion: A 
higher M:P Ratio likely reflects an increased risk of developing intratumoral heterogeneity and 
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producing aggressive clones; thus, a higher M:P ratio may provide an explanation for the 
observed greater metastatic propensity exhibited in AA compared to EA patients. Thus, our 
novel metric provides new insights into the KI-MI relationship in tumors, exposes previously 
unrecognized differences in cycling kinetics among early stage AA and EA breast tumors, and 
proffers additional metastatic risk predictive information currently unavailable in the clinic.  
3.2 Introduction 
Despite the vast array of cliniopathological prognostic markers available in clinics today, 
African Americans (AAs) exhibit a 39% higher mortality rate than EA breast cancer patients(4). 
This stark disparity is explicated by increased tumor metastasis and tumor infiltration among AA 
breast cancer patients (Yancy, et al., 2007). These circumstances underscore the urgent need for 
deeper insight into the biological properties of early stage and low-grade breast tumors. Faster 
tumor kinetic progression underlie the more aggressive behavior exhibited by AA compared to 
EA breast tumors (Yancy, et al., 2007). Thus, procurement of improved perceptions of cell cycle 
kinetics may be beneficial in discerning motives for enhanced metastatic risk in AA breast 
tumors. Previous studies have reported that early stage tumors demonstrate high mitotic turnover 
and this surge in mitotic events promotes an increase in erroneous cell divisions (Laroye and 
Minkin, 1991). Consequently, genomic integrity is compromised, fostering karyotypic diversity 
and spawning the emergence of aggressive clones harboring superior metastatic proficiency 
(Hanahan and Weinberg, et al., 2011). Thus, advanced insight into cell proliferation may be 
critical to disentangling the enigma of varying metastatic propensities among racially-distinct 
breast tumors. With a present lack of markers that can adequately assess risk for tumor 
metastasis, further examination of cell cycle mechanics may generate a promising new direction 
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in enhancing efficacy of existing prognostic markers and illuminate differences among racially 
distinct breast tumors. 
Existing cliniopathological prognosticators that elucidate cell cycle dynamics in breast 
carcinomas include mitotic index (MI) and Ki-67 proliferation index (KI). MI, a component of 
histological grade, signifies actively dividing cells or cells in M phase, thus capturing the 
frequency of mitotic occurrences within a tumor (Reyal, et al., 2012). KI, an independent 
prognostic marker, ascertains cells merely in the cell cycle (G1, S, G2, and M phases), thus 
capturing a holistic view of cell proliferation within lesions (Reyal, et al., 2012). Both indices 
proffer valuable information in stratifying patients into high-risk and low-risk groups for tumor 
metastasis and fatal outcomes. A high MI has been linked to an increased risk of death and 
recurrence irrespective of tumor size and lymph node metastasis and high Ki-67 has been 
associated with worse disease-free survival (DFS) and overall survival (OS) in breast cancer(85, 
141-144). Illumination of mitotic frequency within early stage breast tumors may reflect the 
predisposition of incipient breast lesions acquiring aggressive traits, and thus offers vital 
metastatic risk-predictive information. Evaluation of cell proliferation within a tumor may 
expose inclinations of a tumor to spread and infiltrate distant sites within a patient. A high KI 
and MI  among early stage breast tumors has been reported to be synonymous with a poor patient 
prognosis (Azambuja, et al., 2007, Laroye and Minkin, 1991, Medri, et al., 2003). Additionally, 
clinical studies have observed notably higher MI and KI-67 expression in AA in comparison to 
EA primary breast tumors (Porter, et al., 2004). This knowledge may rationalize the considerably 
higher aggressive behavior exhibited by AA breast tumors than EA breast tumors, thus MI and 
KI serve as useful metastatic risk-predictive markers.  
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Despite the prognostic advantages of these independent parameters and the valuable role 
they play in metastatic risk assessment, MI and KI possess unsettling limitations that spark 
reservations in their ability to accurately assess metastatic dispositions of breast tumors. With 
both indices functioning autonomously, KI and MI portray an incomplete picture of the precise 
relationship of mitotic cells amongst proliferative cells by proffering information on distinct 
aspects of cell cycle progression within a tumor. KI is quantified as a percentage of nuclear Ki-
67 stained invasive carcinoma cells observed in low-power microscopic fields (Reyal, et al., 
2012). In contrast, MI is quantified as the number of mitotic cells per 10 high-power microscopic 
fields within the periphery of the tumor (Elston and Ellis, et al, 1991, Haapasalo, et al., 1989, 
Reyal, et al., 2012). The substantial variations in acquirement of these indices and the vastly 
different fields in which they are perceived deems it difficult to decipher the frequency of 
dividing cells among proliferating cells within breast tumors. This lack of depth poses a limited 
view of cell cycle dynamics within lesions and thus restricts the predictive power of these 
prognosticators for metastatic risk. Furthermore, discordancy between MI and KI scores has been 
observed in some studies. Fluctuations in cell cycle duration during M-phase can influence the 
number of mitoses visualized at different times within the same tumor. Hence, shorter cell cycle 
durations or a large fraction of growing cells may contribute to a faster tumor-doubling time 
thus, the correlation between the number of mitotic events and proliferation rate may be not be 
exactly linear(145). Lee and colleagues recently observed a poor correlation between MIB-1 
(antibody against Ki-67 antigen) and mitotic and phosphorylated histone H3 (pHH3) scores 
among breast adenocarcinomas after adjusting for intratumoral heterogeneity(146). Factors such 
as differences in the proportion of time that a cell spends between the mitotic phase and 
interphase as well as variability in cell cycle time among different tissue and tumor types have 
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been suspected to underlie the discordance(146)  Rossi and colleagues also observed a lack of 
correlation between MI and KI among breast cancer patients(147). In their study, patients with 
discrepancies between MI and KI exhibited a worse prognosis than patients with low MI and KI 
and a better prognosis than patients with high MI and KI. Thus, these findings stress the need for 
joint analyzation of these markers in order to improve risk-prognostication.         
 
In addition to this narrow understanding of the MI and KI relationship in tumors, there 
exist many glitches in MI and KI as independent prognostic markers and illuminators of cell 
proliferation. The accuracy of quantifying mitotic figures within a patient tumor sample is 
consistently jeopardized by extraneous factors present within the tumor microenvironment such 
as, apoptotic bodies and piknotic nuclei, that create an impediment in distinguishing mitotic 
nuclei (Veras, et al., 2009). Delays in fixation of tumor tissue samples can attribute to a 
diminution in accuracy and reproducibility of mitotic counts (Cross, et al., 1990, Diest, et al., 
2004). Furthermore, mitotic counts are often miscalculated owing to exclusion of prophase cells 
during acquirement of mitotic figures (Elston and Ellis, et al, 1991). Despite Ki-67 proliferation 
expression as an acceptable measure of breast cancer outcomes, uncertainties remain in its 
competence as an efficacious prognostic tool in the clinical arena. Ki-67 proliferation index lacks 
dependability with poorly defined and established cut-offs that can effectively stratify breast 
cancer patients into high and low risk groups for tumor proliferation, undermining its strength in 
clinical prognostication (Reyal, et al., 2012, Dowsett, et al., 2011). Moreover, there remains 
ample room for improvement in the acquisition of Ki-67 index owing to discrepancies in 
interpretation of Ki-67 immunohistochemical staining (Dowsett, et al., 2011).  These 
shortcomings threaten the ability of the two indices to precisely assess cell cycle progression 
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within breast tumors, thus impeding accurate evaluation of metastatic risk in breast cancer 
patients. Hence, this imprecision presents an obstacle in comprehending inconsistencies in 
metastatic rate among AA and EA breast tumors.  
We have developed a novel metric that rationalizes the inconsistencies and limitations of 
MI and KI as autonomous prognosticators and the lack of depth these indices convey in 
elucidating cell cycle mechanics. The metric cleverly integrates MI and KI onto the same 
measurement scale to ascertain the frequency of mitotic cells among Ki-67 positive cycling cells, 
in which we have termed mitosis to proliferation (M:P) ratio. Hence, this novel metric allows 
clinicians to conveniently visualize and assess proliferation and mitotic counts in the same 
microscopic field simultaneously, increasing efficiency and rapidness of evaluating cell cycle 
kinetics among breast cancer patients. Thus, combining their measurement scales may 
significantly strengthen the correlation between MI and KI in the clinic. Furthermore, this 
improved index derives an opportunity to deduce the relationship between mitotic cells and 
proliferating cells within low grade breast tumors, providing an additional layer of predictive 
information that was previously unavailable. Thus, this clinically translatable prognostic tool 
may infer enhanced interpretations of cell cycle kinetics within early stage breast tumors and 
augment clinical inferences of metastatic predispositions of early stage breast lesions. This 
heightened comprehension of metastatic inclinations of incipient breast tumors may improve 
understanding of the perplexing dissimilar metastatic proclivities among AA and EA breast 
tumors. We analyzed differences in M:P ratio between AA and EA breast tumor tissue 
specimens from Northside Hospital (NH) in Atlanta, GA and patient-derived TNBC cell lines to 
evaluate the prognostic ability of M:P ratio among racially-distinct breast tumors. We postulate 
that M:P ratio may reveal notable variations in mitotic tendencies within AA and EA breast 
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tumors and consequently serve as a tool to enhance profiling of metastatic risk among racially 
distinct breast tumors. This enhanced scope of understanding of cell cycle kinetics within breast 
tumors, may aid in unraveling the mystery still puzzling pathologists today that of the 
substantially higher migratory potential harbored by AA breast tumors in comparison to EA 
breast tumors.  
3.3 Results 
3.3.1 Demographic and clinico-pathological variables among racially-distinct breast cancer 
patients 
Descriptive characteristics of the NH patient cohort are provided in Table 1. We 
examined differences in clinico-pathological characteristics between AA (n=81) and EA (n=124) 
breast cancer patients observed at NH. We observed significant differences in nuclear grade 
between the races as 53.1% of AA and 37.1% of EA patients presented as grade 2 and 23.5% of 
AA and 42% of EA patients as grade 3 (p=0.02). We also observed significant differences in 
mitotic index in which 45.7% of AA and 31.45% of EA patients presented with a score of 2 and 
8.6% of AA and 36.3% of EA patients with a score of 3 (p<0.0001). Furthermore, we observed 
weakly significant differences in stage in which 24.7% of AAs presented at late stage (III-IV) 
compared to 21% of EAs (p=0.09).     
3.3.2 A novel metric may predict patient survival 
We derived a novel metric that integrates MI and KI onto the same measurement scale to 
enhance our understanding of cycling kinetics and mitotic propensity among breast tumors. In 
order to combine the two indices into the same field, we performed a 3 color 
immunofluorescence staining on formalin-fixed paraffin-embedded (FFPE) AA and EA breast 
tumor tissue sections from Northside Hospital (NH) in Atlanta, GA as shown in Figure 1A. 
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Histone H3 is a nuclear core histone on DNA chromatin and its serine residues are 
phosphorylated during mitosis to facilitate chromosome condensation hence, metaphase 
chromosomes are heavily phosphorylated as opposed to interphase chromosomes(148, 149). 
Thus, the antibody against pHH3, has been show to strongly correlate with mitotic counts and 
mitotic activity index (MAI)(146, 150). Recently, pHH3 was shown to have significantly better 
reproducibility, predictability and better represent proliferation than Ki-67 and has better 
sensitivity for detecting mitosis than MAI among invasive breast carcinomas(151). Thus, pHH3 
was used as a mitotic marker and Ki-67 as a proliferation marker. The nuclei were stained with 
propidium iodide. The stained samples were imaged using immunofluorescence confocal 
microscopy and approximately 10-12 fields were captured per specimen. The number of mitotic 
and proliferative cells were quantitated and integrated into our proposed mitosis: proliferation 
(M:P) ratio formula, which is the proportion of mitotic cells per field to the total number of Ki-
67 positive cycling cells in the same field (Figure 1B). 
3.3.3 M:P ratio differentiates racially-distinct breast tumors 
M:P ratios were computed in AA (n=81) and EA (n=124) breast cancer patient specimens 
and compared between the racial groups . Interestingly, we observed that M:P ratio was 
significantly higher among AA compared to EA breast cancer patients (p=0.002) (Figure 2A). 
We also observed a trend of higher M:P ratio in AA compared to nuclear grade-matched EA 
breast cancer patients (Figure 2B). M:P ratio was weakly higher in AA compared to EA among 
grade 1 (p=0.1), grade 2 (p=0.08) and grade 3 (p=0.1) breast cancer patients.  Furthermore, we 
observed significantly higher M:P ratio in AA compared to EA among early stage (I-IIa) breast 
cancer patients (p=0.015) but not among late stage (IIb-IV) patients (p=0.2) (Figure 2C). We 
performed a multivariate linear regression analysis to determine if demographic and clinico-
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pathological variables such as age, race, nuclear grade, stage, and receptor status have a 
confounding influence on M:P ratio. Interestingly, we observed that race was the only covariate 
that exhibited a significant confounding influence on M:P ratio (p=0.042) (Table 2).  
3.4 Discussion 
The vast differences in tumor kinetic progression between breast cancer patients of 
African and European ancestry continue to challenge clinicians. Evaluating risk of metastatic 
progression among a heterogeneous breast cancer patient population remains imprecise with 
current clinico-pathological parameters measuring cell proliferation unable to provide an 
accurate assessment of the mitotic propensity of breast tumors. Our study proposes a novel 
metric termed M:P ratio that is able to glean an additional layer of risk-predictive information by 
capturing the frequency of actively dividing cells among the proliferative cell population, which 
has not yet been achieved in the clinic today. Our innovative metric combines the more widely 
accepted marker of mitosis, pHH3, and the most robust marker of proliferation today, Ki-67, 
onto the same uniform measurement scale to discern the cycling kinetics of breast tumors. To 
investigate the clinical utility of our novel metric among breast cancer patients of varying kinetic 
progression, we analyzed differences in M:P ratio between AA and EA breast cancer patients as 
they posit the ideal model system to assess cycling kinetics between aggressive and less 
aggressive breast tumors. 
We observed that M:P ratio differentiates racially-distinct breast cancer patients and AA 
and EA TNBC patient-derived cell lines with a trend of higher M:P ratio among patients of 
African ancestry. M:P ratio was significantly higher in AA compared to EA among early-stage 
breast cancer patients suggesting that AAs may be exhibiting faster cycling kinetics during the 
early stages of the disease, which may be predisposing them to a poorer patient prognosis. 
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Interestingly, our multivariate regression analyses revealed that race was the only variable that 
exhibited a significant confounding influence on M:P ratio. Furthermore, M:P ratio may be able 
to predict a poorer patient prognosis among early-stage breast cancer patients as we found that 
M:P ratio negatively correlated with a poorer overall survival among low grade patients. Thus, 
M:P ratio may be able to serve as a risk-prognostic marker in the clinic and stratify early-stage 
patients into high- and low- risk groups to guide clinical-decision making and optimize treatment 
paths, especially for patients of African ancestry.       
Hence, our study proposes a hitherto untapped parameter of cycling kinetics that may 
transform clinical oncology by refining measurement of cell proliferation in the clinic. MI and 
KI serve as conventional clinical measures of cell proliferation in the clinic today but present 
with many shortcomings prompting the urgent need for more robust clinically-applicable 
parameters that reconcile their weaknesses. M:P ratio serves as an innovative metric that 
successfully rationalizes the limitations of MI and KI as independent parameters and provides an 
additional layer of valuable risk-prognostic information currently unavailable in the clinic today. 
This novel metric is clinically-applicable as it can be measured through conventional 
immunohistochemical staining methods. Moreover, the unique index proffers clinicians a more 
efficient and less time consuming method to successfully assess cell proliferation among breast 
cancer patients by allowing visibility of mitotic and proliferating cell counts in one microscopic 
field. Hence, this novel methodology of employing one measurement scale may strengthen the 
correlation between mitotic and proliferating cell counts, reduce inter- and intra- observer 
variability and refine risk-prognostication. As mentioned earlier, recent studies have suggested 
that pHH3 marker is a more accurate assessment of mitosis in tumors compared to mitotic 
activity index and is more reproducible than Ki-67 alone thus, our novel index may glean a more 
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accurate assessment of the actively dividing cell population(151, 152). Furthermore, our study 
utilized the ideal model to investigate differences in cycling kinetics between aggressive and less 
aggressive breast tumors by examining disparities in M:P ratio between AA and EA breast 
cancer patients. Thus, our investigation further rationalizes the poorer clinical outcomes 
observed among AA patients and uncovers a novel risk-predictive metric that may enhance 
prognostication among patients of varying tumor kinetic progression. However, validation of the 
prognostic and predictive power of M:P ratio among additional cohorts will be necessary to 
implementing the metric into the clinic as standard routine assessment of cycling kinetics among 
breast cancer patients.   
3.5 Methods 
3.5.1 Breast tumor tissue specimens 
Clinical data on breast cancer patients treated at Northside Hospital (NH) from 2005-
2015 in Atlanta, Georgia was extensively mined from pathology reports. A plethora of breast 
clinico-pathological information and outcome data were extracted from pathology reports on 
10,504 patients evaluated at NH. Demographic characteristics documented include race, gender, 
and age. Breast tumor clinico-pathological variables extracted include nuclear grade, mitotic 
score, stage, Nottingham grade, and Ki-67 percentage. The outcome data acquired include OS. 
Archival formalin-fixed, paraffin-embedded tissue specimens were provided by NH to 
accompany clinical patient data. Research Collaborative Agreements were instituted with NH 
who consented to supplementing our mined clinical patient data with tumor tissue specimens. 




3.5.2 Immunofluorescence tissue staining and confocal microscopy  
Formalin-fixed, paraffin-embedded tissue sections were incubated at 60°C-70°C for 2h, 
followed by 2 xylene washes (5 min each) and sequential ethanol washes (100%, 95%, 70% and 
50%). Antigen retrieval was carried out in citric acid buffer (pH 6.0) at 98°C for 20 min. Slides 
were allowed to cool down and blocked in 5% BSA/PBS (30 min). Tissue sections were then 
incubated for 1h with a cocktail of rat anti-human pHH3 antibody (1:500) (Abcam, Cambridge, 
UK) and mouse anti-human DM1A (α-tubulin, 1:1000) (Sigma-Aldrich, MO, USA) followed by 
donkey anti-rat Alexa 488 (1:2000) and goat anti-mouse Cy5 (1:2000) (Invitrogen, Grand Island, 
NY) secondary antibody incubation for 1h at room temperature. Slides were then washed 3 times 
in PBS followed by 1h incubation with rabbit anti-human Ki67 (1:1000) (Abcam, Cambridge, UK) 
and goat anti-rabbit Alexa 405 (Invitrogen, 1:2000) secondary antibody incubation for 1h at room 
temperature. Slides were again washed 3 times in PBS followed by incubation with Propidium 
Iodide (0.1ug/ml) for 15 min at room temperature and washing in PBS. Finally, coverslips were 
mounted on the slides using Prolong Antifade mounting medium (Invitrogen, Grand Island, NY). 
Zeiss LSM 700 confocal microscope was used to capture immunofluorescence images at 63X 
objective magnification. Approximately, 10-12 randomly selected fields were captured per sample.  
3.5.3 Cell lines  
All cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-236, HCC1143, HCC1937, 
HCC1187, HCC38, HCC70, HCC1806, DU4475, MFM-223, BT-549, BT-20) were procured from 
American Type Cell Culture (ATCC) and cultured according to ATCC recommendations.  
3.5.4 Cell lysates preparation and immunoblotting  
Cell lysates were collected after cells reached ~80% confluence and lysed with 1x lysis 
buffer (Cell Signaling) as previously described(153). Protein concentration in cell lysates was 
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determined using Bradford Protein Assay (BioRad) and spectrometry. Cell lysates were resolved 
in 10% SDS-PAGE gels as previously described(154). SuperSignal West Pico Chemiluminescent 
Substrate (ThermoScientific) was used to visualize the bands. PARP, Hif-1a, and E-cadherin 
primary antibodies were obtained from BD Biosciences. Cyclin-E, Centrin-2, VEGF, Vimentin, 
uPAR, RAD51, MMP9, p53, and β-actin primary antibodies were obtained from Santa Cruz 
Biotech. γ-tubulin, PLK4, pericentrin, integrin-α2, MMP2, and ALDHA1 primary antibodies were 
obtained from Abcam. p21 and CD44 antibodies were obtained from Cell Signaling. Secondary 
antibodies were obtained from Abcam. Protein expression was semi-quantitated using 
densitometry with the ImageJ Software and normalized to β-actin.  
3.5.5 Cell viability assay  
All cell lines were treated with gefitinib (LC Laboratories) and carboplatin (Abcam). 
Sensitivities of cell lines to these drugs were assessed by performing MTT assay as previously 
described(155). IC50 values were computed using GraphPad Prism Software Inc.      
3.5.6 Immunocytochemistry staining and FACS  
AA and EA TNBC cell lines were seeded into triplicates and fixed in 70% ethanol once 
cells reached ~80% confluence. Cells were blocked with 2% bovine serum albumin (BSA) in 1x 
PBS and 0.05% Triton X-100 at room temperature for 1 h. Cells were then incubated in the 
antibodies anti-Ki-67 PE (BioLegend) and anti-pHH3 conjugated to AlexaFluor488 (Sigma) 
diluted in blocking buffer at 1:1000 for 45min in 37°C. Antibodies were rinsed from cells with 
1x PBS 5 times and then cells were incubated in 7-Aminoactinomycin D (7-AAD) (BioLegend) 
(0.25µg/ml) for 10 min at room temperature to stain DNA. The stained cells were subjected to 
FACS to isolate the populations of pHH3 and Ki-67 positively stained cells for each cell line. 
The single cell population was first gated for the total number of 7-AAD positive cells. The 
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population of 7-AAD positive cells was then gated for the number of cells positive for Ki-67 and 
the percentage of cells positive for Ki-67 was determined.  The cells positive for Ki-67 were then 
gated for cells positive for pHH3 and the percentage of cells positive for pHH3 was determined. 
FlowJo V10 software was used to analyze the data. Dot plots of side scatter area (SSC-A) were 
plotted.  
3.5.7 Statistical Analyses  
Chi-square tests were performed to analyze differences in breast clinico-pathological 
variables, biomarkers, and treatment information between AA and EA breast cancer patients. A 
one-tailed student t-test was performed to analyze significant differences in M:P ratios, protein 
expression, and drug sensitivities between 2 groups. A multivariate regression analysis was 
performed to evaluate potential confounding influences of demographic and clinico-pathological 
variables on M:P ratio. A linear regression plot was constructed to determine association of M:P 
ratio with overall survival (OS). SAS 9.4 program was used to perform hierarchical clustering to 
stratify TNBC cell lines into high and low M:P ratio subgroups by using Ward’s method to 
identify an ideal threshold value of 2.02. Results with p<0.05 were considered statistically 
significant.  


























Table 3.2 Multivariate regression analysis of demographic and clinico-pathological 





Figure 3.1 Quantitation of M:P ratio among breast tumors. Confocal micrographs of positive 
staining for pHH3 (mitotic marker), Ki-67 (proliferation marker) and propodium iodide (PI) in 
breast tumor tissue specimens in same field from NH (A). M:P ratio equation integrating the 
number of mitotic and proliferating cells in same field to yield the proportion of mitotic cells 




Figure 3.2 Comparison of M:P ratio among racially-distinct breast tumors. Comparison of 
M:P ratio among all (A), grade-matched (B) and stage-matched (C) AA and EA breast tumor 
tissue specimens. *p<0.05. **p<0.01. 
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4 CENTROSOME AMPLIFICATION IN BREAST CANCER: A BIOMARKER OF 
AGGRESSIVE DISEASE FEATURES AND RACIAL DISPARITIES 
4.1 Abstract 
Centrosome amplification (CA), a key property of malignant tumor cells, has emerged as 
a marker of breast cancer (BC) aggressiveness that is highly associated with triple-negative BC 
(TNBC). TNBC is a BC subtype that disproportionately afflicts African American (AA) women. 
However, the association of CA with TNBC molecular subtypes and self-reported race, the value 
of CA as an independent risk-predictive biomarker in early-stage TNBC, and the mechanisms by 
which CA may drive aggressive TNBC behavior remains under-studied. Using confocal 
microscopy, we quantitatively compared numerical CA profiles in a panel of race-annotated non-
TNBC and TNBC cell lines of different subtypes based on AR expression and TNBC molecular 
subtypes. We then compared race-annotated patient non-TNBCs and TNBCs of different AR 
expression levels and molecular subtypes in terms of their CA20 - an established signature of 20 
genes implicated in CA - and evaluated the prognostic value of CA20 in multivariate Cox models 
of disease-free survival (DFS) using public gene expression data. To discern mechanisms by which 
CA may fuel aggressive TNBC behavior, we induced CA in TNBC cell lines with aphidicolin and 
assessed expression of protein biomarkers of BC aggressiveness. Numerical CA was higher in 
TNBC than non-TNBC in vitro analyses and CA20 was higher among AA compared to EA BCs. 
Furthermore, high CA20 as a continuous variable predicted worse DFS in early-stage TNBC 
patients in adjusted analysis (p=0.03, hazard ratio=1.20). Induction of CA in TNBC cell lines 
upregulated expression of markers of angiogenesis and epithelial-mesenchymal transition (EMT) 
suggesting that CA may promote TNBC aggressiveness through these mechanisms. Collectively, 
these findings support an association between numerical CA and more aggressive TNBC features, 
70 
 
poorer DFS among early-stage BC patients and AA race. Our study also reveals novel mechanisms 
by which CA may promote aggressive TNBC behavior. Hence, our work suggests CA as a risk-
predictive biomarker for TNBC patients that may also represent a viable therapeutic target.  
4.2 Introduction 
TNBC accounts for approximately 10-30% of invasive BC cases in the U.S. It is a unique 
BC subtype that lacks expression of the estrogen and progesterone receptors and amplification of 
the human epidermal growth factor receptor 2 (HER2/neu). The absence of these targets 
eliminates conventional endocrine therapy and HER2-targeted systemic treatments as therapeutic 
options and traditional chemotherapy is unable to eradicate most TNBCs. The disease is 
characterized by an aggressive clinical course, evidenced by its greater metastatic propensity, 
more unfavorable clinico-pathological characteristics upon presentation, and higher inter-patient 
and intratumor heterogeneity compared with non-TNBCs [1-3]. The disease is significantly more 
prevalent among premenopausal women and predominantly afflicts women of African ancestry, 
who experience poorer clinical outcomes than EA TNBCs. Currently, no reliable biomarkers or 
effective targeted treatments exist for TNBC patients; thus, AA TNBC patients often suffer 
abysmal outcomes. Novel biomarkers to risk-stratify TNBC patients, ideally ones that also 
represent possible therapeutic targets, are urgently needed to identify patients requiring more 
aggressive treatment regimens so that mortality rates can be reduced in these patients. CA is a 
hallmark of BC that causes ITH by fostering erroneous mitoses, which drive genetic instability 
and the generation of diverse karyotypes [4, 5]. It is well established that CA is associated with 
BC progression and imparts aggressive phenotypes, thus representing a possible anti-cancer 
target [6-11]. Furthermore, TNBCs harbor greater incidence and severity of CA than non-TNBCs 
[12, 13], although the potential prognostic and therapeutic value of CA in TNBC is unclear. The 
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goal of the present study was to shed light on the potential of CA as a biomarker of aggressive 
TNBC features and poor DFS, and mechanisms by which CA may promote TNBC progression, 
which could be exploited therapeutically. 
4.3 Results 
4.3.1 TNBC cell lines exhibit higher numerical CA than non-TNBC cell lines  
Our group recently uncovered more extensive numerical CA and more severe structural 
centrosomal aberrations in several TNBC compared to non-TNBC cell lines [12]. In this study, we 
quantitated numerical centrosomal profiles in a more extensive panel of established cell lines 
derived from TNBCs (n=10) and non-TNBCs (n=2). We found a non-significant trend towards 
higher numerical CA in TNBC compared with non-TNBC cell lines (p=0.10) (Figures 1A and 
B). We also assessed the severity of numerical CA in each cell line (i.e., the percentage of cells 
with 3, 4, or 5+ centrosomes) and discovered that TNBC cell lines exhibit a non-significant trend 
towards more severe numerical CA, with a higher percentage of cells with 4 centrosomes 
(p=0.056) and ≥5 centrosomes (p=0.07) (Figure 1C). We immunoblotted TNBC and non-TNBC 
cell lines for expression of centrosomal proteins and CA markers. We observed significantly 
higher expression of γ-tubulin (p=0.049) and Cyclin-E (p=0.034) in TNBC compared to non-
TNBC cell lines (Figure 1D). We also observed a trend of higher pericentrin expression in TNBC 
compared to non-TNBC cell lines (p=0.08). Furthermore, we assessed whether there were 
differences in expression of KIFC1, a minus-end directed microtubule binding protein that 
participates in centrosome clustering [23], between TNBC and non-TNBC cell lines. Interestingly, 




4.3.2 Aggressive TNBC subtypes exhibit higher numerical CA than less aggressive TNBC 
subtypes  
Accumulating evidence has exposed the vastly heterogeneous landscape of TNBC. 
Lehmann and colleagues uncovered six distinct intrinsic molecular subtypes in the disease based 
on shared gene ontologies (“TNBCtype”), including basal-like 1 (BL1), basal-like 2 (BL2), 
mesenchymal stem cell-like (MSL), mesenchymal (M), immunomodulatory (IM), and luminal 
androgen receptor (LAR) subtypes [24]. The IM and MSL subtypes in patient TNBCs may reflect 
gene expression profiles of substantial infiltrating lymphocytes and stromal cells, respectively 
[19], which led to refinement of the classification scheme (“TNBCtype-4”) [19]. We compared 
centrosomal profiles between TNBC cell lines of different molecular subtypes (representative 
micrographs in Figure 2A). Interestingly, we observed that BL1 and MSL TNBC cell lines 
exhibited higher numerical CA than BL2, M, and LAR TNBC cell lines, with the exception of 
MDA-MB-438 cell line (p=0.016) (Figure 2B). BL1 and MSL TNBC cell lines also exhibited 
more severe numerical CA than BL2, MSL, M, and LAR TNBC cell lines, specifically, exhibiting 
a greater percentage of cells with ≥5 centrosomes (p=0.01) (Figure 2C). We also found that BL1 
TNBC cell lines exhibited significantly higher numerical CA than BL2, MSL, M and LAR TNBC 
cell lines, with the exception of MDA-MB-468 cell line (p=0.036) (Figure 2D) and BL1 TNBC 
cell lines exhibited a trend towards a greater proportion of cells with 4 or ≥5 centrosomes (p=0.089 
and 0.10, respectively) (Figure 2E). Furthermore, western blot analyses revealed a weakly 
significant trend of higher g-tubulin expression in BL1 and MSL compared to BL1, MSL, M, LAR, 
and IM TNBC cell lines (p=0.059) (Figure 2F) and significantly higher g-tubulin expression in 
BL1 compared to BL2, MSL, M, LAR, and IM TNBC cell lines (p=0.015) (Figure 2G). These 
results suggest that CA may be more extensive and severe in BL1 and/or MSL TNBCs.  
73 
 
4.3.3 Racial disparities in numerical CA exist between AA and EA TNBC cell lines  
Women of African ancestry are 2-3 times more likely to develop TNBC than women of 
European ancestry [1]. Distinctions in inherent tumor biology between the races have been 
suggested to underlie this disparate burden; however, there is a limited understanding of the 
biological factors contributing to the racial disparity in TNBC. Thus, we were interested to see if 
disparities in centrosomal profiles exist between AA and EA TNBCs (representative 
micrographs in Figure 3A). Interestingly, we found that EA TNBC cell lines exhibited a greater 
percentage of cells with numerical CA than AA TNBC cell lines (p=0.01) (Figure 3B). 
Furthermore, EA TNBC cell lines exhibited more severe CA, with a greater percentage of cells 
with 4 (p=0.007) or ≥5 (p=0.029) centrosomes than AA TNBC cell lines (Figure 3C). However, 
immunoblotting for centrosome structural proteins and markers of CA revealed that AA TNBC 
cell lines exhibited higher expression of pericentrin (p=0.027) and Cyclin-E (p=0.024) (Figure 
3D). Furthermore, we assessed whether there were differences in expression of KIFC1 between 
AA and EA TNBC cell lines. Interestingly, we found higher expression of this marker in AA 
than EA TNBC cell lines (p=0.05) (Figure 3D). This finding suggests that centrosome clustering 
may be more robust in AA than EA TNBC cell lines cells. Thus, we investigated the sensitivity 
of AA and EA TNBC cell lines to the centrosome declustering agent, griseofulvin (Figure 4). 
We observed that AA TNBC cell lines exhibited significantly lower IC50 values to griseofulvin 
than EA TNBC cell lines (79.5 vs. 105.7) (p=0.04), suggesting greater sensitivity to centrosome 
declustering agents among AA TNBCs and corroborating our findings of higher KIFC1 
expression and increased centrosome clustering among AA compared to EA TNBC cell lines.   
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4.3.4 CA20 is higher in more aggressive BC subtypes  
Previoulsy, our group developed a transcriptional signature that may reflect CA and 
correlates with chromosomal instability and worse prognosis in multivariable models, referred to 
as the CA20 score, which is the sum of the normalized expression of 20 genes whose dysregulation 
causes CA [1]. To confirm our in vitro findings, we used publicly available microarray data to 
compute CA20 scores and determine differences between AA and EA BCs, TNBCs and non-
TNBCs, and among TNBC subtypes. TCGA Breast dataset includes annotation about the variables 
of interest; thus, we queried it using Oncomine [2] to obtain normalized expression values for the 
CA20 genes, which were summed as previously described to derive CA20 scores [1]. CA20 was 
higher for AAs than EAs among all BC patients (p=0.008) (Figure 5A). However, AAs are 
predisposed to TNBC, which exhibits higher CA20 than non-TNBC [2]. CA20 is also associated 
with more aggressive disease features, such as higher tumor grade [18].  As a result, TNBC status 
and other aggressive disease features like TNBC status, higher tumor stage (for both TNBCs and 
non-TNBCs), HER2+ status (for non-TNBCs), low AR expression (for both TNBCs and non-
TNBCs), and TNBC molecular subtype (for TNBCs) could confound analyses. Due to non-
homogeneity of variances between BC subtypes, we only explored differences in CA20 within BC 
subtypes. We found a non-significant trend towards different mean CA20 by AJCC stage within 
non-TNBCs, which exhibited higher mean CA20 in higher-stage cases (p=0.095), and within 
TNBCs, which exhibited higher CA20 in lower-stage cases (p=0.063) (Figure 5Bi,ii). CA20 was 
also higher in HER2+ than HER2- non-TNBCs (p=0.004) (Figure 5C). Thus, amongst non-
TNBCs, CA20 is higher in more aggressive subtypes. 
We were interested to compare mean CA20 between racially distinct non-TNBCs and 
TNBCs after adjusting for potentially confounding factors. As CA20 was found to differ 
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significantly based on HER2 and AR statuses among non-TNBCs, and a non-significant trend was 
also noted for AJCC stage, we included these factors along with self-reported race in a generalized 
linear model to predict CA20. Tests of between-subjects effects revealed that AJCC stage was not 
a significant predictor (p=0.37), whereas all other factors exhibited p<0.10. Considering this 
finding and that CA20 did not significantly differ by stage in unadjusted models, were removed 
stage from the model and refit it. Among non-TNBCs, we found that CA20 was higher in AA than 
EA tumors (p=0.054, adjusted mean=26.41 vs. 22.65) and HER2+ than HER2- tumors (p=0.001, 
adjusted mean=26.68 vs. 22.37) (Table 1). Although the difference in the adjusted mean CA20 by 
race did not reach the threshold for significance, the observed power was low (0.49), likely due to 
the small number of AA TNBCs (n=11). By contrast, the observed powers for other factors and 
the corrected model were ≥0.89. In addition, full-factorial models did not reveal any interactions 
among factors (p>0.20 for all). Thus, among non-TNBCs, CA may be higher in breast tumors from 
AA patients and in the setting of HER2 positivity. When these factors are considered, CA20 does 
not differ by AJCC stage.  
We also fit generalized linear models to predict CA20 among TNBCs adjusting for race 
and stage. Among TNBCs, AJCC stage did not significantly predict CA20 although a non-
significant trend was noted (p=0.075, with the trend in the same direction as noted in unadjusted 
analyses). By contrast, CA20 did not differ by race according in the adjusted model (p=0.92), but 
the analysis was severely underpowered to detect a racial difference (observed power=0.051). 
Thus, we sought a different dataset to explore racial differences, the Yale TNBC dataset. The 
CA20 distribution was approximately normal for EA patients, whereas it was non-normal for AA 
patients (p=0.013), exhibiting two distinct peaks, which we suspected existed due to some 
underlying grouping, such as lymph node status. Indeed, a trend towards different nodal status by 
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race was found (p=0.092), with AAs exhibiting a higher frequency of node-positive disease. In 
addition, CA20 was higher in node-positive than node-negative TNBCs from AA patients 
(p=0.016) (Figure 5D), suggesting it could be a confounding factor in analyses of racial 
differences. Because only 2 node-positive EA TNBCs were present in the dataset, we decided to 
focus exclusively on node-negative disease in exploring racial differences in CA20 using this 
dataset. Among node-negative TNBCs, we found that CA20 was higher in EA than AA cases 
(p=0.034, mean rank=22.00 vs. 14.63) (Figure 5E). Thus, in the case of node-negativity, EA 
TNBCs may exhibit higher CA20 than AA TNBCs, which supports our in vitro results of higher 
numerical CA in EA compared with AA among TNBC cell lines.  
Unlike the TCGA data, the Yale data showed that mean CA20 may differ by TNBCType6 
(p<10-6). Specifically, the MSL and LAR subtypes exhibited lower CA20 than the other TNBC 
subtypes (p<0.05 for all per Tukey’s HSD post-hoc testing, Figure 5F; Table 2). These results 
support our in vitro finding of higher numerical CA among BL1 TNBCs. Lower CA20 among 
LAR TNBCs also corroborates our in vitro results of higher CA being associated with TNBCs 
lacking AR expression. We compared mean CA20 between node-negative AA and EA TNBCs 
after adjusting for TNBCType and did not detect a significant difference (p=0.21), although the 
mean was higher in EA than AA TNBCs; however, the analysis was underpowered to detect a 
difference (observed power=0.24).  
4.3.5 High CA20 predicts poorer survival among early stage BC patients 
Finally, we were interested to test the ability of CA20 to stratify early-stage BCs regardless 
of subtype in terms of DFS. In univariate Cox models, higher CA20 score (continuous and 
categorical) predicted significantly worse DFS (p=0.026, HR=1.047, and p=0.013, HR=2.85, 
respectively) (Table 3). In multivariate Cox models, only CA20 (continuous or dichotomized by 
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the mean) was a significant predictor, with all other covariates eliminated from the final model. 
This finding suggests that higher CA20, rather than the other covariates considered, uniquely 
confers poor DFS among early-stage BC patients.  
4.3.6 CA promotes aggressiveness in TNBC in vitro 
CA has long been associated with chromosomal instability, aneuploidy, and mitotic spindle 
abnormalities [31]. Greater centrosomal aberrations has recently been associated with enhanced 
cell migration in BC patient specimens as well as in cultured cell lines [32]. However, the precise 
role of CA in TNBC remains elusive. We induced CA in TNBC cell lines, MDA-MB-468 and 
MDA-MB-231, and immunoblotted cells for markers of angiogenesis and EMT to investigate the 
role of CA in TNBC (Figure 6). Upregulation of CA was confirmed through immunoblotting for 
centrosome structural proteins and CA markers for which we observed ≥4-fold increased 
expression. Interestingly, in the MDA-MB-468 cell line there was ~2.7-fold increase in expression 
of angiogenesis markers (Fig 6A) and ~2.1-fold increase in expression of EMT markers with the 
exception of E-cadherin, which exhibited an ~1.5 fold decrease in expression (Fig 6B). Our results 
also suggest more robust upregulation of angiogenesis and metastasis markers upon induction of 
CA in the AA TNBC cell line, MDA-MB-468, compared with the EA TNBC cell line, MDA-MB-
231. These observations suggest that CA may be promoting disease progression in AA and EA 
TNBCs via different mechanisms. 
4.4 Discussion 
The limited availability of prognostic biomarkers and therapeutic strategies for TNBC 
contributes to the significant disparity in outcomes between TNBC and non-TNBC patients and 
underscores the need for (a) novel, alternative biomarkers that can predict the risk of a more 
aggressive disease course in patients, and (b) new and robust therapeutic targets to slow or prevent 
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disease progression in TNBC patients. Our study investigated the role of CA in TNBC to support 
the viability of CA as a potential risk-predictive biomarker in TNBC. A strength of our study is 
that a variety of TNBC cell lines of different molecular subtypes and derived from racially-distinct 
patients was used, although a limitation of any study of cell lines is generalizability to patient 
populations. Indeed, our group recently reported discordance in CA between patient tumors and 
patient-derived cancer cell lines [15]. Thus, to corroborate our in vitro work, we analyzed patient 
tumor data as well, another strength of our study, although it may have been underpowered to 
detect racial differences among TNBCs. At present, we are not aware of any publicly available 
microarray datasets with a large sample of race-annotated TNBCs, for which there is an urgent 
unmet need.  
Our study is the first study to compare CA between molecular TNBC subtypes, uncovering 
more extensive and severe numerical CA among BL1 and MSL TNBC cell lines, which was 
corroborated by analysis of patient TNBCs. Our results are consistent with previous studies 
reporting the BL1 TNBC subtype to be associated with AA race [22, 33]. Keenan and colleagues 
found that BL1 and MSL tumors were more present among AA compared to EA TNBCs. Lindner’s 
group reported that transcriptional features of BL1 subtype correspond to AA TNBC tumors and 
transcriptional features of MSL and LAR correspond to EA TNBC tumors. AA TNBC cell lines 
also exhibited evidence of enhanced clustering, which may empower cancer cells with enhanced 
migratory ability and foster the acquisition of more aggressive cellular phenotypes [28, 34-36]. 
Given the literature detailing the role of CA and clustering in promoting aggressive behavior of 
TNBC cells and our finding that higher CA20 is an independent predictor of poor DFS in early-
stage TNBC, targeting TNBCs with numerical CA and centrosome clustering may be a promising 
therapeutic strategy. Collectively, our findings suggest that AA TNBCs may be more susceptible 
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to centrosome declustering drugs than EA TNBCs, and it is imperative that preclinical models 
testing declustering drugs consider race. 
The precise mechanisms in which CA may be promoting aggressive TNBC remain under 
investigation. To gain deeper insights into how CA may be contributing to rapid progression in 
TNBC, we induced CA in TNBC cell lines and evaluated the effect on various markers of BC 
aggressiveness. Interestingly, upon induction of CA we observed a significant upregulation of 
angiogenesis and EMT markers, suggesting a role of CA in upregulating these processes in TNBC. 
Our results corroborate our recent findings revealing that CA strongly correlates with expression 
of the metastasis marker, vimentin, in breast tumor tissue samples, as well as with enhanced 
migration and invasion in TNBC in vitro [30]. Our work is also the first to provide evidence of a 
direct association of CA and key angiogenesis molecules in TNBC cells suggesting novel 
mechanisms excessive centrosomes may be employing to promote tumor progression in TNBC. 
Interestingly, we also observed racial differences in these markers following induction of CA, with 
BC angiogenesis and EMT markers significantly more upregulated in the AA TNBC cell line. Our 
study lays the foundation for larger studies investigating whether mechanisms by which CA may 
promote TNBC progression differ based on race. Future studies evaluating the role of CA in TNBC 
patient specimens with accompanying patient clinico-pathological variables and clinical outcomes 
would be necessary to establish CA as a robust risk-predictive and prognostic biomarker for TNBC 
patients.  
CA is a cancer-cell specific trait that distinguishes them from normal, healthy cells [46]. 
Thus, targeting CA offers a minimally cytotoxic therapeutic strategy that selectivity targets cancer 
cells burdened with severe centrosomal aberrations. Conveniently, there are already rationally 
designed drugs that selectively kill cancer cells harboring CA and are currently under clinical 
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evaluation as promising anti-cancer therapeutics. These novel agents include putative centrosome 
declustering drugs such as griseofulvin and noscapine, commercially available HSET inhibitors 
such as CW069 and AZ82, and poly-ADP ribose polymerase inhibitors such as PJ34 and GF-15 
[28, 47-51]. Hence, these agents may aid in abrogating an aggressive disease course in TNBC 
patients, perhaps in particular AA TNBC patients. Furthermore, non-invasive methods that can 
detect centrosomal status (i.e. fine-needle aspirate cytology, immunohistochemistry) may 
demonstrate feasibility in the clinic for selecting TNBC patients that will exhibit susceptibility to 
these agents. Thus, assessing CA in the clinic may provide a novel strategy to stratify TNBC 
patients into high- and low- risk groups for an aggressive disease course and allow for optimization 
of treatment plans. According to our results, CA-targeting agents may be particularly promising 
therapeutic options for QNBC and BL1 TNBC patients. These agents may serve as a novel 
alternative therapeutic target for TNBC patients exempt from receiving AR-targeted therapy as 
well as potentially attenuate racial disparities in BC and TNBC.  
4.5 Methods 
4.5.1 BC cell lines 
All cell lines, including TNBC cell lines (MDA-MB-231, MDA-MB-468, HCC1143, 
HCC1937, HCC38, HCC70, HCC1806, DU4475, MFM-223, BT-549, BT-20) and non-TNBC 
(MCF-7, T47D) cell lines, were procured from American Type Cell Culture (ATCC) and cultured 
according to ATCC recommendations.  
4.5.2 Cell lysate preparation and immunoblotting 
Cell lysates were collected after cells reached ~80% confluence and lysed with 1x lysis 
buffer (Cell Signaling) as previously described [14]. Protein concentration in cell lysates was 
determined using Bradford Protein Assay (BioRad) and spectrometry. Cell lysates were resolved 
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in 10% SDS-PAGE gels as previously described [15]. SuperSignal West Pico Chemiluminescent 
Subtrate (ThermoScientific) was used to visualize the bands. PARP, Hif-1a, and E-cadherin 
primary antibodies were obtained from BD Biosciences. Cyclin-E, Centrin-2, VEGF, Vimentin, 
uPAR, RAD51, MMP9, p53, and β-actin primary antibodies were obtained from Santa Cruz 
Biotech. γ-tubulin, PLK4, pericentrin, integrin-α2, MMP2, and ALDHA1 primary antibodies were 
obtained from Abcam. p21 and CD44 antibodies were obtained from Cell Signaling. Secondary 
antibodies were obtained from Abcam. Protein expression was semi-quantitated using 
densitometry with the ImageJ Software and normalized to β-actin.  
4.5.3 Immunoflourescence staining 
Cells were seeded onto glass coverslips. After reaching ~80% confluence, cells were fixed 
in ice-cold methanol. Coverslips were blocked in 2% bovine serum albumin (BSA) in 1x PBS and 
0.05% Triton X-100 at room temperature for 1 h. Coverslips were incubated in primary antibodies 
for g-tubulin (Abcam) and a-tubulin (Sigma-Aldrich) diluted in blocking buffer at 1:1000 for 
45min in 37°C. Coverslips were incubated in Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 
555 goat anti-mouse secondary antibodies (Invitrogen) diluted in blocking buffer at 1:3000 for 
40min in 37°C. Primary and secondary antibodies were washed from cover slips with 1x PBS. 
Cover slips were incubated in Hoechst (Life Technologies) at room temperature for 10 min and 
mounted with Prolong Gold Antifade Reagent (Invitrogen). DU4475 is a suspension cell line and 
thus, was not assessed for numerical CA in this study.  
4.5.4 Numerical CA Quantitation 
Cells were imaged with the Zeiss LSC 700 confocal microscope using 63x objective 
(Oberkochen, Germany). All images were processed with Zen software (Oberkochen, Germany). 
Approximately 250-300 randomly selected cells were counted per cell line. The percentage of cells 
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exhibiting numerical CA (i.e., >2 centrosomes) and multipolar mitoses (i.e., mitotic spindles with 
>2 poles) were quantitated in each cell line. In addition, the severity of CA was assessed by 
quantitating the percentage of cells with 3, 4, or ³5 centrosomes in each cell line.  
4.5.5 Induction of CA 
Each cell line was seeded in duplicate. After reaching ~70% confluence, cells were treated 
with 25 µM aphidicolin from Nigrospora sphaerica (Sigma-Aldrich) for 72 h to induce CA 
through S-phase arrest. Cells treated with solvent containing no drug were used as a negative 
control. Cell lysates were collected after 24-36 h. Induction of CA was confirmed through 
immunoblotting for centrosomal proteins (g-tubulin, centrin-2, and pericentrin) and CA markers 
(Cyclin-E, PLK4).  
4.5.6 Cell viability assay 
 AA (MDA-MB-468 and HCC1806) and EA (BT-20, HCC1143, and MDA-MB-231) 
TNBC cell lines were treated with griseofulvin (Sigma-Aldrich). Sensitivities of cell lines to 
griseofulvin were assessed through MTT assay as previously described[30]. IC50 values were 
computed using GraphPad Prism Software Inc. Griseofulvin concentrations versus percentage of 
cell survival was plotted for each cell line using GraphPad Prism Software, Inc.    
4.5.7 Statistical analysis of in vitro data 
A one-tailed student t-test or one-way ANOVA was performed for analyses comparing 2 
or >2 groups, respectively. Results with p<0.05 were considered statistically significant. 
4.5.7 CA20 analyses 
Datasets: To determine whether CA20 differs between breast cancers from AAs and EAs, 
we queried the Cancer Genome Atlas (TCGA) breast dataset [16] using Oncomine [17] to obtain 
normalized expression values of CA20 genes, which were summed as previously described to 
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derive CA20 scores [18]. Metastases, normal breast samples, male breast cancers, and ductal 
carcinomas in situ were excluded, resulting in n=524 cases. Annotation about TNBC status, TNBC 
subtype, PAM50, and PAM50lite data were obtained from Lehmann et al. [19], except for one 
missing case (TCGA-E2-A14W), the annotation for which was obtained from cBioPortal [20, 21]. 
All other demographic and clinical annotation was obtained from cBioPortal. Publically available 
ER/PR/HER2 IHC data was used to determine TNBC status. HER2 status was determined by IHC 
results, but for cases with equivocal or indeterminate IHC values, FISH was used instead. The 
Yale TNBC dataset [22] was downloaded from GEO (accession GSE46581), and TNBCType6 
values for this dataset were obtained using the TNBCtype tool [20].  
Statistical analysis: Levene’s test was used to assess equality of variances between groups. 
The Shapiro-Wilk test was used to assess whether samples derived from normally distributed 
populations. Exploratory analysis of TCGA breast data revealed the CA20 distribution for EA 
TNBCs was non-normal, exhibiting negative skew and leptokurtosis; however, after trimming the 
bottom 5% of CA20 values (n=3 cases), the distribution was approximately normal, and so this 
5% trimmed dataset was used for all subsequent analyses. Exploratory analysis of the Yale TNBC 
data revealed a single outlier in the BL1 TNBC subtype, so the outlier-trimmed dataset was used 
for all subsequent analyses. CA20 was compared between groups using parametric (independent-
samples, 2-tailed t-test or one-way ANOVA) or non-parametric (Mann-Whitney or Kruskall-
Wallis tests) depending on satisfaction of test assumptions. For significant ANOVA tests, Tukey’s 
HSD post-hoc testing was performed. The association between categorical variables (race, nodal 
status, and TNBC) was assessed using Fisher’s exact test due to the small sample size of TNBCs. 
The relationship between CA20 and AR expression was found to be non-monotonic based on 
examination of scatterplots; thus, AR groups were defined based on expression levels. To obtain 
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adjusted mean CA20 values for non-TNBCs, generalized linear models of main effects were fit 
after ensuring satisfaction of assumptions, with CA20 as the dependent variable and including 
potentially confounding factors (i.e., with p<0.10). DFS was computed as the time in months from 
initial treatment to the event (recurrence or progression) or last follow-up for censored cases. We 
tested the impact of high CA20 (continuous or categorized based on the mean) on DFS among 
early-stage (i.e., AJCC stage I/II) BC patients in univariate and multivariate Cox models adjusted 
for self-reported race and other potentially confounding factors, first ensuring non-violation of the 
proportional hazards assumption for all covariates by entering each one as a time-dependent 
covariate in univariate Cox models. Kaplan-Meier product-limit DFS estimates were plotted for 
categorical CA20 groups, and differences in DFS times were tested using the log-rank test. 
Univariate Cox models of DFS were fit including CA20 (continuous) or CA20 (mean as a cutpoint) 
for early-stage BC patients of all subtypes. In addition, multivariate Cox models were fit entering 
relevant clinicopathologic and demographic covariates, including ER, PR, and HER2 statuses; 
nodal status (+/-); tumor size (2 cm cutpoint); PAM50 type (Normal-Like, Luminal A, Luminal B, 
HER2-enriched, or Basal-Like); AR status (10th percentile cutpoint); race (AA or EA); and age at 
diagnosis (continuous), subject to backward stepwise elimination if p≥0.10. In addition, we tested 
the impact of CA20 score on DFS among early-stage TNBCs using Kaplan-Meier analysis with 
the log-rank test and univariate and Cox regression. Covariates with p<0.10 in univariate Cox 
models were entered into multivariate models. Observed power was computed using α=0.05. IBM 
SPSS v. 21 was used and results with p<0.05 were considered statistically significant. 





Table 4.1 Adjusted mean difference in CA20 scores among non-TNBCs based on the race and 






Table 4.2 Turkey post-hoc testing of mean CA20 scores by TNBC subtypes. 
CI=Confidence Interval; SE=Standard Error 
Table 4.1 Adjusted mean difference in CA20 scores among non-TNBCs based on race and 















AA 3.76 1.95 -0.07 7.59 0.054 0.49 

















BL1 BL2 4.7499 3.4768 .747 -5.455 14.955 
M 5.7671 2.8709 .349 -2.659 14.193 
MSL 19.6127* 3.1607 .000 10.336 28.890 
IM 3.9741 2.7954 .714 -4.231 12.179 
LAR 19.7339* 4.0870 .000 7.738 31.730 
BL2 
BL1 
-4.7499 3.4768 .747 -14.955 5.455 
M 
1.0172 3.3969 1.000 -8.953 10.987 
MSL 
14.8628* 3.6451 .002 4.164 25.562 
IM -.7758 3.3334 1.000 -10.560 9.008 
LAR 14.9840* 4.4722 .016 1.858 28.110 
M 
BL1 -5.7671 2.8709 .349 -14.193 2.659 
BL2 -1.0172 3.3969 1.000 -10.987 8.953 
MSL 13.8456* 3.0726 .000 4.827 22.864 
IM -1.7930 2.6954 .985 -9.704 6.118 
LAR 13.9667* 4.0192 .011 2.170 25.764 
MSL BL1 -19.6127* 3.1607 .000 -28.890 -10.336 
BL2 -14.8628* 3.6451 .002 -25.562 -4.164 
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Only final model covariates are given. BC=Breast Cancer; CI=Confidence Interval; HR=Hazard 










Figure 4.1 Quantitation of numerical CA in TNBC and non-TNBC cell lines.  
A. Representative immunofluorescent confocal micrographs of TNBC and non-TNBC cell lines 
stained for centrosomes (g-tubulin, green), microtubules (a-tubulin, red), and nuclei (using 
Hoechst, blue). B. Comparison of the prevalence of numerical CA in TNBC and non-TNBC cell 
lines. C. Comparison of the severity of numerical CA between TNBC and non-TNBC cell lines. 
250-300 cells were counted per cell line. D. Western blots comparing centrosomal protein and CA 






Figure 4.2 Quantitation of numerical CA in TNBC cell lines of different molecular subtypes.  
A. Representative immunofluorescent confocal micrographs of TNBC cell lines stained for 
centrosomes (g-tubulin, green), microtubules (a-tubulin, red), and DNA (Hoechst, blue). B. 
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Quantitation of the extent of numerical CA in BL1 and MSL cell lines compared to that in BL2, 
M, and LAR TNBC cell lines. C. Quantitation of the severity of CA (i.e., the percentage of cells 
with 3, 4, or 5+ centrosomes) in BL1 and MSL cell lines compared to that in BL2, M, and LAR 
TNBC cell lines. D. Quantitation of the prevalence of numerical CA in BL1 cell lines compared 
to its prevalence in cell lines from all other TNBC molecular subtypes. E. Quantitation of the 
severity of CA (i.e., the percentage of cells with 3, 4, or 5+ centrosomes) in BL1 cell lines and its 
comparison with that in all other TNBC subtypes. F. Western blots comparing g-tubulin expression 
between BL1 and MSL and BL2, M, LAR, and IM TNBC cell lines. G. Western blots comparing 
g-tubulin expression between BL1 and MSL, BL2, M, LAR, and IM TNBC cell lines. *p<0.05, 




Figure 4.3 Quantitation of numerical CA in AA and EA TNBC cell lines.  
A. Representative immunofluorescent confocal micrographs of EA and AA TNBC cell lines 
stained for centrosomes (g-tubulin, green), microtubules (a-tubulin, red), and DNA (Hoechst, 
blue). B.  Quantitative comparison of the percentage of cells with numerical CA between EA and 
AA TNBC cell lines. C. Quantitative comparison of the severity of CA (i.e., the percentage of 
cells with 3, 4, or 5+ centrosomes) between EA and AA TNBC cell lines. D. Western blots in EA 







Figure 4.4 Sensitivity of AA and EA TNBC cell lines to griseofulvin.  
MTT assays were performed on AA and EA TNBC cell lines and IC50 values were compared 
between the racially-distinct cell lines. i. Comparison of IC50 values from griseofulvin treatment 
between AA and EA TNBC cell lines. ii. Plot of percent cell survival vs concentration (uM) in 






Figure 4.5 Differences in CA20 scores between groups of BC patients.  
A-C: TCGA data, D-F: Yale data. A. Boxplots of CA20 by race among all breast cancer subtypes 
(Mann-Whitney test p=0.008, mean rank=244.55 vs. 193.90; median=27.22 vs. 23.36; in AAs and 
EAs, respectively); B. Bar graphs of mean CA20 by AJCC stage in (i) non-TNBCs (ANOVA 
p=0.095, means=19.01, 21.60, 22.37, and 23.39, respectively, for stages I-IV, respectively) and 
(ii) TNBCs (ANOVA p=0.063, means=31.59, 32.63, 28.84, and 26.11, for stages I-IV, 
respectively). C. Boxplots of CA20 by HER2 status in non-TNBCs (Mann-Whitney test p=0.004, 
mean rank=160.1 vs 126.7; median =20.64 vs. 24.40, in HER- vs. HER2+ cases). D. Boxplots of 
CA20 by lymph node (LN) status in AA TNBCs (Mann-Whitney test p=0.016, mean rank=20.55 
vs. 12.58; median=192.45 vs. 209.81; for LN- and LN+ cases, respectively). E. Boxplots of CA20 
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by race among LN- TNBCs (Man-Whitney test p=0.034, mean rank=14.63 vs. 22.00; 
median=192.45 vs. 203.10, for AAs and EAs, respectively). F. Means plot from ANOVA of CA20 
by TNBCType. For all bar graphs, error bars reflect +/- 2X standard error. Open circles in boxplots 







Figure 4.6 Induction of CA in TNBC in vitro and expression of proteins involved in disease 
progression.   
Western blots using MDA-MB-468 and MDA-MB-231 TNBC cell lines of proteins associated 
with A. angiogenesis and B. EMT. “C” denotes untreated cells (controls) and “T” denotes cells 
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5 CENTROSOME AMPLIFICATION AS A NOVEL BIOMARKER OF QUADRUPLE 
NEGATIVE BREAST CANCER DISEASE 
5.1 Abstract 
Centrosome amplification (CA), a key property of malignant tumor cells, has emerged as 
a marker of breast cancer (BC) aggressiveness that is highly associated with triple-negative BC 
(TNBC). Although controversial, the absence of androgen receptor (AR) expression in TNBC, or 
quadruple negative breast cancer (QNBC), has been reported to confer a more aggressive disease 
course. However, the role of CA in QNBC and the mechanisms by which CA may be driving 
aggressive QNBC behavior remains under-studied. Using confocal microscopy, we quantitatively 
compared numerical CA profiles in a panel of AR-positive and AR-negative TNBC cell lines. We 
then compared CA20 - an established signature of 20 genes implicated in CA – between QNBC 
and TNBC patients and evaluated the prognostic value of CA20 in multivariate Cox models of 
disease-free survival (DFS) using public gene expression data. To discern mechanisms by which 
CA may fuel aggressive QNBC behavior, we induced CA in a QNBC and TNBC cell line with 
aphidicolin and assessed aggressive BC biomarkers. Numerical CA was higher in AR-negative 
than AR-positive TNBC in in vitro analyses, findings that were substantiated by gene expression 
studies of CA20 in patient BCs. Furthermore, high CA20 as a continuous variable predicted worse 
DFS in early-stage TNBC patients in adjusted analysis (p=0.03, hazard ratio=1.20). Induction of 
CA in TNBC cell lines upregulated expression of markers of BC stem cells and the DNA damage 
response, suggesting that CA may promote TNBC aggressiveness through these mechanisms. 
Collectively, these findings support an association between numerical CA and QNBC disease and 
poorer DFS among early-stage TNBC patients. Our study also reveals novel mechanisms by which 
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CA may promote aggressive QNBC behavior. Hence, our work suggests CA as a potential risk-
predictive biomarker for QNBC patients that may also represent a viable therapeutic target.  
5.2 Introduction 
TNBC accounts for approximately 10-30% of invasive BC cases in the U.S. It is a unique 
BC subtype that lacks expression of the estrogen and progesterone receptors and amplification of 
the human epidermal growth factor receptor 2 (HER2/neu). The absence of these targets eliminates 
conventional endocrine therapy and HER2-targeted systemic treatments as therapeutic options and 
traditional chemotherapy is unable to eradicate most TNBCs. The disease is characterized by an 
aggressive clinical course, evidenced by its greater metastatic propensity, more unfavorable 
clinico-pathological characteristics upon presentation, and higher inter-patient and intratumor 
heterogeneity compared with non-TNBCs [1-3]. The disease is significantly more prevalent among 
premenopausal women and predominantly afflicts women of African ancestry who, according to 
some studies, experience a more aggressive disease course and poorer clinical outcomes than EA 
TNBCs [1, 4, 5]. Currently, no reliable biomarkers or effective targeted treatments exist for TNBC 
thus, patients often suffer abysmal outcomes. Thus, alternative risk-prognostic and therapeutic 
targets are urgently needed to successfully manage the disease.  
Androgen receptor (AR) has recently emerged as a promising alternative therapeutic target 
for TNBC patients. AR is expressed in approximately 10-43% of TNBCs depending on the 
threshold of positivity used[6]. Knockdown and inhibition of AR with enzalutamide among AR-
expressing TNBCs resulted in a reduction in proliferation, migration, invasion and an increase in 
apoptosis[7-9]. Also, Traina and colleagues observed that enzaluatmide elicited a clinical benefit 
rate (CBR) of 25% at 24 weeks and a median progression-free survival (PFS) of 14.7 weeks among 
AR-positive TNBC patients but a CBR of only 20% at 24 weeks and a median PFS of 12.6 weeks 
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among patients with less AR expression in a nonrandomized phase II clinical trial (unpublished 
data). The AR antagonist, bicalutamide, also performed well in a phase II clinical trial as the drug 
elicited a CBR of 19% at 24 weeks and a median PFS of 12 weeks among AR-positive TNBC 
patients[10]. However, the remaining 76-90% of TNBCs that lack expression of AR, often referred 
to as quadruple negative breast cancer (QNBC), may not be as sensitive to these novel AR-targeted 
agents. Furthermore, some studies have reported that a lack of AR expression in TNBC confers a 
more aggressive disease course[11-16]. Moreover, a lack of AR expression has been observed to 
be more prevalent among TNBC patients of African compared to European ancestry[17]. Thus, 
this subgroup of TNBC patients are even more at a disadvantage than AR-positive TNBC patients 
and are in urgent need for alternative biomarkers and treatment options.       
CA is a hallmark of BC that causes ITH by fostering erroneous mitoses, which drive genetic 
instability and the generation of diverse karyotypes [18, 19]. It is well established that CA is 
associated with BC progression and imparts aggressive phenotypes, thus representing a possible 
anti-cancer target [20-25]. Emerging evidence suggest that TNBCs harbor greater incidence and 
severity of CA than non-TNBCs and that CA underlies an aggressive disease course among 
TNBCs [26, 27]. However, the role of CA in QNBC and it’s a potential as an alternative biomarker 
and therapeutic target in the disease remains elusive. In this study, we investigate the potential 
prognostic and therapeutic value of CA in QNBC and mechanisms by which CA may promote 
QNBC progression, which could be exploited therapeutically. ‘ 
5.3 Results 
5.3.1 Numerical CA is higher in AR-negative compared to AR-positive TNBC cell lines 
As previously mentioned, a subset of TNBCs lack expression of AR and are classified as 
AR-negative or QNBCs, which exhibit a more basal-like molecular subtype, are more common 
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among individuals of African ancestry, are not susceptible to AR-targeted therapy, and are 
characterized by poor DFS [41-43]. Hence, we were interested to determine if QNBCs exhibit 
more numerical CA than TNBCs (representative micrographs in Figure 1A). We compared 
numerical CA between QNBC and TNBC cell lines and found that numerical CA was higher in 
QNBC cell lines (p=0.050) (Figure 1B). We also found that QNBC cell lines exhibited a greater 
proportion of cells with ≥5 centrosomes than TNBC cell lines (p=0.037) (Figure 1C). We also 
tested whether numerical CA differs between QNBCs, TNBCs, and non-TNBCs and uncovered a 
non-significant trend towards increasing numerical CA with decreasing hormone receptor 
expression (p=0.10) (Figure 1D). We found that the percentage of cells with or ≥5 centrosomes 
increased with decreasing hormone receptor expression as well (p=0.039) (Figure 1E). The effects 
of AR signaling on centrosome homeostasis in BC are unknown, but our study suggests AR loss 
is associated with CA in TNBC. 
5.3.2 CA20 is higher in AR-low compared to AR-high expressing TNBCs 
Previoulsy, our group developed a transcriptional signature that may reflect CA and 
correlates with chromosomal instability and worse prognosis in multivariable models, referred to 
as the CA20 score, which is the sum of the normalized expression of 20 genes whose dysregulation 
causes CA [1]. To confirm our in vitro findings, we used publicly available microarray data to 
compute CA20 scores. TCGA breast dataset includes annotation about the variables of interest; 
thus, we queried it using Oncomine [2] to obtain normalized expression values for the CA20 genes, 
which were summed as previously described to derive CA20 scores [1].  
CA20 was higher in AR-low than AR-high non-TNBC cases (p=0.002) (Figure 3A; Table 
1). Thus, amongst non-TNBCs, CA20 is higher in more aggressive subtypes. We also discovered 
that CA20 was higher in the AR-low group among TNBCs when the 10th percentile was used 
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(p=0.013, mean rank=56.88 vs. 36.32) (Figure 3B). This finding supports our in vitro results of 
higher CA being associated with QNBC.  
5.3.3 High CA20 predicts poorer survival among early stage TNBC patients 
Finally, we were interested in testing the ability of CA20 to stratify early-stage TNBCs 
regardless of subtype in terms of DFS. Among early-stage TNBCs, higher CA20 score 
(continuous) was associated with worse DFS in univariate analysis (p=0.040, HR=1.16) and 
multivariate analysis (p=0.013, HR=1.23) (Table 2) with the exception of age at diagnosis 
(p=0.11). The QNBC patient sample size was too small to analyze for survival. Thus, higher CA20 
score (continuous) may offer reliable prognostic information among early-stage TNBC patients 
regardless of commonly considered clinicopathologic and demographic information. We 
suspected categorizing based on mean CA20 score among early-stage TNBCs was not ideal 
because TNBCs have very high CA20 scores (relative to non-TNBCs), and the threshold at which 
these high levels confer poor prognosis may be lower than the mean value among TNBCs.   
5.3.4 CA promotes aggressiveness in QNBC in vitro  
CA has long been associated with chromosomal instability, aneuploidy, and mitotic spindle 
abnormalities [45]. Greater centrosomal aberrations have recently been associated with enhanced 
cell migration in BC patient specimens as well as in cultured cell lines [46]. However, the precise 
role of CA in TNBC and QNBC remains elusive. We induced CA in the TNBC cell line, MDA-
MB-468, and the QNBC cell line, MDA-MB-231, by arresting the cells in S-phase with 
aphidocolin treatment and immunoblotted each cell line for markers of stem cells (i.e. CD44, 
ALDHA1, Integrin-α) and DNA damage (PARP, p53, RAD51, p21) to investigate the role of CA 
in AR-low and AR-high expressing TNBC cell lines (Figure 4). Upregulation of CA was 
confirmed through immunoblotting for centrosome structural proteins and CA markers for which 
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we observed ≥4-fold increased expression. Interestingly, in the MDA-MB-468 cell line there was 
~2-fold increase in expression of stem cell markers (Fig 4A) and ~2.3 fold increase in expression 
of DNA damage markers (Fig 4B). In MDA-MD-231 cells there was a ~4-fold increase in DNA 
damage markers. The results suggest a potential role of CA in TNBC aggressiveness via this 
mechanism. Our results also suggest more robust upregulation of stem cell, angiogenesis, and 
metastasis markers upon induction of CA in the TNBC cell line, MDA-MB-468, compared with 
the QNBC cell line, MDA-MB-231. Conversely, there was notably more upregulation of DNA 
damage markers observed in the QNBC compared to the TNBC cell line.   
5.4 Discussion 
The recent emergence of QNBC disease has left this novel subgroup of TNBCs with an 
even more limited availability of prognostic biomarkers and therapeutic strategies than AR-
positive TNBC. Although, controversial, some studies suggest that lack of AR expression confers 
a more aggressive disease course which underscores the need for (a) novel, alternative biomarkers 
that can predict the risk of a more aggressive disease course and (b) new and robust therapeutic 
targets to slow or prevent disease progression in QNBC patients. Our study investigated the role 
of CA in QNBC to support the viability of CA as a potential risk-predictive biomarker and 
therapeutic target in QNBC. Indeed, our group recently reported discordance in CA between 
patient tumors and patient-derived cancer cell lines [29]. Thus, to corroborate our in vitro work, 
we analyzed patient tumor data as well.  
Our study is the first to compare centrosome profiles in TNBCs based on AR status, 
uncovering more extensive and severe CA in the AR-negative subgroup.  
The precise mechanisms in which CA may be promoting aggressiveness in QNBC remain 
elusive. To gain deeper insights into how CA may be contributing aggressive disease in QNBC, 
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we induced CA in MDA-MB-231 and MDA-MB-468 QNBC and TNBC cell lines, respectively 
and evaluated the effect on various markers of BC aggressiveness. Interestingly, upon induction 
of CA we observed a significant upregulation of stem cell, angiogenesis, DNA damage, and EMT 
markers in both cell lines, suggesting a role of CA in upregulating these processes in TNBC. Our 
work is consistent with previous literature reporting a link between CA and DNA damage in BC. 
As previously mentioned, several studies have suggested that CA drives chromosomal instability 
to foster tumor progression [45, 48, 49]. Aberrant function of tumor suppressor genes involved in 
the DNA repair pathway, such as p53 and BRCA1/2, have been associated with amplified 
centrosomes and subsequent erroneous cell division in BC cell lines [18, 19, 45]. Our results also 
corroborate our recent findings revealing that CA strongly correlates with expression of the 
metastasis marker, vimentin, in breast tumor tissue samples, as well as with enhanced migration 
and invasion in TNBC in vitro [30]. Denu et. al recently observed a decrease in CD24 expression 
and increase in CD44 expression upon induction of CA in normal breast epithelial cells by PLK4 
overexpression[27]. However, our work is also the first to provide evidence of a direct association 
of CA and key stem cell and angiogenesis molecules in TNBC cells suggesting novel mechanisms 
excessive centrosomes may be employing to promote tumor progression in TNBC. Approximately 
30% of TNBCs are chemosensitive and achieve a complete pathological response to neoadjuvant 
chemotherapy, however the remaining 70% of TNBC patients often succumb to residual disease 
and relapse, which underlies their poorer clinical outcomes compared with other subtypes of BC 
patients [50, 51]. Cancer stem cells have been implicated in drug resistance and relapse from 
chemotherapy in BC [52-56]; thus, upregulation of stem cell markers upon induction of CA in 
TNBC cell lines may reveal a potential role of CA in chemoresistance in TNBC. Further validation 
of a link between CA and stem cell generation may support screening of early-stage TNBC patients 
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for centrosomal status to allow for early risk-prediction of patient response to chemotherapy. An 
early detection of an unfavorable response to chemotherapy may prompt clinicians to recommend 
the addition of CA-targeting agents to chemotherapy regimens to elicit a more robust response and 
prevent TNBC patients from experiencing relapse. However, DNA damage markers were notably 
more regulated in the QNBC compared to the TNBC cell line suggesting the DNA damage 
response pathway may be particularly more active in QNBC tumors.  
CA is a cancer-cell specific trait that distinguishes them from normal, healthy cells [57]. 
Thus, targeting CA offers a minimally cytotoxic therapeutic strategy that selectivity targets cancer 
cells burdened with severe centrosomal aberrations. Conveniently, there are already rationally 
designed drugs that selectively kill cancer cells harboring CA and are currently under clinical 
evaluation as promising anti-cancer therapeutics. These novel agents include putative centrosome 
declustering drugs such as griseofulvin and noscapine, commercially available HSET inhibitors 
such as CW069 and AZ82, and poly-ADP ribose polymerase inhibitors such as PJ34 and GF-15 
[58-63]. Hence, these agents may aid in abrogating an aggressive disease course in QNBC and 
BL1 TNBC patients in addition to platinum-based drugs. Furthermore, non-invasive methods that 
can detect centrosomal status (i.e. fine-needle aspirate cytology, immunohistochemistry) may 
demonstrate feasibility in the clinic for selecting QNBC patients that will exhibit susceptibility to 
these agents. Thus, assessing CA in the clinic may provide a novel strategy to stratify QNBC 
patients into high- and low- risk groups for an aggressive disease course and allow for optimization 
of treatment plans. Thus, these agents may serve as a novel alternative therapeutic target for TNBC 
patients exempt from receiving AR-targeted therapy. However, future studies evaluating the role 
of CA in QNBC patient specimens with accompanying patient clinico-pathological variables and 
clinical outcomes would be critical to establishing CA as a robust risk-predictive and prognostic 
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biomarker for QNBC patients. 
5.5 Methods 
5.5.1 BC cell lines 
All cell lines, including TNBC cell lines (MDA-MB-231, MDA-MB-468, HCC1143, 
HCC1937, HCC38, HCC70, HCC1806, DU4475, MFM-223, BT-549, BT-20) and non-TNBC 
(MCF-7, T47D) cell lines, were procured from American Type Cell Culture (ATCC) and cultured 
according to ATCC recommendations.  
5.5.2 Cell lysate preparation and immunoblotting 
Cell lysates were collected after cells reached ~80% confluence and lysed with 1x lysis 
buffer (Cell Signaling) as previously described [28]. Protein concentration in cell lysates was 
determined using Bradford Protein Assay (BioRad) and spectrometry. Cell lysates were resolved 
in 10% SDS-PAGE gels as previously described [29]. SuperSignal West Pico Chemiluminescent 
Subtrate (ThermoScientific) was used to visualize the bands. PARP, Hif-1a, and E-cadherin 
primary antibodies were obtained from BD Biosciences. Cyclin-E, Centrin-2, VEGF, Vimentin, 
uPAR, RAD51, MMP9, p53, and β-actin primary antibodies were obtained from Santa Cruz 
Biotech. γ-tubulin, PLK4, pericentrin, integrin-α2, MMP2, and ALDHA1 primary antibodies were 
obtained from Abcam. p21 and CD44 antibodies were obtained from Cell Signaling. Secondary 
antibodies were obtained from Abcam. Protein expression was semi-quantitated using 
densitometry with the ImageJ Software and normalized to β-actin.  
5.5.3 Immunoflourescence staining 
Cells were seeded onto glass coverslips. After reaching ~80% confluence, cells were fixed 
in ice-cold methanol. Coverslips were blocked in 2% bovine serum albumin (BSA) in 1x PBS and 
0.05% Triton X-100 at room temperature for 1 h. Coverslips were incubated in primary antibodies 
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for g-tubulin (Abcam) and a-tubulin (Sigma-Aldrich) diluted in blocking buffer at 1:1000 for 
45min in 37°C. Coverslips were incubated in Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 
555 goat anti-mouse secondary antibodies (Invitrogen) diluted in blocking buffer at 1:3000 for 
40min in 37°C. Primary and secondary antibodies were washed from cover slips with 1x PBS. 
Cover slips were incubated in Hoechst (Life Technologies) at room temperature for 10 min and 
mounted with Prolong Gold Antifade Reagent (Invitrogen). DU4475 is a suspension cell line and 
thus, was not assessed for numerical CA in this study.  
5.5.4 Numerical CA Quantitation 
Cells were imaged with the Zeiss LSC 700 confocal microscope using 63x objective 
(Oberkochen, Germany). All images were processed with Zen software (Oberkochen, Germany). 
Approximately 250-300 randomly selected cells were counted per cell line. The percentage of cells 
exhibiting numerical CA (i.e., >2 centrosomes) and multipolar mitoses (i.e., mitotic spindles with 
>2 poles) were quantitated in each cell line. In addition, the severity of CA was assessed by 
quantitating the percentage of cells with 3, 4, or ³5 centrosomes in each cell line.  
5.5.5 Cell viability assay 
QNBC and TNBC cell lines were treated with griseofulvin (Sigma-Aldrich). Sensitivities 
of cell lines to griseofulvin were assessed through MTT assay as previously described[30]. IC50 
values were computed using GraphPad Prism Software Inc. Griseofulvin concentrations versus 
percentage of cell survival was plotted for each cell line using GraphPad Prism Software, Inc.    
5.5.6 Induction of CA 
Each cell line was seeded in duplicate. After reaching ~70% confluence, cells were treated 
with 25 µM aphidicolin from Nigrospora sphaerica (Sigma-Aldrich) for 72 h to induce CA 
through S-phase arrest. Cells treated with solvent containing no drug were used as a negative 
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control. Cell lysates were collected after 24-36 h. Induction of CA was confirmed through 
immunoblotting for centrosomal proteins (g-tubulin, centrin-2, and pericentrin) and CA markers 
(Cyclin-E, PLK4).  
5.5.7 Statistical analysis of in vitro data 
A one-tailed student t-test or one-way ANOVA was performed for analyses comparing 2 
or >2 groups, respectively. Results with p<0.05 were considered statistically significant. 
5.5.8 CA20 analyses 
Datasets: To determine whether CA20 differs between QNBC and TNBC patients, we 
queried the Cancer Genome Atlas (TCGA) breast dataset [31] using Oncomine [32] to obtain 
normalized expression values of CA20 genes, which were summed as previously described to 
derive CA20 scores [33]. Metastases, normal breast samples, male breast cancers, and ductal 
carcinomas in situ were excluded, resulting in n=524 cases. Publically available ER/PR/HER2/AR 
IHC data was used to determine TNBC status. The Yale TNBC dataset [37] was downloaded from 
GEO (accession GSE46581) [35].  
Statistical analysis: Levene’s test was used to assess equality of variances between groups. 
The Shapiro-Wilk test was used to assess whether samples derived from normally distributed 
populations. CA20 was compared between groups using parametric (independent-samples, 2-
tailed t-test or one-way ANOVA) or non-parametric (Mann-Whitney or Kruskall-Wallis tests) 
depending on satisfaction of test assumptions. For significant ANOVA tests, Tukey’s HSD post-
hoc testing was performed. The association between categorical variables (race, nodal status, and 
TNBC) was assessed using Fisher’s exact test due to the small sample size of TNBCs. The 
relationship between CA20 and AR expression was found to be non-monotonic based on 
examination of scatterplots; thus, AR groups were defined based on expression levels. DFS was 
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computed as the time in months from initial treatment to the event (recurrence or progression) or 
last follow-up for censored cases. We tested the impact of high CA20 (continuous or categorized 
based on the mean) on DFS among early-stage (i.e., AJCC stage I/II) TNBC patients in univariate 
and multivariate Cox models adjusted for self-reported race and other potentially confounding 
factors, first ensuring non-violation of the proportional hazards assumption for all covariates by 
entering each one as a time-dependent covariate in univariate Cox models. Univariate Cox models 
of DFS were fit including CA20 (continuous) or CA20 (mean as a cutpoint) for early-stage BC 
patients of all subtypes. In addition, multivariate Cox models were fit entering relevant 
clinicopathologic and demographic covariates, including ER, PR, and HER2 statuses; nodal status 
(+/-); tumor size (2 cm cutpoint); PAM50 type (Normal-Like, Luminal A, Luminal B, HER2-
enriched, or Basal-Like); AR status (10th percentile cutpoint); and age at diagnosis (continuous), 
subject to backward stepwise elimination if p≥0.10. Covariates with p<0.10 in univariate Cox 
models were entered into multivariate models. Observed power was computed using α=0.05. IBM 






6 TUMOR-INFILTRATING LYMPHOCYTES AS RISK-PROGNOSTIC 
BIOMARKER AMONG EARLY-STAGE AFRICAN-AMERICAN TRIPLE 
NEGATIVE BREAST CANCER PATIENTS 
6.1 Abstract 
Triple negative breast cancer (TNBC) is defined by a lack of pharmacologically-targetable 
breast cancer biomarkers and disproportionately afflicts and affects African-American (AA) 
women. Tumor-infiltrating lymphocytes (TILs) have been associated with better clinical 
outcomes, response to neoadjuvant chemotherapy (NAC) but more aggressive breast tumor 
features. Among formalin-fixed, paraffin-embedded resection samples, we compared stromal and 
peripheral TILs between early-stage AA and EA TNBC patients at Emory University Hospital in 
Atlanta, GA. We also compared proportions of infiltrating immune subsets and performed 
differential gene expression analyses between AA and EA TNBC patients in a publically available 
gene expression dataset. Among early-stage (I-II) patients (N=103), we observed more stromal 
TILs among AAs (N=71) compared to EAs (N=32) (p=0.02). Among early-stage AA patients, 
stromal TILs correlated negatively with age at diagnosis (ρ=-0.25; p=0.03) and androgen receptor 
expression (ρ=-0.26; p=0.04) and positively with BRCA1-associated protein (ρ=0.30; p=0.02) and 
programmed cell death protein 1 (ρ=0.56; p<0.0001). High peripheral TIL count predicted better 
10-year overall survival (p=0.045; hazard ratio (HR): 0.27; 95% CI:0.08-0.97) and 10-year 
disease-free survival (p=0.027; HR:0.30; 95% CI:0.10-0.87) among early-stage AA patients in 
multivariate analyses. In silico analyses revealed greater proportions of T regulatory cells 
(p=0.046) among AA compared to EA TNBC samples as well as more upregulation of 
proinflammatory genes, gene ontologies, and biological pathways reflecting cytokine activity, 
lymphocyte differentiation, and immune effector processes among AA patients. Our findings 
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uncover previously unrecognized racial disparities in the tumor immune microenvironment among 
triple negative breast tumors and suggests that TILs may serve as a promising risk-prognostic 
biomarker for early-stage AA TNBC patients. 
6.2 Introduction 
Triple negative breast cancer (TNBC) is a highly aggressive breast cancer (BC) subtype 
that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal 
growth factor receptor 2 (HER2/neu) (1). Therefore, TNBC patients do not benefit from 
conventional endocrine and HER2-targeted systemic treatments leaving chemotherapy and 
radiation as the mainstay of treatments (2, 3). African-American (AA) women are 2-3 times more 
prone to developing TNBC and experiencing onset of the disease at a younger age compared to 
European-American (EA) women (4, 5). TNBC patients of African descent also exhibit more 
unfavorable clinico-pathological tumor characteristics, acquire more aggressive TNBC subtypes, 
and display poorer clinical outcomes compared to TNBC patients of European descent (2, 5-11). 
Novel, alternative biomarkers are urgently needed to manage an aggressive disease course and 
reduce mortality rates among this patient population.  
Neoplastic transformation induces tumor-infiltrating lymphocytes (TILs) to migrate to the 
tumor site and control progression (12, 13). TILs that migrate to the tumor stroma are considered 
stromal TILs and TILs that migrate to the stroma adjacent to the invasive tumor front are 
considered to be peripheral TILs (14, 15). Stromal TILs have been associated with improved 
overall survival (OS), increased metastasis-free survival, reduced risk of relapse and reduced 
distance recurrence in TNBC (16). Furthermore, a high level of stromal TILs has been associated 
with improved pathological complete response (pCR) following neoadjuvant chemotherapy 
(NAC), validating TILs as a predictive biomarker in TNBC (15-17). In a non-NAC setting, 
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peripheral TILs have been associated with longer OS and disease-free survival (DFS) among 
TNBC patients in multivariate analyses (14). Paradoxically, the presence of TILs has been 
associated with more aggressive clinico-pathological tumor characteristics in BC such as high 
grade, high stage, high Ki-67, lymph node metastasis, a triple negative breast tumor phenotype, 
and young age at diagnosis (17-23). Thus, we were interested in evaluating if there was a disparity 
in the presence of TILs between AAs and EAs and if TILs can function as a risk-prognostic 
biomarker among TNBC patients of African ancestry. We compared the presence of stromal and 
peripheral TILs between AA and EA TNBC patients, in a non-NAC setting, observed at Emory 
University Hospital (EUH) in Atlanta, GA and assessed the predictive and prognostic value of 
TILs among these patient populations.   
6.3 Results 
6.3.1 Clinico-pathological characteristics among racially-distinct TNBC patients  
We compared clinico-pathological characteristics between AA (N=87) and EA (N=34) 
TNBC patients observed at EUH (Table 1). We observed a significant difference in nuclear grade 
(p=0.04) between AA and EA TNBC patients, with 94.3% of AA and 82.4% of EA patients 
classified as grade 3. A significant difference was observed in mitotic index (p=0.0001) between 
the races wherein which 78.2% of AAs exhibited a score of 3 compared to 38.2% of EAs. We also 
observed significantly higher Nottingham grade in AA compared to EA TNBC patients (p=0.008), 
in which 85.1% of AAs were diagnosed at grade 3 compared to 58.8% of EAs. These findings 
corroborate previous studies reporting higher grade and mitotic index among AA compared to EA 
TNBCs. We also compared BC biomarker expression between AA and EA TNBC patients (Table 
2). We observed significant differences in retinoic acid receptor-α (RARα) (p=0.02) and β-catenin 
(p=0.01) between the racial groups in which 50.6% of AAs and 67.7% of EAs were positive for 
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RARα expression and 80.5% of AAs and 50% of EAs were positive for β-catenin expression. 
Elevated levels of RARα have been associated with more ER-positive compared to ER-negative 
BCs (32). β-catenin has been shown to be required for tumorigenesis of TNBC cells through 
promoting migration, stemness, anchorage-independent growth, and chemosensitivity (33). Like 
TILs, β-catenin has been shown to be more upregulated in TNBCs compared to non-TNBCs and 
both nuclear and cytoplasmic β-catenin expression levels were recently found to positively 
correlate with stromal lymphocytic infiltration in BC, suggesting that Wnt/β-catenin signaling may 
be playing a critical role in BC anti-tumoral immunity (23). Thus, differential expression of these 
markers observed between AA and EA TNBCs may be playing a role in the disparity in clinical 
outcomes between the racial groups.  
6.3.2 AAs harbor more TILs than EAs among early-stage TNBC patients  
We analyzed differences in the presence of stromal and peripheral TILs between AA 
(N=87) and EA (N=34) TNBC patients (Figure 1). We discovered a trend of higher levels of 
stromal TILs in AAs compared to EAs among all TNBC patients (p=0.06) and significantly higher 
among non-adjuvant chemotherapy treated AA compared to EA patients (p=0.01) (Fig 1A). 
Interestingly, among early-stage (I-II) (N=103) TNBC patients, AAs (N=71) harbored 
significantly more stromal TILs than EAs (N=32) (p=0.02) however, not among late-stage (III-
IIIC) (N=18) TNBC patients (p=0.62) (Fig 1B,C). Among non-adjuvant chemotherapy treated 
early-stage TNBC patients, stromal TILs were also higher in AAs compared to EAs (p=0.01) (Fig 
1B). Among radiation and non-radiation treated early-stage TNBC patients, we observed a trend 
of high levels of stromal TILs in AAs than EAs (p=0.07) (Fig1B). We did not observe significant 
differences in peripheral TILs between the races (data not shown).  
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6.3.3 TILs are associated with more aggressive disease features among early-stage AA 
TNBC patients 
We examined associations between stromal TILs (Table 3) and peripheral TILs (Table 4) 
with demographic variables and clinico-pathological parameters among racially-distinct early-
stage TNBC patients to elucidate the prognostic role of TILs among these patient populations. 
Among treated and non-treated early-stage AA and EA patients, stromal and peripheral positively 
correlated with aggressive clinico-pathological features such as higher tubule formation, nuclear 
grade, mitotic index, Ki-67 and Nottingham grade (p<0.05).  However, among early-stage AA 
patients, stromal and peripheral TILs negatively correlated with age at diagnosis (ρ=-0.25; p=0.03 
and ρ=-0.30; p=0.01, respectively) and among early-stage EA patients, high levels of stromal TILs 
were associated with increased lymph node positivity (ρ=0.43; p=0.02) and greater total lymph 
node involvement (ρ=0.45; p=0.01).  
To glean additional insight into the role of TILs in TNBC, we examined if TILs are 
associated with biomarkers routinely assessed among BC patients in the clinic. Correlations of 
stromal and peripheral TILs with breast clinico-pathological biomarker expression among racially-
distinct TNBC patients can be found in Tables 5 and 6, respectively. Among early-stage AA 
patients, stromal TILs negatively correlated with AR expression (ρ=-0.25; p=0.04) and positively 
correlated with PD-1 (ρ=0.56; p<0.0001) and BAP1 (ρ=0.3; p=0.02). However, among early-stage 
EA TNBC patients, stromal TILs positively correlated with BAP1 (ρ=0.44; p=0.03), PD-1 
(ρ=0.43; p=0.02), nuclear HSET (ρ=0.50; p=0.02), and EGFR (ρ=0.58; p=0.004) expression. 
Similar associations were also observed with peripheral TILs except among adjuvant 
chemotherapy treated early-stage AA patients, peripheral TILs negatively correlated with protein 
regulator of cytokinesis 1 (PRC1) expression (ρ=-0.28; p=0.05) and among non-radiation treated 
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early-stage AA patients, peripheral TILs positively correlated with human epidermal growth factor 
receptor 4 (HER4) expression (ρ=0.43; p=0.02). 
6.3.4 High TIL levels predict better survival among early-stage AA TNBC patients 
We next investigated if the presence of TILs is associated with better or worse survival 
among all and racially-distinct TNBC patients. TILs were stratified into high and low subgroups 
and Kaplan-Meier analyses were performed to determine the impact of TILs on 10-year OS 
(Figure 2). We also assessed unadjusted and adjusted associations of peripheral TILs (Table 7) 
with 10-year OS using Cox proportional hazard regression models. Stromal TILs were unable to 
significantly predict OS (data not shown). However, we discovered that high peripheral TIL levels 
predicted better 10-year OS among all patients as well as among radiation treated patients after 
adjusting for age, Nottingham grade, and stage (p=0.019; hazard ratio (HR): 0.344; 95% CI:0.141-
0.838 and p=0.043; HR:0.284; 95% CI:0.084-0.963, respectively). Among all AA patients, high 
peripheral TIL levels also predicted significantly longer 10-year OS in Kaplan-Meier analysis 
(p=0.007) (Fig 2A) and after controlling for age, Nottingham grade, and stage (p=0.003; 
HR:0.229; 95% CI:0.084-0.622). High peripheral TIL levels also predicted longer 10-year OS 
among adjuvant chemotherapy (p=0.015; HR:0.230; 95% CI:0.070-0.755) and radiation (p=0.014; 
HR:0.167; 95% CI:0.040-0.697) treated AA patients irrespective of age, Nottingham grade, and 
stage and in Kaplan-Meier analyses (p<0.05) (Fig 2B,C). Among early-stage AA patients, high 
peripheral TIL levels predicted better 10-year OS after adjusting for age, Nottingham, and stage 
(p=0.045; HR:0.273; 95% CI:0.077-0.969) and in Kaplan-Meier analyses (p=0.05) (Fig 2D). 
Furthermore, high peripheral TIL levels predicted better 10-year OS among non-adjuvant 
chemotherapy treated early-stage AA patients in multivariate (p=0.041; HR:0.031; 95% CI:0.001-
0.865) and Kaplan-Meier analyses (p=0.006) (Fig 2E). High peripheral TIL levels also predicted 
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better 10-year OS among non-radiation treated early-stage AA patients in Kaplan-Meier analyses 
(p=0.04) (Fig 2F). Peripheral TILs were unable to significantly predict OS among EA TNBC 
patients (data not shown).  
We also performed Kaplan-Meier analyses and computed Cox proportional hazard 
regression models to determine the impact of stromal and peripheral TIL levels on DFS over a 5- 
and 10-year period among TNBC patients. High stromal (Table 8) and peripheral (Table 9) TIL 
levels were able to predict significantly better 10-year DFS among radiated-treated AA patients in 
multivariate analyses (p=0.015; HR:0.230; 95% CI:0.070-0.755 and p=0.029; HR:0.31; 95% 
CI:0.11-0.89, respectively). High peripheral TIL levels were able to predict better 10-year DFS 
among all AA patients in multivariate analyses (p=0.035; HR:0.36; 95% CI:0.14-0.93) (Table 13). 
Among early-stage AA patients, high peripheral TIL levels were able to predict better 10-year 
DFS (p=0.027; HR:0.30; 95% CI:0.10-0.87) as well as among radiation-treated early-stage AA 
patients (p=0.022; HR:0.259; 95% CI:0.08-0.823) (Table 13). Our Kaplan-Meier analyses reveal 
that high peripheral TIL levels were able to predict significantly better 5-year DFS among 
radiation-treated early-stage AA patients  (p=0.047) (Figure 3). Peripheral TILs were unable to 
significantly predict DFS among EA TNBC patients (data not shown).  
6.3.5 Distinctions in TIL subsets between AA and EA TNBC patients  
TILs represent a heterogeneous population of immune cells harboring pro-tumorigenic and 
anti-tumorigenic properties. To glean deeper insight into distinctions in the types of infiltrating 
immune cells present in the tumor microenvironment among racially-distinct triple negative breast 
tumors, we utilized the CYBERSORT tool and LM22 to estimate the relative proportions of 22 
immune cell phenotypes among gene expression profiles from AA (N=41) and EA (N=87) TNBC 
patient tissue specimens in TCGA dataset and analyzed for significant differences between the 
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races (Figure 4). Interestingly, we observed AAs harbored a significantly higher proportion of T 
regulatory cells (Tregs) (p=0.046) and lower proportion of M2 macrophages (p=0.04) than EAs 
among TNBCs (Fig 4A). We also observed that AAs harbored a weakly significantly lower 
proportion of naïve B cells (p=0.08) and weakly significantly higher proportion of memory B cells 
(p=0.09) than EAs among TNBC samples (Fig 4B).  
6.3.6 Differentially expressed immune-related genes, pathways and gene ontologies between 
AA and EA TNBC patients 
We also investigated differential expression of immune-related genes, pathways, and gene 
ontologies between AA compared to EA TNBC patients isolated from TCGA breast dataset. 
Utilizing the DESeq2 software tool, we analyzed differences in expression of 15,942 genes 
between AA (N=41) and EA (N=87) TNBC patients in TCGA breast dataset. We observed that 
resistin (RETN), triggering receptor expressed on myeloid cells like 4 (TREML4), C-C motif 
chemokine ligand 3 like 1 (CCL3L1), and leukocyte associated immunoglobulin like receptor 2 
(LAIR2) immune-related genes were significantly more upregulated among AA compared to EA 
TNBC patients (p<0.00001) (Figure 5). Log2 fold changes can be found in Table 10. RETN and 
TREM-4 genes were expressed with a log2 fold change of almost 2 times higher among AA 
compared to EA TNBCs. We also utilized the GAGE and Pathview packages to analyze 
differences in biological pathways or experimentally-derived differential expression sets and gene 
ontologies, respectively between AA and EA TNBCs in TCGA breast dataset. We observed 
significantly more upregulation of the proinflammatory expression sets, intestinal immune 
network for IgA production (p=0.006) and hematopoietic cell lineage (p=0.028), in AA compared 
to EA TNBC patients (Table 11). We also discovered significantly more upregulation of the 
proinflammatory gene ontologies hematopoietic or lymphoid organ development, hemopoiesis, 
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leukocyte differentiation, immune effector process, lymphocyte differentiation, and immune 
system development among AA compared to EA TNBC patients (p<0.001) (Table 12). Significant 
downregulation of immune-related genes and processes were not observed among AA compared 
to EA TNBCs (data not shown).    
6.4 Discussion 
TNBC remains a formidable challenge for clinicians worldwide, underscoring the urgent 
need for more promising pharmacologically-targetable and/or risk-predictive biomarkers. AA 
women are even more at a disadvantage as they exhibit notably higher TNBC incidence and 
mortality rates than women of other ethnicities. The advent of cancer immunology and studies 
investigating the role of the tumor microenvironment in tumor progression has birthed an array of 
alternative and promising immunological targets that may enhance clinical risk-prognostication 
and serve as viable therapeutic options for TNBC patients.  
Our group discovered that stromal TILs were significantly higher in AAs compared to EAs 
among early-stage but not among late-stage TNBC patients suggesting racial disparities in TILs 
exist in the early-stages of the disease and a greater presence of TILs may be associated with 
African ancestry. This finding is consistent with previous studies reporting that TILs are associated 
with more aggressive breast tumor phenotypes such as TNBC status, advanced grade and stage, 
lymph node metastasis, and younger age at diagnosis, which are features typically associated with 
BC patients of African descent. Among early-stage AA TNBC patients, stromal and peripheral 
TILs were associated with younger age at diagnosis and aggressive tumor characteristics such as 
high nuclear grade, mitotic index, tubule formation, and Nottingham grade, which may rationalize 
younger age at diagnosis and a more aggressive disease course among AA compared to EA TNBC 
patients. Ma et. al reported that CD8+ T cells strongly correlated with stromal TIL in BC 
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suggesting that CD8+ T cells, in particular, may be more prevalent among AA compared to EA 
TNBCs, although further investigation is needed (23).  
Interestingly, we discovered that stromal and peripheral TILs were associated with lack of 
AR expression among early-stage AA TNBC patients suggesting that the increased presence of 
TILs may be associated with their higher prevalence of quadruple negative breast cancer (QNBC) 
among AA compared to EA TNBC patients (11). Stromal and peripheral TILs also positively 
correlated with PD-1 among early-stage AA TNBC patients. A high TIL count has been predictive 
of a positive response to anti-PD-1 or anti-PD-L1 antibodies (16). Hence, anti-PD-1/PD-L1 
therapy may be beneficial for AA TNBC patients with high TIL counts and TILs may serve as a 
strong predictive biomarker for immune checkpoint therapy response for AA patients. Stromal and 
peripheral TILs also positively correlated with BAP1 among early-stage AA and EA TNBC 
patients suggesting a link between an anti-tumor inflammatory/immune response and DNA 
damage. Thus, TILs may also serve as a predictive biomarker for response to platinum-based 
agents such as cisplatin and carboplatin. Among early-stage AA TNBC patients, high peripheral 
TIL levels predicted longer 10-year OS in Kaplan-Meier analyses and after controlling for age, 
Nottingham grade, and stage suggesting that a high peripheral TIL count may be predictive of a 
better prognosis. We also observed that high peripheral TIL levels predicted longer 10-year OS 
among adjuvant chemotherapy- and radiation- treated AA TNBC patients and longer 5-year DFS 
among radiation-treated early-stage AA patients, suggesting peripheral TILs may be able to predict 
response to treatment in AA patients. Thus, the administration of adoptive cell therapy using TILs 
to TNBC patients of African ancestry harboring low levels of lymphocytic infiltration may be 
beneficial in improving their survival rates. A combination of TIL immunotherapy and PD-1/PD-
L1 checkpoint blockade therapy may elicit a more robust response.  
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Our in silico analyses revealed a trend of lower proportions of naïve B cells and higher 
proportions of memory B cells in AA compared to EA TNBCs corroborating our in vivo findings 
of increased lymphocytic infiltration among AA TNBC patients. Furthermore, we observed 
significantly lower proportions of M2 macrophages in AA compared to EA TNBCs, although 
previous studies have reported higher counts of tumor-associated macrophages of a M2 phenotype 
in AA compared to EA breast tumors (34-36).  M2 macrophages are immunosuppressive and 
implicated in interfering with the anti-tumoral immune response thus, our finding further suggest 
increased anti-tumor immune activity in AA compared to EA TNBCs (37). However, interestingly 
we observed a significantly greater proportion of Tregs among AA compared to EA TNBCs 
suggesting increased immunosuppressive activity among TNBC patients of African ancestry. Ma 
and colleagues recently showed that FOXP3+ Tregs strongly correlated with stromal TILs, and 
particularly CD8+ T cells, in BC suggesting that our observation of increased lymphocytic 
infiltration among AA compared to EA triple negative breast tumors may be associated with their 
higher levels of Tregs observed in our study (23). Perhaps a greater presence of suppressive T cells 
could be counteracting a greater presence of antitumoral TILs, still subjecting AAs to a worse 
clinical prognosis. Further investigation is warranted to determine how differences in the 
composition of the tumor immune microenvironments among racially-distinct TNBCs could be 
underlying the disparate clinical outcomes observed among AA patients.   
Further in silico analyses by our group revealed that the proinflammatory genes, RETN, 
TREM-4, CCL3L1, and LAIR2, were significantly more upregulated in AA compared to EA 
TNBCs. RETN and TREM-4 genes were expressed almost 2 folds higher among AA compared to 
EA TNBCs. Stewart and colleagues also reported that RETN was expressed 2.25 folds higher in 
AA compared to EA BC patients in TCGA dataset (38). Martin et. al observed C-X-C motif 
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chemokine 10 and 11 being expressed 5.96 and 1.96 folds higher, respectively in AA compared to 
EA BC patients (34). We also observed more upregulation of proinflammatory KEGG pathways 
among AAs compared to EAs such as the intestinal immune network for IgA production and 
hematopoietic cell lineage as well as key proinflammatory gene ontologies such as lymphoid organ 
development, leukocyte and lymphocyte differentiation, hemopoiesis, and immune effector 
process.  
Our study is the first to uncover a previously unrecognized disparity in an important member 
of the tumor immune microenvironment, TILs, between racially distinct TNBC patients and 
encourages further investigation of racial disparities in TILs among these patient populations. Our 
work provides valuable risk-prognostic information of TILs to better guide clinicians in the 
optimization of treatment paths for early-stage AA TNBC patients. These findings support the 
need for increased evaluation of TILs in the clinic for early-stage AA TNBC patients and suggest 
immunotherapy could be exploited as an effective therapeutic strategy for TNBC patients of 
African ancestry with low lymphocytic infiltration. However, robust validation of our findings in 
additional non-NAC and NAC treated patient cohorts as well as more characterization of immune 
cell subsets among racially-distinct triple negative breast tumors will be critical to achieving these 
aims.  
6.5 Methods 
6.5.1 Study Cohort 
We analyzed a cohort of 121 TNBC patients treated at EUH in Atlanta, GA from 2002 
(initial day of diagnosis) to 2016 (last day of contact). The percentage of stromal and peripheral 
TILs was assessed in hematoxylin- and eosin- stained patient specimens as described by 
Krishnamurti and colleagues (14). Stromal TILs were evaluated according to the International 
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TILs working group 2014 in which the percentage of stromal tissues occupied by infiltrating 
lymphocytes and plasma cells were estimated (24). Intratumoral lymphocytes, or lymphocytes in 
direct contact with tumor cells, were excluded from the evaluation as no patients in this study 
underwent NAC. Peripheral TILs were also evaluated as the percentage of stromal lymphocytes 
occupying the entire circumference of the invasive tumor front with a width of roughly one dozen 
tumor cells (14). The percentage of stromal and peripheral TILs were estimated in intervals 
including <5%, 5-10%, 11-50% and >50%. Patient demographic characteristics, clinico-
pathological variables, and BC biomarker status were recorded for each patient. Demographic 
characteristics include self-reported race and age at the time of diagnosis. This article referred to 
the 7th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer 
Control (UICC) TNM Classification and Stage groupings for BC (25). Expression of all BC 
biomarkers investigated in this study was determined through immunohistochemical (IHC) 
staining and scored as Hscore (percentage x intensity), Nper (nuclear percentage) and Nhscore 
(nuclear percentage x intensity). Negativity was determined as <1% expression and positivity was 
determined as ≥1% expression for all biomarkers. Information on patient treatment was recorded 
including adjuvant chemotherapy and radiation therapy.  
6.5.2 Follow Up 
Initial diagnosis and follow-up of patients occurred between 2002 and 2016. Initial dates 
of diagnoses, treatment start and completion dates, and last dates of contact were recorded for each 
patient. Survival status (alive/dead) was also recorded for each patient in addition to survival time. 
The date of last follow-up for the last patient seen is March 3, 2016. 
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6.5.3 Infiltrating Immune Cell Composition and Differential Gene Expression 
Determination  
We queried The Cancer Genome Atlas (TCGA) breast dataset from the TCGA portal in 
Oncomine for all TNBC patients (26, 27). Publically-available ER/PR/HER2 IHC data was used 
to determine TNBC status. We utilized the Cell type Identification By Estimating Relative Subsets 
of known RNA Transcripts (CIBERSORT) tool, which is a deconvolution algorithm that uses a 
set of reference gene expression values, to resolve intratumoral immune cell composition in gene 
expression data from tumor samples of mixed cell types (28). The Leukocyte gene signature matrix 
(LM22), which is comprised of 547 genes that resolves 22 human hematopoietic cell phenotypes 
[seven T cell types, naïve and memory B cells, plasma cells, natural killer (NK) cells, and myeloid 
subsets] in tumor samples, was used to identify proportions of each immune cell type in TNBC 
patients based on their gene expression profiles in the TCGA dataset (28). To avoid false positives, 
gene expression data was processed using 1000 permutations. As the input data was normalized, 
the quantile normalization option was disabled. According to the available race data, we selected 
128 AA and EA samples out of 145 TNBC samples. We performed differential gene expression 
analysis between the ethnic groups using the DESeq2 software tool (29). Differentially expressed 
genes with a p value of <0.05 and log2fold change of above +1 and below -1 were selected in this 
study. Differential expression analyses of Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways and gene ontologies between the ethnic groups were predicted by GAGE and Pathview 
packages, respectively (30, 31). Heat maps were generated to depict the relative proportion of 
select immune cells and differentially expressed genes among each patient group of interest.   
6.5.4 Statistical Analysis 
The significance level for all analyses was p<0.05 with 95% confidence intervals (CIs). 
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Chi-square tests were performed to analyze differences in demographic characteristics, breast 
clinico-pathological variables and biomarker expression, as well as treatment information between 
AA and EA TNBC patients. SAS 9.4 program was used to generate test statistics and 2-tailed 
univariate p-values were reported. Wilcoxon rank-sum tests were performed to determine 
differences in the means of stromal and peripheral TILs between AA and EA patient populations. 
Pearson correlation coefficients (ρ) were computed to determine associations between stromal and 
peripheral TILs with demographic and breast clinico-pathological variables and biomarker 
expression among AA and EA TNBC patients. Spearman’s rank correlation coefficients (ρ) were 
computed for categorical covariates. Unadjusted and adjusted multivariate Cox proportional 
hazard regression models were computed to assess the impact of TILs on 10-year OS and DFS 
before and after controlling for age, Nottingham grade, and stage. The Kaplan-Meier analysis was 
conducted using SAS 9.4 program to estimate survival function for AA and EA TNBC patients 
over a 5- or 10- year period based on high and low TIL levels. A log-rank test was used to stratify 
stromal and peripheral TILs into high (³10) and low (<10) groups to evaluate associations of a 
high and low presence of TILs with better or worse survival among racially-distinct TNBC 
patients. Wilcoxon rank-sum tests were performed to determine significant differences in the 
proportions of immune cell fractions between AA and EA TNBCs after generating CYBERSORT 
outputs. P-value cut-offs were not used. The Wald test was used to test for significance among 
differentially expressed genes between the racial groups using the DESeq2 software tool.    


























Clinical characteristic n % n % p value
Age
20-40 6 6.9 3 8.82
41-60 53 60.92 16 47.06
61-80 28 32.18 15 44.12
Nuclear grade
1 N/A N/A N/A N/A
2 5 5.75 6 17.65
3 82 94.25 28 82.35
Tubule formation
1 1 1.15 1 2.94
2 11 12.64 6 17.65
3 75 86.21 27 79.41
Mitotic Index
1 8 9.2 10 29.41
2 11 12.64 11 32.35
3 68 78.16 13 38.24
Nottingham grade
1 1 1.15 1 2.94
2 12 13.79 13 38.24
3 74 85.06 20 58.82
Stage
I 28 32.18 18 52.94
II 43 49.43 14 41.18
III 13 14.94 2 5.88
IIIC 3 3.45 0 0
Nodal status
Negative 61 70.11 27 79.41
Positive 26 29.89 7 20.59
Total lymph node involvement
0 3 3.45 1 2.94
3-Jan 26 29.88 10 29.41
9-Apr 27 31.05 14 41.17
>=10 31 35.62 9 26.48
Ki-67 (%)
0-20 21 24.14 12 35.29
21-40 10 11.49 1 2.94
41-60 7 8.05 7 20.59
61-80 15 17.24 3 8.82






T1 34 39.08 22 64.71
T2 45 51.72 11 32.35
T3 5 5.75 0 0
T4 3 3.45 1 2.94
N
N0 58 66.67 26 76.47
NX 3 3.45 1 2.94
N1 14 16.09 5 14.71
N2 9 10.34 2 5.88
N3 3 3.45 0 0
M
M0 N/A N/A
MX 87 100 34 100
M1 N/A N/A
Adjuvant Chemotherapy
Yes 63 72.41 25 73.53
No 8 9.2 3 8.82
Missing/Unknown 16 18.39 6 17.65
Radiation therapy
Yes 46 52.87 24 70.59
No 26 29.89 9 26.47
Missing/Unknown 15 17.24 1 2.94
*P value s were calculated using the chi-square test. 













Table 6.1 Clinico-pathological characteristics of AA and EA TNBC patients observed at EUH






Table 6.2 Breast cancer biomarker expression among AA and EA TNBC patients observed at 
EUH 
 
Biomarkers n % n % p value
AR (Nper)
Negative 61 70.11 22 64.71
Positive 16 18.39 5 14.71
Missing/Unknown 10 11.5 7 20.58
HSET (Nhscore)
Negative N/A N/A
Positive 64 73.56 24 70.59
Missing/Unknown 23 26.44 10 29.41
FOXM1 (Nper)
Negative 1 1.15 2 5.88
Positive 65 74.71 23 67.65
Missing/Unknown 21 24.14 9 26.47
PRC1 (Nper)
Negative 36 41.38 15 44.12
Positive 26 29.89 10 29.41
Missing/Unknown 25 28.73 9 26.47
RARα (Nper)
Negative 27 31.03 6 17.65
Positive 44 50.57 23 67.65
Missing/Unknown 16 18.4 5 14.7
Aurora A (Nhscore)
Negative 37 42.53 15 44.12
Positive 40 45.98 11 32.35
Missing/Unknown 10 11.49 8 23.53
Survivin (Nper)
Negative 3 3.45 1 2.94
Positive 70 80.46 23 67.65
Missing/Unknown 14 16.09 10 29.41
BAP1 (Nper)
Negative 6 6.9 5 14.71
Positive 67 77.01 20 58.82
Missing/Unknown 14 16.09 9 26.47
β-catenin  (Hscore)
Negative 7 8.05 5 14.71
Positive 70 80.46 17 50
Missing/Unknown 10 11.49 12 35.29
PD1 (Hscore)
Negative 17 19.54 6 17.65
Positive 70 80.46 28 82.35
EGFR (Hscore)
Negative 26 29.89 8 23.53
Positive 43 49.43 17 50
Missing/Unknown 18 20.68 9 26.47
HER3 (Hscore)
Negative 36 41.38 11 32.35
Positive 33 37.93 13 38.24
Missing/Unknown 18 20.69 10 29.41
HER4 (Hscore)
Negative 37 42.53 12 35.29
Positive 39 44.83 15 44.12





Abbreviations; AA, African-American; EA, European-American; AR, Androgen Receptor; FOXM1, Forkhead box 1 protein; PRC1, protein regulator of 
cytokinesis 1; RARα, Retinoic acid receptor α; BAP1, BRCA1 associated protein 1, PD1, Programmed cell death protein 1; EGFR, epidermal growth 
factor receptor; HER3, human epidermal growth factor receptor 3; HER4, human epidermal growth factor receptor 4; Hscore (percentage x intensity), 
Nper (nuclear percentage), and Nhscore (nuclear percentage x intensity); N/A, non-applicable.*P value s were calculated using the chi-square test. 







Table 6.2 Breast cancer biomarker expression among AA and EA TNBC patients observed at EH






Table 6.3 Correlation of stromal TILs with demographic and clinico-pathological variables 















Patients Agea LN_posa LN_tota Tumor size (cm)a Tubule formationb Nuclear gradeb Mitotic indexb Nott. gradeb
ρ -0.25 0.11 0.08 -0.07 0.28 0.2 0.18 0.3
p  value 0.03 0.37 0.49 0.57 0.02 0.1 0.14 0.01
ρ -0.26 0.11 0.09 -0.09 0.27 0.2 0.16 0.3
p  value 0.04 0.37 0.5 0.49 0.03 0.11 0.2 0.01
ρ -0.31 0.08 -0.12 0.28 0.55 0.34 0.51 0.54
p  value 0.18 0.73 0.62 0.22 0.01 0.13 0.02 0.01
ρ -0.24 0.04 0.04 -0.03 0.37 0.17 0.17 0.34
p  value 0.1 0.77 0.81 0.83 0.01 0.27 0.26 0.02
ρ -0.23 0.28 0.2 -0.19 0.34 0.33 0.31 0.39
p  value 0.28 0.18 0.34 0.39 0.03 0.04 0.06 0.02
ρ -0.3 0.43 0.45 0.01 0.06 0.27 0.42 0.42
p  value 0.09 0.02 0.01 0.95 0.75 0.14 0.02 0.02
ρ -0.3 0.42 0.43 -0.05 0.16 0.28 0.34 0.37
p  value 0.12 0.02 0.02 0.78 0.41 0.15 0.07 0.05
ρ 0.56 . 0.05 0.72 -0.64 0.19 0.55 0.37
p  value 0.11 . 0.9 0.03 0.06 0.63 0.12 0.32
ρ -0.37 0.4 0.45 0.08 -0.04 0.15 0.36 0.43
p  value 0.08 0.06 0.03 0.71 0.86 0.49 0.09 0.04
ρ -0.12 . 0.23 -0.04 0.24 0.62 0.5 0.41
p  value 0.73 . 0.52 0.91 0.51 0.05 0.14 0.23
aPearson correlation test (ρ)
bSpearman’s rank correlation test (ρ)
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; LN, lymph node; Pos, positive; Tot, total; Nott, Nottingham. Missing values are attributed to an insufficient number of 
patients to analyze. 
















Table 6.4 Correlation of peripheral TILs with demographic and clinico-pathological variables 













Patients Agea Nuclear gradeb Mitotic indexb Nott. gradeb Ki67%a
ρ -0.3 0.12 0.2 0.26 0.03
p  value 0.01 0.31 0.1 0.03 0.83
ρ -0.28 0.13 0.18 0.27 0.04
p  value 0.03 0.3 0.14 0.03 0.74
ρ -0.51 0.34 0.48 0.51 0.1
p  value 0.02 0.13 0.03 0.02 0.68
ρ -0.25 0.04 0.16 0.27 0.15
p  value 0.09 0.78 0.27 0.06 0.33
ρ -0.44 0.37 0.36 0.44 -0.12
p  value 0.01 0.02 0.02 0.01 0.46
ρ -0.32 0.4 0.48 0.53 0.35
p value 0.07 0.02 0.01 <0.01 0.05
ρ -0.34 0.5 0.42 0.52 0.33
p value 0.07 0.01 0.02 <0.01 0.08
ρ -0.27 0.18 0.64 0.46 0.56
p  value 0.49 0.63 0.06 0.21 0.12
ρ -0.44 0.24 0.41 0.47 0.34
p  value 0.04 0.27 0.05 0.02 0.11
ρ -0.13 0.74 0.6 0.65 0.4
p  value 0.73 0.01 0.07 0.04 0.26
aPearson correlation test (ρ)
bSpearman’s rank correlation test (ρ)
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; Nott, Nottingham.
















Table 6.5 Correlations of stromal TILs with clinico-pathological biomarkers among early-












Patients AR HSET EGFR BAP1 PD-1
ρ -0.255 -0.023 0.049 0.296 0.56
p  value 0.044 0.87 0.715 0.022 <.0001
ρ -0.258 -0.018 0.055 0.284 0.589
p  value 0.053 0.902 0.704 0.038 <.0001
ρ -0.35 0.023 0.023 0.376 0.445
p  value 0.131 0.931 0.929 0.113 0.043
ρ -0.191 0.036 -0.007 0.35 0.705
p  value 0.32 0.865 0.973 0.068 <.0001
ρ -0.235 0.084 0.018 0.314 0.672
p  value 0.134 0.623 0.917 0.048 <.0001
ρ -0.223 0.495 0.576 0.445 0.427
p  value 0.284 0.019 0.004 0.03 0.015
ρ -0.164 0.473 0.575 0.394 0.412
p  value 0.454 0.03 0.005 0.07 0.026
ρ -0.818 0.749 -0.669 0.34 0.305
p  value 0.09 0.145 0.217 0.455 0.425
ρ -0.219 0.634 0.695 0.551 0.512
p  value 0.399 0.006 0.002 0.018 0.013
ρ -0.106 -0.318 0.123 0.479 0.67
p  value 0.802 0.602 0.817 0.337 0.048
Abbreviations: ρ, pearson correlation coefficient; Chemo, adjuvant chemotherapy; Rad, radiation.
















Table 6.6 Correlation of peripheral TILs with clinico-pathological biomarkers among racially-












Patients AR HSET PRC1 BAP1 PD-1 HER4
ρ -0.241 -0.063 -0.268 0.262 0.323 0.065
p value 0.057 0.656 0.05 0.044 0.006 0.617
ρ -0.263 -0.051 -0.284 0.271 0.35 0.057
p value 0.048 0.732 0.051 0.047 0.004 0.673
ρ -0.364 0.058 -0.016 0.368 0.212 0.064
p value 0.115 0.825 0.947 0.121 0.355 0.8
ρ -0.273 0.104 -0.26 0.264 0.432 -0.067
p value 0.08 0.54 0.12 0.1 0.002 0.671
ρ -0.263 -0.215 -0.286 0.324 0.125 0.427
p value 0.133 0.271 0.133 0.071 0.454 0.015
ρ -0.295 0.572 -0.005 0.431 0.317 -0.133
p value 0.153 0.005 0.983 0.036 0.077 0.517
ρ -0.216 0.549 0.003 0.361 0.307 -0.179
p value 0.323 0.01 0.989 0.099 0.105 0.403
ρ -0.645 0.64 -0.368 0.548 0.668 -0.02
p value 0.24 0.245 0.542 0.203 0.049 0.97
ρ -0.287 0.646 0.009 0.463 0.293 -0.063
p value 0.264 0.005 0.971 0.053 0.174 0.805
ρ -0.326 0.444 . 0.373 0.339 -0.292
p value 0.431 0.454 . 0.41 0.337 0.482
Abbreviations: ρ, pearson correlation coefficient; Chemo, adjuvant chemotherapy; Rad, radiation. Missing values are attributed to an 
insufficient number of patients to analyze.























All patients p-value; HR (95% CI) p-value; HR (95% CI)
Unadjusted model Adjusted model 
Early and late stage  
Overall 0.1159; 0.518 (0.228, 1.176) 0.0189; 0.344 (0.141, 0.838) 
Chemotherapy 0.2790; 0.598 (0.236, 1.517) 0.0879; 0.403 (0.142, 1.144)
 Non-Chemotherapy 0.2097; 0.422 (0.110, 1.624) 0.2426; 0.368 (0.069, 1.968)
Radiation 0.1277; 0.428 (0.144, 1.275) 0.0434; 0.284 (0.084, 0.963) 
Non-Radiation 0.1761; 0.463 (0.152, 1.412) 0.1682; 0.380 (0.096, 1.505)
Early-stage
Overall 0.3981; 0.633 (0.219, 1.828) 0.2861; 0.545 (0.179, 1.662)
Chemotherapy 0.8389; 0.880 (0.258, 3.009) 0.9041; 0.923 (0.249, 3.415)
 Non-Chemotherapy 0.1023; 0.234 (0.041, 1.336) 0.0887; 0.200 (0.031, 1.276)
Radiation 0.4018; 0.504 (0.102, 2.499) 0.3716; 0.464 (0.086, 2.498)
Non-Radiation 0.1227; 0.367 (0.103, 1.310) 0.1574; 0.371 (0.094, 1.467)
AA p-value; HR (95% CI) p-value; HR (95% CI)
Unadjusted model Adjusted model 
Early and late stage  
Overall 0.0106; 0.303 (0.121, 0.757) 0.0026; 0.229 (0.084, 0.622)
Chemotherapy 0.0387; 0.326 (0.113, 0.994) 0.0154; 0.230 (0.070, 0.755)
 Non-Chemotherapy 0.0449; 0.218 (0.049, 0.966) 0.0818; 0.147 (0.017, 1.274)
Radiation 0.0228; 0.239 ( 0.070, 0.819) 0.0141; 0.167 (0.040, 0.697)
Non-Radiation 0.0965; 0.358 (0.107, 1.202) 0.1399; 0.301 (0.061, 1.483)
Early-stage
Overall 0.0653; 0.326 (0.099, 1.074) 0.0445; 0.273 (0.077, 0.969)
Chemotherapy 0.2313; 0.428 (0.107, 1.716) 0.265; 0.429 (0.097, 1.900)
 Non-Chemotherapy 0.0249; 0.075 (0.008, 0.721) 0.0408; 0.031 (0.001, 0.865)
Radiation 0.1344; 0.255 (0.042, 1.527) 0.1159; 0.208 (0.029, 1.473)
Non-Radiation 0.0524; 0.235 (0.054, 1.015) 0.1199; 0.283 (0.058, 1.389)
Peripheral TILs were treated as a categorical variable. 
Table 6.7. Prediction of peripheral TILs on 10-year OS among racially-distinct TNBC patients.
Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional hazard model adjusted for age, Nottingham grade, and stage. 










Table 6.8 Prediction of stromal TILs on 10-year DFS among racially-distinct TNBC 
patients.  
All patients p-value; HR (95% CI) p-value; HR (95% CI) 
  Unadjusted model Adjusted model  
Early and late stage       
Overall  0.399;  0.58 ( 0.17,  2.02)  0.079;  0.31 ( 0.08,  1.14) 
Chemotherapy  0.253;  0.42 ( 0.09,  1.86)  0.093;  0.27 ( 0.05,  1.24) 
 Non-Chemotherapy  0.637;  1.78 ( 0.16,  19.6)  0.575;  0.40 ( 0.01,  9.62) 
Radiation  0.189;  0.36 ( 0.08,  1.63)  0.047;  0.21 ( 0.04,  0.98) 
Non-Radiation  0.566;  2.01 ( 0.18,  22.2)  0.748;  0.59 ( 0.02,  13.9) 
Early-stage     
Overall  0.155;  0.22 ( 0.03,  1.75) 0.0607; 0.139 (0.018, 1.093) 
Chemotherapy  0.175;  0.24 ( 0.03,  1.88)  0.098;  0.17 ( 0.02,  1.38) 
 Non-Chemotherapy  0.997;  0.00 ( - )  0.998;  0.00 ( - ) 
Radiation  0.126;  0.20 ( 0.02,  1.56) 0.0546; 0.131 (0.016, 1.041) 
Non-Radiation  0.997;  0.00 ( - )  0.997;  0.00 ( - ) 
  
AA p-value; HR (95% CI) p-value; HR (95% CI) 
  Unadjusted model Adjusted model  
Early and late stage       
Overall  0.522;  0.65 ( 0.18,  2.36)  0.154;  0.38 ( 0.10,  1.42) 
Chemotherapy 0.3610; 0.493 (0.108, 
2.250) 
0.1968; 0.363 (0.078, 
1.692) 
 Non-Chemotherapy 
0.5600; 2.281 (0.142, 
36.51)  1.000;  0.02 ( - ) 
Radiation  0.298;  0.44 ( 0.09,  2.05)  0.123;  0.29 ( 0.06,  1.39) 
Non-Radiation  0.733;  1.51 ( 0.13,  16.7)  0.669;  0.51 ( 0.02,  11.0) 
Early-stage     
Overall 0.1779; 0.243 (0.031, 1.902)  0.097;  0.17 ( 0.02,  1.37) 
Chemotherapy  0.215;  0.27 ( 0.03,  2.14)  0.175;  0.23 ( 0.02,  1.90) 
 Non-Chemotherapy  0.997;  0.00 ( - )  1.000;  0.11 (- ) 
Radiation  0.152;  0.21 ( 0.02,  1.75)  0.113;  0.18 ( 0.02,  1.49) 
Non-Radiation  0.997;  0.00 ( - )  0.997;  0.00 ( - ) 
Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional hazard model 
adjusted for age, Nottingham grade, and stage. Overall TILs were treated as a 










All patients p-value; HR (95% CI) p-value; HR (95% CI)
Unadjusted model Adjusted model 
Early and late stage  
Overall  0.330;  0.63 ( 0.24,  1.59)  0.035;  0.36 ( 0.14,  0.93)
Chemotherapy  0.484;  0.69 ( 0.24,  1.94)  0.164;  0.47 ( 0.17,  1.35)
 Non-Chemotherapy  0.342;  0.31 ( 0.02,  3.45)  0.997;  0.00 ( - )
Radiation  0.341;  0.61 ( 0.22,  1.68)  0.029;  0.31 ( 0.11,  0.89)
Non-Radiation  0.949;  0.92 ( 0.08,  10.1)  0.334;  0.25 ( 0.01,  4.17)
Early-stage
Overall  0.184;  0.49 ( 0.17,  1.40)  0.027;  0.30 ( 0.10,  0.87)
Chemotherapy  0.393;  0.60 ( 0.19,  1.91)  0.195;  0.46 ( 0.14,  1.48)
 Non-Chemotherapy  0.997;  0.00 ( - )  0.998;  0.00 ( - )
Radiation 0.2176; 0.490 (0.158, 1.523) 0.0219; 0.259 (0.082, 0.823)
Non-Radiation  0.615;  0.49 ( 0.03,  7.85) 0.3801; 0.281 (0.016, 4.793)
AA p-value; HR (95% CI) p-value; HR (95% CI)
Unadjusted model Adjusted model 
Early and late stage  
Overall  0.308;  0.57 ( 0.20,  1.66)  0.111;  0.42 ( 0.14,  1.22)
Chemotherapy  0.343;  0.57 ( 0.18,  1.80)  0.302;  0.54 ( 0.17,  1.72)
 Non-Chemotherapy  0.607;  0.48 ( 0.03,  7.72)  1.000;  0.00 ( - )
Radiation  0.245;  0.49 ( 0.15,  1.62)  0.135;  0.39 ( 0.11,  1.34)
Non-Radiation  0.936;  0.90 ( 0.08,  9.99)  0.386;  0.29 ( 0.01,  4.74)
Early-stage
Overall  0.195;  0.45 ( 0.13,  1.49)  0.120;  0.38 ( 0.11,  1.28)
Chemotherapy 0.2856; 0.501 (0.141, 1.781) 0.4096; 0.584 (0.162, 2.099)
 Non-Chemotherapy  0.998;  0.00 ( - )  1.000;  0.00 ( - )
Radiation  0.102;  0.33 ( 0.08,  1.24) 0.1144; 0.292 (0.063, 1.346)
Non-Radiation  0.613;  0.48 ( 0.03,  7.82)  0.427;  0.32 ( 0.01,  5.30)
Table 6.9. Prediction of peripheral TILs on 10-year DFS among racially-distinct TNBC patients.
Significant p values and corresponding HR and confidence intervals in table are in bold font.
Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional hazard model adjusted for age,
Nottingham grade, and stage. Overall TILs were treated as a categorical variable. (-), indicates that 95%
CIs were unable to be generated. 
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Table 6.10 Immune-related genes upregulated in AA compared to EA TNBC patients in 
TCGA dataset.  
 
 














Gene Gene name log2FoldChange p  value
RETN resistin 1.890840792 4.97E-10
TREML4 triggering receptor expressed on myeloid cells like 4 1.677117556 2.34E-09
CCL3L1 C-C motif chemokine ligand 3 like 1 1.356316644 1.50E-06
LAIR2 leukocyte associated immunoglobulin like receptor 2 1.238761571 4.96E-06
Table 6.10. Immune-related genes upregulated in AA compared to EA TNBC patients in TCGA dataset.
Pathway p-value 
hsa04672 Intestinal immune network for IgA production 0.006
hsa04640 Hematopoietic cell lineage 0.028





Figure 6.1 Comparison of stromal TILs among racially-distinct TNBC patients.  
Comparison of stromal TILs among AA and EA TNBC patients (39), among early-stage AA and 
EA TNBC patients, (39) and late-stage AA and EA TNBC patients overall and with or without 
adjuvant chemotherapy (chemo) or radiation (rad) treatment. No record of not having received 






Figure 6.2 Peripheral TILs predict OS among early-stage AA TNBC patients.    
Peripheral TILs were stratified into high (≥10) and low (<10) subgroups using a log-rank test. 
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on 
survival over a 10-year period among AA TNBC patients. Prediction of high and low peripherals 
TILs on 10-year OS among (39) all AA patients, (39) adjuvant chemotherapy-treated AA patients, 
(39) radiation-treated AA patients, (39) early-stage AA patients, (39) non-adjuvant chemotherapy 






Figure 6.3 Peripheral TILs predict DFS among early-stage AA TNBC patients.   
 Peripheral TILs were stratified into high (≥10) and low (<10) subgroups using a log-rank test. 
Kaplan-Meier curve was generated to estimate impact of high and low peripheral TIL levels on 


















Figure 6.4 Comparison of intratumoral immune cell fractions between AA and EA TNBC 
samples. 
CIBERSORT tool was used to determine the proportions of distinct infiltrating immune cells 
among AA and EA TNBCs isolated from the TCGA breast dataset. No cut-offs for p-values were 
used. The color gradient from green to red represents the increasing fractions of intratumoral 
immune cells. (39) Immune cell fractions that showed statistically significant differences between 
the races with a greater proportion of Tregs and smaller proportion of M2 macrophages among 
AAs compared to EAs. (39) Immune cell fractions that showed weakly statistically significant 
differences (0.05>p<0.1) between the races with a smaller proportion of naïve B cells and greater 





Figure 6.5 Differentially expressed immune-related genes among AA and EA TNBC samples.   
The DESeq2 tool was used to determine differences in the expression of immune-related genes 
between AA and EA TNBC patients isolated from the TCGA breast dataset. Genes that were 
significantly differentially expressed between the racially-distinct TNBC patients (p<0.05) and a 
log2fold change of above +1 were included in the heat map to depict the relative expression levels 
of each gene. The color gradient from red to green represents increasing expression of each gene. 
RETN (resistin), LAIR2 (leukocyte associated immunoglobulin like receptor 2), TREML4 
(triggering receptor expressed on myeloid cells like 4), and CCL3L1 (C-C motif chemokine ligand 
3 like 1) genes were found to be significantly more upregulated in AA compared to EA samples 
(p<0.00001).   
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7 TUMOR-INFILTRATING LYMPHOCYTES AS RISK-PROGNOSTIC 
BIOMARKER AMONG EARLY-STAGE QUADRUPLE NEGATIVE BREAST 
CANCER PATIENTS 
7.1 Abstract 
Quadruple negative breast cancer (QNBC) is defined by a lack of estrogen and 
progesterone receptors, human epidermal growth factor receptor 2, and androgen receptor (AR). 
Some studies suggest the absence of AR expression in triple negative breast cancer (TNBC) 
confers a more aggressive disease course. We compared stromal and peripheral TILs between 
early-stage AR-negative and AR-positive TNBC patients at Emory Hospital in Atlanta, GA and 
analyzed a publically-available gene expression dataset for distinctions in infiltrating immune cell 
phenotypes between AR- low and high expressing TNBC patents. Among early-stage TNBC 
patients (N=94), we observed more stromal (p=0.002) and peripheral (p=0.018) TILs in AR-
negatives (N=76) compared to AR-positives (N=18). Our in silico results suggest increased anti-
tumoral immune activity among AR-low compared to AR-high expressing TNBCs. Among early-
stage AR-negative patients, stromal and peripheral TILs correlated negatively with younger age at 
diagnosis (p<0.01). High peripheral TILs count was associated with longer 10-year disease-free 
survival among AR-negative patients in multivariate analyses (p=0.026; HR: 0.062). Our findings 
uncover previously unrecognized distinctions in the tumor immune microenvironment between 
AR-negative and AR-positive triple negative breast tumors and suggest that TILs may be a 
promising, alternative risk-prognostic biomarker that could be exploited therapeutically for early-




Triple negative breast cancer (TNBC) is an aggressive form of breast cancer defined by the 
absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 
2 (HER2/neu) expression. Thus, TNBC patients do not benefit from conventional endocrine 
therapy and HER2-targeted systemic treatments as therapeutic options 1,2. Furthermore, 
anthracycline-taxane based chemotherapy is unable to completely eliminate most triple negative 
breast tumors. Quadruple negative breast cancers (QNBCs) represent a subgroup of TNBCs that 
lack androgen receptor expression. Approximately 45-88% of TNBCs lack nuclear AR expression 
3,4. Thus, unlike AR-positive TNBCs, QNBC patients are excluded from receiving AR-targeted 
therapy as an alternative treatment option.  Although the prognostic role of AR in TNBC remains 
controversial, a lack of AR expression has been associated with poor differentiation, high clinical 
stage, high Ki-67, high mitotic index, increased lymphovascular invasion, increased risk of 
recurrence and distant metastasis, and worse 5-year disease-free survival (DFS) and overall 
survival 5-9. Thus, novel, alternative risk-prognostic biomarkers and therapeutic targets are 
urgently needed to abrogate an aggressive disease course and avert a poor prognosis among this 
patient population.  
Upon neoplastic transformation, tumor-infiltrating lymphocytes migrate to the tumor site 
to prevent tumor progression 10,11. Stromal TILs reside in the stromal compartment of the tumor, 
while peripheral TILs occupy the invasive tumor front 12,13. Stromal TILs have been reported to 
be more prognostic in TNBC than peripheral TILs as stromal TILs have been associated with 
longer OS, increased metastasis-free survival and reduced distance recurrence as well as 
improved pathological complete response (pCR) following neoadjuvant chemotherapy in TNBC 
12,14,15. In fact, for every 10% increase in stromal TILs, a 15% reduction in relapse risk and 17% 
146 
 
reduction in death risk has been reported. However, recently among TNBC patients not treated 
with neoadjuvant chemotherapy, peripheral TILs were similarly associated with longer OS and 
DFS 13. Paradoxically, an increased presence of stromal TILs have been associated with more 
aggressive breast tumor features such as high grade, high stage, high Ki-67, lymph node 
metastasis, a triple negative breast tumor phenotype and younger age at diagnosis 15-20. Thus, we 
were interested in evaluating if there are differences in the presence of stromal and peripheral 
TILs between AR-negative and AR-positive TNBCs and investigating if stromal and peripheral 
TILs can function as a risk-predictive and prognostic biomarker for early-stage QNBC patients. 
We compared TIL counts between AR-negative and AR-positive TNBC patients observed at 
Emory University Hospital (EH) in Atlanta, GA in a non-neoadjuvant chemotherapy setting and 
assessed the predictive and prognostic role of TILs among QNBC patients.   
7.3 Results 
7.3.1 Clinico-pathological characteristics and biomarker expression among AR-negative and 
AR-positive TNBC patients  
We analyzed differences in associations with demographic and clinico-pathological 
characteristics as well as treatment status between AR-negative (N=89) and AR-positive (N=21) 
TNBC patients observed at EH (Table 1). We observed a significant difference in associations 
with nuclear grade between the groups. Among AR-negative patients, 96% presented as grade 3 
as opposed to 81% among AR-positive patients (p=0.02). We also observed modest differences in 
associations with Nottingham grade and radiation therapy administration based on AR status. 
Among AR-negative patients, 85% presented with a Nottingham grade of 3 while only 71% of 
AR-positive patients presented with a grade of 3 (p=0.06). Among AR-negative patients, 62% 
were reported to have received radiation therapy while only 38% of AR-positive patients 
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underwent the treatment (p=0.05). We also compared differences in associations with breast cancer 
biomarker expression between AR-negative and AR-positive TNBC patients (2). We observed 
differences in associations with HSET expression between the patient groups. Among AR-positive 
patients, 76% were positive for HSET expression as opposed to 82% of AR-negative patients 
(p=0.01). Similarly, modest differences in HER3 expression emerged, where 46% of AR-positive 
patients were positive for the marker as opposed to 43% of AR-negative patients (p=0.07).  
7.3.2 Early-stage AR-negative harbor more TILs than early-stage AR-positive TNBC 
patients 
We investigated differences in the presence of stromal and peripheral TILs between AR-
negative (N=89) and AR-positive (N=21) TNBC patients (Figure 1). We observed that stromal 
TIL levels were higher in AR-negative compared to AR-positive TNBC patients (p=0.001) as well 
as among non-adjuvant chemotherapy-treated (p=0.012) and radiation-treated (p=0.011) TNBC 
patients (Fig 1A). Stromal TILs were also higher in AR-negative (N=76) compared to AR-positive 
(N=18) early-stage (I-II) (N=94) TNBC patients (p=0.002) as well as among non-adjuvant 
chemotherapy-treated (p=0.040) and radiation-treated (p=0.049) early-stage TNBC patients 
(p=0.01) (Fig 1B). We also observed significant differences in peripheral TIL count between AR-
negative and positive TNBC patients. Peripheral TIL levels were higher in AR-negative compared 
to AR-positive TNBC patients (p=0.017) as well as among non-adjuvant chemotherapy-treated 
(p=0.012) and radiation-treated (p=0.025) TNBC patients (Fig 1C). Peripheral TILs were also 
higher in AR-negative compared to AR-positive early-stage TNBC patients (p=0.018) as well as 
among non-adjuvant chemotherapy-treated (p=0.039) and radiation-treated (p=0.031) early-stage 
TNBC patients (Fig 1D). We observed no differences in stromal or peripheral TIL count among 
late-stage (III-IIIC) patients.  
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7.3.3 TILs are associated with more aggressive disease among AR-negative TNBC patients 
We examined correlations between stromal (Table 3A) and peripheral (Table 3B) TILs 
with demographic and clinico-pathological variables among AR-negative and AR-positive TNBC 
patients. Regarding demographic variables, stromal TILs negatively correlated with age at 
diagnosis among all (ρ=-0.325; p=0.002) and early-stage (ρ=-0.320; p=0.005) AR-negative 
patients. Stromal TILs positively correlated with tubule formation (ρ=0.221; p=0.038) among AR-
negative patients and positively correlated with nuclear grade among early-stage AR-positive 
patients (ρ=0.499; p=0.035). Peripheral TILs also negatively correlated with age at diagnosis 
among all (ρ=-0.307; p=0.003) and early-stage (ρ=-0.318; p=0.005) AR-negative patients as well 
as among early-stage AR-positive patients (ρ=-0.495; p=0.037). Among AR-positive patients, 
peripheral TILs were associated with high nuclear (ρ=0.603; p=0.008) and Nottingham (ρ=0.589; 
p=0.010) grades.  
To further explore the prognostic role of TILs in QNBC, we analyzed associations of 
stromal (Table 4A) and peripheral (Table 4B) TILs with expression of common breast cancer 
biomarkers among AR-negative and AR-positive TNBC patients. Interestingly, stromal TILs 
positively correlated with BRCA1-associated protein 1 (BAP1) and programmed death cell protein 
1 (PD1) expression among all (ρ=0.292; p=0.011, ρ=0.469; p<0.0001, respectively)  and early-
stage (ρ=0.282; p=0.024, ρ=0.480; p<0.0001, respectively) AR-negative patients. Among AR-
positive patients, stromal TILs positively correlated with BAP1 expression (ρ=0.531; p=0.034). 
Peripheral TILs positively correlated with PD1 among all (ρ=0.401; p<0.0001) and  early-stage 
(ρ=0.392; p<0.001) AR-negative patients as well. However, peripheral TILs positively correlated 
with forkhead box protein 1 (FOXM1) expression among all AR-negative patients (ρ=0.253; 
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p=0.028). Peripheral TILs also positively correlated with BAP1 expression (ρ=0.60; p=0.02) 
among all (ρ=0.652; p=0.006) and early-stage (ρ=0.603; p=0.017) AR-positive patients.  
7.3.4 High TIL levels were associated with better survival among early-stage AR-negative 
TNBC patients 
We investigated the prognostic power of TILs among AR-negative TNBC patients in both 
Kaplan-Meier analyses and Cox proportional hazard regression models. We examined associations 
of stromal and peripheral TILs with DFS among AR-negative patients in Kaplan-Meier analyses 
(Figure 2). High peripheral TIL levels were associated with significantly longer 10-year DFS 
among all (p=0.037) (Fig 2A) and moderately longer 10-year DFS among early-stage AR-negative 
patients (p=0.053) (Fig 2B).  High peripheral TIL count was also associated with longer 10-year 
DFS among all non-adjuvant chemotherapy-treated (p=0.001) (Fig 2C) and early-stage non-
adjuvant chemotherapy treated (p<0.0001) AR-negative patients (Fig 2D). Furthermore, high 
peripheral TIL levels were associated with better 10-year DFS among radiation-treated early-stage 
AR-negative patients (p=0.044) (Fig 2E). We did not observe associations of stromal TILs with 
DFS among AR-negative patients. We also observed associations with peripheral TILs and DFS 
in univariate and multivariate Cox proportional hazard regression models among AR-negative 
TNBC patients (Table 5). High peripheral TIL levels were associated with longer 10-year DFS 
before (p=0.013; HR: 0.055 95% CI: 0.005-0.542) and after (p=0.026; HR: 0.062 95% CI: 0.005-
0.721) adjusting for age at diagnosis and Nottingham grade among non-adjuvant chemotherapy-
treated AR-negative TNBC patients.  
Peripheral TILs were also associated with OS among AR-negative TNBC patients in 
Kaplan Meier analysis (Figure 3) and in Cox proportional hazard regression models (Table 6). 
High peripheral TIL count was associated with longer 10-year OS among all (p=0.001) (Fig 3A) 
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and early-stage (p<0.0001) (Fig 3B) non-adjuvant chemotherapy-treated AR-negative patients. 
We observed similar results in univariate and multivariate analyses in which high peripheral TIL 
levels were associated with longer 10-year OS among non-adjuvant chemotherapy-treated AR-
negative patients before (p=0.013; HR: 0.055 95% CI: 0.005-0.542) and after (p=0.026; HR: 0.158 
95% CI: 0.027-0.930) adjusting for age at diagnosis and Nottingham grade.     
7.3.5 Distinctions in TIL subsets between aggressive and less aggressive TNBCs 
TILs are comprised of a heterogeneous population of immune cell phenotypes harboring 
pro-tumorigenic and anti-tumorigenic characteristics. To discern distinctions in the types of 
infiltrating immune cells present in the tumor microenvironment between AR-negative and AR-
positive TNBCs, we used the CYBERSORT tool and LM22 to estimate the relative proportions of 
22 immune cell phenotypes among gene expression profiles from AR-low and AR-high expressing 
TNBC patient tissue specimens in the TCGA dataset and analyzed for significant differences 
(Figure 4). We observed significantly lower proportions of naïve B cells (p=0.04) and resting mast 
cells (p=0.048) among AR-low (N=16) compared to AR-high (N=41) TNBCs using a p-value cut-
off of p<0.01 (Fig 4A). Furthermore, we observed weakly significantly lower proportions of 
resting natural killer (NK) cells (p=0.05) and weakly significantly higher proportions of activated 
NK cells (p=0.097) among AR-low (N=37) compared to AR-high (N=106) TNBCs without using 
a p-value cut-off (Fig 4B).     
7.4 Discussion 
TNBC patients have the least amount of targeted treatment options compared to other 
breast cancer patients. A subgroup of TNBCs that lack expression of AR are even more at a 
disadvantage as they are often exempt from receiving AR-targeted therapy as opposed to AR-
expressing TNBCs. Hence, there is an urgent need for alternative pharmacologically-targetable 
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and/or risk-predictive biomarkers for this unique group of TNBC patients. However, studies 
uncovering novel therapeutic targets or biomarkers for QNBC patients remain scarce. Cancer 
immunotherapy or exploiting intrinsic mechanisms of the tumor-host immune system is rapidly 
gaining momentum as a promising alternative strategy in eradicating tumors 21. The immune-rich 
TNBC landscape has identified TNBC patients as strong candidates for novel immunotherapeutic 
intervention 21. However, the role of the tumor immune microenvironment in QNBC remains 
elusive. Xiu and colleagues recently revealed that PD-L1 is overexpressed in QNBC compared to 
TNBC tumors (unpublished data) and PD-L1 is associated with a high level of TILs 22. Hence, we 
investigated differences in TIL levels between QNBC and TNBC patients in a non-neoadjuvant 
chemotherapy setting and investigated the role of TILs as a potential, novel risk-prognostic 
biomarker and therapeutic target for QNBC patients.  
We examined differences in associations with demographic, clinico-pathological variables, 
treatment, and biomarker expression between AR-negative and AR-positive TNBCs. We observed 
that high nuclear and Nottingham grades (grade 3) was more associated with AR-negative 
compared to AR-positive status among TNBC patients. This finding corroborates previous studies 
revealing a lack of AR expression is associated with high-grade tumors. AR-negative status was 
also modestly more associated with receipt of radiotherapy compared to AR-positive status. 
Furthermore, positive HSET and HER3 expression was more associated with AR-positivity 
compared to AR-negativity among TNBC patients. A previous study reported HER4 mRNA 
expression levels were higher in AR-positive compared to AR-negative TNBCs suggesting 
expression of EGFR family members may be associated with AR status 23. 
We observed a significantly higher presence of stromal and peripheral TILs in AR-
negatives compared to AR-positives among all and early-stage TNBC patients. This finding is 
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consistent with a recent study by Davis and colleagues reporting expression of CD4 and CD8 T 
cell markers as well as expression of key immune checkpoint inhibitors, PD-1, PD-L1, and CTLA-
4, were significantly more upregulated among AR-negative compared to AR-positive TNBC 
patients in TCGA dataset24. Thus, within the highly immunogenic TNBC landscape, the QNBC 
subgroup may exhibit increased immune signaling activity compared to AR-expressing TNBCs 
suggesting QNBCs to be even more of an ideal candidate for immunotherapeutic intervention. 
Furthermore, this finding corroborates previous reports of increased lymphocytic infiltration 
among more aggressive breast tumor phenotypes and parallels literature reports of TILs being 
more prevalent among TNBCs compared to non-TNBCs. 
We also examined associations of TILs with demographic and clinico-pathological 
characteristics among AR-negative and AR-positive TNBCs. Stromal and peripheral TILs were 
associated with younger age at diagnosis and aggressive clinico-pathological characteristics such 
as higher tubule formation, nuclear grade, and Nottingham grade among all and early-stage AR-
negative and AR-positive patients, which is consistent with previous studies, cited earlier, 
reporting that TILs are associated with younger age at diagnosis and more aggressive disease.  
We also analyzed associations of TILs with breast clinico-pathological biomarkers among 
AR-negative and AR-positive TNBC patients to glean additional insight into the prognostic and 
mechanistic role of TILs among these patient populations. Both stromal and peripheral TILs were 
associated with increased PD-1 among QNBC patients. PD-1 is frequently expressed on cytotoxic 
CD8+ T cells and thus, is associated with high levels of TILs, which is consistent with our findings 
12. Hence, TILs may serve as a predictive biomarker for response to immune checkpoint therapy 
for QNBC patients. Stromal TILs were also linked to high BAP1 expression among early-stage 
AR-negative patients suggesting increased lymphocytic infiltration may be associated with 
153 
 
increased DNA damage response in QNBC patients. BAP1 is a nuclear-localized, ubiquitin 
carboxy-terminal hydrolase, that binds to the RING finger domain of BRCA1 to facilitate BRCA1-
mediated DNA damage response and arrest of breast cancer cell proliferation25. Thus, high TIL 
levels may also predict positive response to platinum-based agents such as cisplatin and 
carboplatin among QNBC patients. Peripheral but not stromal TILs were associated with high 
FOXM1 expression among AR-negative patients. FOXM1 is a transcription factor that regulates 
cell cycle progression, specifically mitotic division, chromosome segregation and genomic 
stability26,27. It has been found to be overexpressed in approximately 85% of TNBCs and its 
upregulation has been suggested to play a critical role in carcinogenesis through stimulating cell 
proliferation and tumor metastasis28. Thus, the increased presence of stromal TILs among AR-
negative patients may reflect increased aberrant cell division and chromosome segregation errors 
and may predict a positive response to FOXM1 inhibitors. Among AR-positive patients, high 
peripheral TIL levels were also linked to increased BAP1 expression or DNA damage suggesting 
an increased anti-tumor inflammatory response may be associated with genomic instability among 
TNBC patients irrespective of AR status.  
To further explore the role of TILs as a potential prognostic biomarker for QNBC patients, 
we investigated associations of TIL levels with clinical outcomes among AR-negative patients. 
We discovered that high peripheral TIL levels were associated with longer DFS and OS among 
early-stage QNBC patients in Kaplan-Meier and all QNBC patients multivariate analyses, which 
corroborate previous studies showing that a greater presence of TILs is associated with a better 
prognosis in TNBC. High peripheral TIL levels were also linked to longer DFS among radiation-
treated early-stage AR-negative patients suggesting that TILs may be able to predict response to 
radiotherapy in QNBC patients.  
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Our in silico analyses discerning distinctions in the proportions of infiltrating immune cell 
subsets between AR-high and AR-low expressing TNBCs supports our findings of increased anti-
tumor immune activity among QNBC patients. We observed significantly lower proportions of 
naïve B cells and resting mast cells as well as a trend of less resting NK cells and more activated 
NK cells in AR-low compared to AR-high TNBCs, suggesting increased anti-tumor immune 
activity in QNBCs compared to TNBCs. These findings corroborate our in vivo findings of 
increased lymphocytic infiltration among AR-negative TNBC patients and support previous 
reports of a greater presence of immune cell infiltration associated with more aggressive breast 
cancer. However, further investigation is necessary to unravel the composition of the tumor 
immune microenvironment of AR-negative TNBC tumors for precise immunotherapeutic 
intervention.  
Our work suggest a novel, alternative risk-predictive and prognostic biomarker for 
QNBC patients who are insusceptible to AR-targeted treatment as opposed to AR-positive 
TNBCs. TILs are currently being tested in clinical trials as a therapeutic strategy for TNBC 
patients29. Adoptive T cell therapy has already shown promising results in clinical trials for 
melanoma patients as an approximate 50% reduction in tumor size was observed among half of 
the patients 30. Thus, the administration of TIL immunotherapy to QNBC patients harboring low 
levels of TILs may be beneficial for this patient population and serves as a potential, alternative 
therapeutic option for this challenging disease.  The addition of PD-1/PD-L1 checkpoint 
blockade therapy to TIL immunotherapy may elicit a more robust response among this patient 
population. Our study may also encourage the development of novel immunotherapeutic 
strategies designed to counteract mechanisms that restrict tumor lymphocytic infiltration, which 
may be advantageous for early-stage QNBC patients. Our work encourages further investigation 
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of tumor-host immune interactions among AR-negative TNBCs to uncover more novel 
immunotherapeutic targets. Conveniently, groups such as the International TILs Working Group 
in 2014 and the International Immuno-Oncology Biomarker Working Group on Breast Cancer 
have developed standardized methodologies for evaluating stromal TILs in hematoxylin and 
eosin (H&E) stained tumor tissue sections as standard routine histopathological practice 31,32. 
These methodologies encourage the implementation of TILs in the clinic as a standard clinico-
pathological parameter for prediction of patient prognosis. Our study suggests evaluation of TILs 
should be done routinely in the clinic for AR-negative TNBC patients, who lack other prognostic 
markers and treatment options. However, our findings were uncovered in a non-neoadjuvant 
chemotherapy setting which represents a limitation to our study. Validation of our findings in 
additional non-neoadjuvant chemotherapy and neoadjuvant chemotherapy treated patient cohorts 
as well as more characterization of immune cell subsets among AR-enriched and non-enriched 
triple negative breast tumors will be critical, however, to establishing TILs as a robust prognostic 
biomarker and therapeutic strategy for QNBC patients. 
7.5 Methods 
7.5.1 Study Cohort 
We analyzed a cohort of 121 TNBC patients observed at EH in Atlanta, GA from 2002 
(initial day of diagnosis) to 2016 (last day of contact). We obtained approval and informed consent 
from the Emory University Institutional Review Board to gain access to patient information and 
samples used in this study and to perform the experiments conducted in this article. We have a 
human subjects assurance on file. The study was conducted in accordance with relevant 
guidelines/regulations. The percentage of stromal and peripheral TILs was assessed in 
hematoxylin- and eosin- stained patient specimens as described by Krishnamurti and colleagues 
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13. Stromal TILs were evaluated according to the International TILs working group 2014 in which 
the percentage of stromal tissues occupied by infiltrating lymphocytes and plasma cells were 
estimated 32. Intratumoral lymphocytes, or lymphocytes in direct contact with tumor cells, were 
excluded from the evaluation as no patients in this study underwent neoadjuvant chemotherapy. 
Peripheral TILs were also evaluated as the percentage of stromal lymphocytes occupying the entire 
circumference of the invasive tumor front with a width of roughly one dozen tumor cells. The 
percentage of stromal and peripheral TILs were estimated in intervals including <5%, 5-10%, 11-
50% and >50%. Patient demographic characteristics, clinico-pathological variables, and breast 
cancer biomarker status were recorded for each patient. This article referred to the 7th edition of 
the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 
TNM Classification and Stage groupings for breast cancer 33. Demographic characteristics include 
self-reported race and age at the time of diagnosis. Patient treatment was recorded including 
adjuvant chemotherapy and radiation therapy.  
7.5.2 Immunohistochemistry and scoring 
Biomarker expression was evaluated through standard immunohistochemical (IHC) 
staining and scored as Hscore (percentage x intensity), Nper (nuclear percentage) and Nhscore 
(nuclear percentage x intensity). Intensity of staining were scored as 0=none, 1=low, 
2=moderate, and 3=high. No patients in this study underwent neoadjuvant chemotherapy. 
Negativity was determined as <1% expression and positivity was determined as ≥1% expression 
for all biomarkers. Antibody details and concentrations can be found in Supplementary Table 
S3. The maximum score for any given H-score is 300. Patient samples were stained, scored, and 
reviewed at EH. Scoring was performed by two independent pathologists blinded to clinical 
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annotation and individual scores were averaged. TNBC patients negative or positive for AR 
(Nper) were classified as AR-negative and AR-positive TNBC patients, respectively.  
7.5.3 Follow Up 
Initial diagnosis of patients occurred between 2002 and 2016. Median duration of follow-
up for EH was approximately 6 years. Initial dates of diagnoses, treatment start and completion 
dates, and last dates of contact were recorded for each patient. Survival status (alive/dead) was 
also recorded for available patients in addition to survival time. The date of last follow-up for the 
last patient seen is March 3, 2016. 
7.5.4 Gene Expression Dataset and Infiltrating Immune Cell Composition Determination 
We queried the publically available The Cancer Genome Atlas (TCGA) breast dataset from 
the TCGA portal for all TNBC patients 34. Publically available ER/PR/HER2/AR 
Immunohistochemical data was used to determine TNBC/QNBC status and a log-rank test was 
performed to stratify TNBC patients into AR-low and AR-high expressing subgroups. We utilized 
the Cell type Identification By Estimating Relative Subsets of known RNA Transcripts 
(CYBERSORT) tool, which is a deconvolution algorithm that uses a set of reference gene 
expression values, to resolve intratumoral immune cell composition in gene expression data in 
tumor samples of mixed cell types 35. The Leukocyte gene signature matrix (LM22), which is 
comprised of 547 genes that resolves 22 human hematopoietic cell phenotypes [seven T cell types, 
naïve and memory B cells, plasma cells, natural killer cells, and myeloid subsets] in tumor samples, 
was used to identify proportions of each immune cell type in TNBC patients based on their gene 
expression profiles in the TCGA dataset 35. To avoid false positives, gene expression data was 
processed using 1000 permutations. As the input data was normalized, the quantile normalization 
option was disabled.  
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7.5.5 Statistical Analysis 
The significance level for all analyses was p<0.05 and 95% confidence intervals estimated. 
SAS 9.4 program was used to generate test statistics and 2-tailed univariate p-values were reported. 
Chi-square tests were performed to analyze differences in associations with demographic 
characteristics, breast clinico-pathological variables and biomarkers, as well as treatment 
information between AR-negative and AR-positive TNBC patients. Wilcoxon rank-sum tests were 
performed to determine differences in the means of stromal and peripheral TILs between AR-
negative and AR-positive TNBC patients. Pearson correlation coefficients (ρ) were computed to 
determine correlations between stromal and peripheral TILs with demographic and clinico-
pathological variables as well as biomarker expression among AR-negative and AR-positive 
TNBC patients. Spearman’s rank correlation coefficients (ρ) were generated for categorical 
variables. Unadjusted and adjusted multivariate Cox proportional hazard models were computed 
to assess the impact of TILs on 10-year OS and disease-free survival (DFS) before and after 
controlling for age and Nottingham grade. The Kaplan-Meier analysis was conducted using SAS 
9.4 program to estimate survival function for AR-negative TNBC patients over a 10- year period 
based on high and low TIL levels. A log-rank test was used to stratify stromal and peripheral TILs 
into high (³10) and low (<10) groups to evaluate associations of a high and low presence of TILs 
with better or worse survival for Kaplan-Meier analyses. Wilcoxon rank-sum tests were performed 
to determine significant differences in the proportions of immune cell fractions between AR-low 
and AR-high expressing TNBCs after generating CIBERSORT outputs.  A p-value cutoff of <0.01 
was used. A log-rank test was also performed to identify the appropriate cut-off for low and high 
expression of AR among TNBC patients in the TCGA dataset.  
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7.6 Tables and Figures 
Table 7.1 Clinico-pathological characteristics of AR-negative and AR-positive TNBC patients 




Table 7.2 Breast cancer biomarker expression among AR-positive and AR-negative TNBC 
















Table 7.4 Correlation of stromal TILs with demographic and clinico-pathological variables 

















Table 7.5 Correlation of stromal TILs with clinico-pathological biomarkers among AR-























Figure 7.1 Comparison of stromal and peripheral TILs between AR- negative and AR-positive 
TNBC patients.  
Comparison of stromal TILs between all AR- negative and AR-positive TNBC patients (A) and 
early-stage AR-negative and AR-positive TNBC patients (B) overall and with or without adjuvant 
chemotherapy (chemo) or radiation (rad) treatment. Comparison of peripheral TILs between all 
AR- negative and AR-positive TNBC patients (C) and early-stage AR-negative and AR-positive 
TNBC patients (D) overall and with or without adjuvant chemotherapy (chemo) or radiation (rad) 









Figure 7.2 Peripheral TILs are associated with disease-free survival among early-stage AR-
negative TNBC patients.    
Peripheral TILs were stratified into high (≥30) and low (<30) subgroups using a log-rank test. 
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on 
disease-free survival  (DFS) over a 10-year period among AR-negative TNBC patients. Prediction 
of high and low peripherals TILs on 10-year DFS among all AR-negative patients (A), early-stage 
AR-negative patients (B), non-adjuvant chemotherapy-treated AR-negative patients (C), non-
adjuvant chemotherapy-treated early-stage AR-negative patients (D), and radiation-treated early-










Figure 7.3 Peripheral TILs are associated with overall survival among early-stage AR-
negative TNBC patients.    
Peripheral TILs were stratified into high (≥15) and low (<15) subgroups using a log-rank test. 
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on 
overall survival over a 10-year period among AR-negative TNBC patients. Prediction of high and 
low peripherals TILs on 10-year OS among all and  early-stage non-adjuvant chemotherapy-



























Figure 7.4 Comparison of intratumoral immune cell fractions between AR- low and high 
TNBC samples.   
CIBERSORT tool was used to determine the proportions of distinct infiltrating immune cells 
among AR- low and high TNBCs isolated from the TCGA breast dataset. The color gradient from 
green to red represents the increasing fractions of intratumoral immune cells. Immune cell 
fractions that showed statistically significant differences between AR- low and high TNBCs with 
lower proportions of naïve B cells and resting mast cells among AR-low compared to AR-high 
TNBCs with a p-value cut-off of <0.01. Immune cell fractions that showed weakly statistically 
significant differences (0.05>p<0.1) between the races with a smaller proportion of resting NK 
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cells and greater proportion of activated NK cells among AR-low compared to AR-high TNBCs 
with no p-value cut-off. 
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8 RACIAL DISPARITIES IN LYMPHOCYTIC INFILTRATION AMONG EARLY-
STAGE AFRICAN-AMERICAN AND EUROPEAN-AMERICAN QUADRUPLE 
NEGATIVE BREAST TUMORS 
8.1 Abstract 
The role of androgen receptor (AR) in TNBC remains controversial, however, some studies 
report that lack of AR expression in TNBC or quadruple negative breast cancer (QNBC) confers 
a more aggressive disease course. Emerging evidence suggests that QNBC is more prevalent 
among women of African descent. Tumor infiltrating lymphocytes (TILs) are inflammatory 
mediators have been associated with favorable clinical outcomes and response to neoadjuvant 
and adjuvant chemotherapy but more aggressive disease characteristics in TNBC. We compared 
stromal and peripheral TILs between AA (N=55) and EA (N=20) QNBC patients treated at 
Emory University Hospital in Atlanta, GA. We also performed differential gene expression 
analysis between AA and EA QNBC patients in a publicly available gene expression dataset. 
Among early-stage (I-II) QNBC patients (N=63), we observed more stromal TILs in AA TNBCs 
(N=44) compared with EA TNBCs (N=19) (p=0.047). Stromal TILs negatively correlated with 
age at diagnosis among all (ρ=-0.272; p=0.044) and positively correlated with programmed cell 
death protein 1 (PD1) expression among early-stage  (ρ=0.460; p=0.001) AA QNBC patients . 
High peripheral TIL levels predicted longer 10-year OS among early-stage AA QNBC patients 
in multivariate analyses (p=0.015; HR:0.155). Our gene expression analyses revealed significant 
upregulation of biological pathways, gene ontologies, and genes reflecting increased pro-
inflammatory activity in AA compared with EA AR-low expressing TNBCs. Our findings 
indicate a previously unrecognized racial disparity in the tumor immune microenvironment 
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among early-stage QNBCs. Furthermore, peripheral TIL levels may be able to serve as a risk-
prognostic biomarker for early-stage AA QNBC patients. 
8.2 Introduction 
Triple negative breast cancer (TNBC) is the most difficult form of breast cancer to treat 
owing to its lack of the pharmacologically targetable biomarkers of proliferation, estrogen 
receptor, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) 
(1) [1]. The disease disproportionately afflicts younger women as well as women of African 
descent(2-4). TNBC patients of African ancestry also exhibit more unfavorable clinico-
pathological characteristics and acquire more aggressive TNBC subtypes such as basal-like and 
androgen receptor-negative TNBC or quadruple negative breast cancer (QNBC) compared with 
TNBC patients of European descent (3, 5-10). Furthermore, our group recently reported that AAs 
experience poorer survival than EAs among QNBC patients (unpublished data). Owing to 
variability in AR staining cut-offs, roughly 45-88% of TNBCs have been reported to lack AR 
nuclear expression(11). AR-targeted therapies have emerged as a promising alternative therapeutic 
strategy for AR-expressing TNBCs(12, 13). However, most AR-negative TNBCs are less 
susceptible to AR-targeted therapy. Furthermore, the prognostic role of AR in TNBC remains 
controversial, however, a lack of AR expression has been associated with poor differentiation, high 
clinical stage, high Ki-67, high mitotic index, increased lymphovascular invasion, increased risk 
of recurrence and distant metastasis, and worse 5-year disease-free survival and overall survival 
(OS) (14-19). Hence, an increased prevalence of AR-negative TNBC among AA women may be 
contributing to the racial disparate burden in TNBC. Thus, novel alternative biomarkers and 
therapies targeting AA QNBC are urgently needed to help alleviate this burden.  
Tumor infiltrating lymphocytes (TILs) have emerged as key mediators of the anti-tumoral 
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inflammatory response. Upon neoplastic transformation, TILs migrate to the tumor site to prevent 
progression (20, 21). TILs that migrate to the tumor stroma are considered stromal TILs and 
stromal TILs that occupy the invasive tumor front or periphery of the tumor are considered 
peripheral TILs(22, 23). Accumulating evidence suggests that stromal TILs have a strong 
prognostic role in TNBC. Stromal TILs have been associated with improved overall survival (14), 
increased metastasis-free survival, reduced risk of relapse and reduced distance recurrence in 
TNBC (24). For every 10% increase in stromal TILs, a 15% reduction in relapse risk and 17% 
reduction in death risk has been reported(24). Furthermore, a high level of stromal TILs has been 
associated with improved pathological complete response following neoadjuvant chemotherapy 
(NAC), validating TILs as a predictive biomarker in TNBC (23-25). Recently in a non-NAC 
setting, peripheral TILs were associated with high Nottingham grade as well as longer OS and 
disease-free survival among TNBC patients in univariate and multivariate analyses(22). 
Paradoxically, the presence of stromal TILs has been associated with more aggressive clinico-
pathological tumor characteristics in BC such as high grade, high stage, high Ki-67, lymph node 
metastasis, a TNBC phenotype, and young age at diagnosis (25-31). Furthermore, Davis et al. 
recently reported that T cell immune response and checkpoint markers were significantly more 
upregulated among QNBC compared to TNBC patients in the TCGA dataset and AA QNBCs were 
more enriched in immune gene signatures compared to EA QNBCs(32). Thus, we were interested 
in evaluating if there was a disparity in the presence of TILs among AA and EA QNBC tumors 
and if TILs could function as a risk-prognostic biomarker in QNBC patients of African descent.  
8.3 Results 
8.3.1 Clinico-pathological characteristics among racially-distinct QNBC patients  
We compared clinico-pathological variables and treatment information between AA 
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(n=55) and EA (n=20) QNBC patients observed at EH (Table 2). We observed a significant 
difference in associations with mitotic index between AA and EA QNBC patients (p=0.012). We 
observed a significantly greater proportion of AA patients with a high mitotic score compared with 
EA patients, wherein 61.33% of AAs and 13.3% of EAs exhibited a mitotic count of 3. We also 
discovered a significant difference in associations with Nottingham grade and race. A significantly 
greater percentage of AA patients exhibited a high Nottingham grade compared with EA patients 
in which, 66.7% of AAs and 17.3% of EAs exhibited a score of 3. We also examined differences 
in associations with expression of established clinical biomarkers in BC between AA and EA 
QNBC patients to gain more insight into differences in disease pathology between these patient 
populations (Table 3). We only observed a significant difference in associations with β-catenin 
expression between the racially-distinct QNBC patients (p=0.049), with 62.7% of AA QNBCs 
positive for β-catenin compared with only 16% of EA QNBCs.    
8.3.2 AAs harbor more TILs than EAs among early-stage QNBC patients  
We investigated differences in the presence of stromal and peripheral TILs between AA 
(N=55) and EA (N=20) QNBC patients (Figure 1). We observed that stromal TILs were weakly 
higher in AAs compared with EAs among all QNBC patients (p=0.1) (Fig 1A). We also examined 
disparities in stromal and peripheral lymphocytic infiltration among racially-distinct early-stage 
QNBC patients to consider if distinctions in TIL count in early-stage disease could be influencing 
differences in prognosis between patients of African and European descent. Among early-stage (I-
II) (N=63) QNBC patients, AAs (N=44) harbored significantly more stromal TILs than EAs 
(N=19) (p=0.047). We also investigated if racial differences persisted based on type of treatment 
received among early-stage patients to evaluate if treatment could be impacting racial disparities 
in tumor lymphocytic infiltration. Among early-stage QNBC patients treated with radiation, AAs 
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(N=24) exhibited a higher presence of stromal TILs than EAs (N=14) (p=0.05) but not among 
chemotherapy-treated patients. We did not observe significant differences in peripheral TILs 
between the racial groups among all QNBC patients and among the subset of early-stage QNBC 
patients regardless of radiation treatment (Fig 1B).  
 
8.3.3 TILs are associated with more aggressive disease features among early-stage AA 
QNBC patients 
We examined correlations of stromal (Table 4) and peripheral TILs (Table 5) with 
demographic and clinico-pathological variables among all and early-stage racially-distinct QNBC 
patients. Correlation coefficients of stromal and peripheral TILs with demographic and clinico-
pathological characteristics among QNBC patients can be found in Tables 6 and 7, respectively. 
Among AA patients, stromal TILs negatively correlated with age at diagnosis (ρ=-0.272; p=0.044). 
Stromal TILs also negatively correlated with age at diagnosis among early-stage EA patients (ρ=-
0.844; p=0.004). Moreover, stromal TILs positively correlated with lymph node involvement 
among all EA patients (ρ=0.461; p=0.041).  Regarding clinical biomarkers, stromal TILs positively 
correlated with programmed cell death protein 1 (PD1) expression among early-stage AA patients 
(ρ=0.460; p=0.001) as well as chemotherapy- and radiation- treated early-stage (ρ=0.662; 
p<0.0001, ρ=0.725; p<0.0001, respectively) AA patients. Furthermore, stromal TILs positively 
correlated with expression of the ligand for PD1, programmed cell death ligand 1 (PD-L1), among 
chemotherapy- and radiation- treated early-stage (ρ=0.513; p=0.004, ρ=0.545; p=0.006, 
respectively) AA patients. Stromal TILs also significantly correlated with PD1 and PD-L1 
expression among early-stage chemotherapy- and radiation- treated early-stage EA patients. 
However, stromal TILs also positively correlated with epidermal growth factor receptor (EGFR) 
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expression among early-stage EA patients (ρ=0.867; p=0.012) as well as with BRCA1-associated 
protein 1 (BAP1) among radiation-treated early-stage EA patients (ρ=0.661; p=0.038).     
We observed similar associations with peripheral TILs among racially-distinct QNBC 
patients. Peripheral TILs also negatively correlated with age at diagnosis among all AA patients 
(ρ=-0.289; p=0.032) and among early-stage EA patients (ρ=-0.784; p=0.012). Furthermore, 
peripheral TILs positively correlated with lymph node involvement and among early-stage 
(ρ=0.440; p=0.015) and chemotherapy-treated early-stage (ρ=0.381; p=0.038) AA patients. 
Peripheral TILs also positively correlated with lymph node involvement (ρ=0.481; p=0.032) and 
lymphovascular invasion (ρ=0.457; p=0.043) among EA patients and these associations persisted 
among chemotherapy- and radiation treated early-stage EA patients. Peripheral TILs also 
positively correlated with PD1 among early-stage AA (ρ=0.289; p=0.034) and chemotherapy- and 
radiation treated (ρ=0.390; p=0.033, ρ=0.476; p=0.019, respectively) early stage AA patients. 
However, peripheral TILs positively correlated with EGFR expression among early-stage 
(ρ=0.867; p=0.012) and radiation-treated early-stage (ρ=0.717; p=0.020) EA patients.  
8.3.4 High TIL levels associated with better survival among early-stage AA QNBC patients 
We investigated the prognostic value of stromal and peripheral TILs among racially-
distinct QNBC patients to elucidate the role of TIL count in the racially disparate burden in QNBC 
disease. We analyzed the impact of TILs on survival in early-stage disease and examined the 
influence of treatment on TILs and prognosis to gain more insight into the prognostic role of 
lymphocytic infiltration. Stromal and peripheral TILs were stratified into high and low subgroups 
using a log-rank test and Kaplan-Meier analyses were performed to determine the impact of TILs 
on survival over a 10-year period (Figure 2). We observed that peripheral TILs were associated 
with significantly with longer 10-year overall survival (14) among all AA QNBC patients 
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(p=0.013) (Fig 2A). Furthermore, peripheral TILs were associated with significantly better 10-
year OS among radiation treated (p=0.032) but not chemotherapy treated (p=0.095) AA patients 
(Fig 2A-C). High peripheral TIL levels were also associated with significantly longer OS among 
early-stage AA QNBC patients (p=0.011) (Fig 2D). Moreover, high peripheral TILs levels were 
associated with significantly better 10-year OS among radiation treated early-stage (p=0.031) but 
not among chemotherapy-treated early-stage (p=0.074) AA patients (Fig 2E-F). Associations of 
peripheral TILs with OS among EA QNBC patients were not observed (data not shown). 
Associations of stromal TILs with OS were also not observed among both AA and EA patients.   
We also assessed unadjusted and adjusted associations of stromal and peripheral TILs with 
10-year OS among AA and EA QNBC patients by computing univariate and multivariate Cox 
proportional hazard regression models adjusted for age, grade, and stage (Table 8). Similarly, in 
Kaplan-Meier analyses, high peripheral TIL levels predicted longer 10-year OS among AA QNBC 
patients in unadjusted (p=0.020; HR:0.290) and in multivariate Cox proportional hazard regression 
model (p=0.027; HR:0.272). Among radiation-treated AA QNBC patients, high peripheral TIL 
levels also predicted significantly longer 10-year OS in adjusted analyses (p=0.042; HR:0.025). 
Furthermore, among early-stage AA QNBC patients, high peripheral TILs predicted significantly 
better 10-year OS before (p=0.020; HR:0.290) and after adjusting for potential confounding factors 
(p=0.015; HR:0.15). Peripheral TILs were unable to predict survival among EA QNBC patients. 
Stromal TIL were unable to predict survival among both AA and EA QNBC patients.    
8.3.5 Increased upregulation of immune response-related genes, pathways and gene 
ontologies among AA compared with EA AR-low expressing TNBC patients 
We investigated differential expression of immune response-related genes, pathways, and 
gene ontologies between AA compared with EA AR-low expressing TNBC patients isolated from 
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TCGA breast dataset. We utilized the GAGE and Pathview packages to analyze differences in 
biological pathways or experimentally-derived differential expression sets and gene ontologies, 
respectively between AA and EA AR-low expressing TNBCs in TCGA breast dataset. We 
observed significantly more upregulation of the leukocyte transendothelial migration expression 
set among AA compared with EA AR-low expressing TNBC samples (p=0.049) (Table 9). We 
also observed significantly more upregulation of gene ontologies reflecting a pro-inflammatory 
immune response such as innate immune response, interferon-gamma-mediated signaling 
pathway, type I interferon-mediated signaling pathway, interleukin-1 secretion, vasodilation, and 
natural killer cell differentiation and activation (p<0.05) among AA compared with EA AR-low 
expressing TNBC patients (Table 10). We also observed significantly more upregulation of pro-
inflammatory genes among AA compared to EA QNBC patients (p<0.05) (Table 11).  
8.4 Discussion 
Recent evidence suggest that women of African ancestry are also disproportionately 
afflicted by QNBC, indicating that AA patients are less susceptible to AR-targeted therapy than 
EA patients. The role of the tumor immune microenvironment in the racial disparate burden in 
QNBC remains elusive. Hence, we investigated the prognostic and predictive role of TIL among 
racially-distinct QNBC patients to determine their potential as a promising risk-prognostic 
biomarker and/or therapeutic target among QNBC patients of African descent.  
We observed a significantly greater proportion of AA patients with a high mitotic score 
and Nottingham grade than EA patients suggesting QNBC patients of African descent exhibit more 
aggressive disease features than QNBC patients of European descent. These findings also 
corroborate Bhattarai et al.’s findings suggesting a poorer prognosis among AA compared with 
EA QNBC patients (unpublished data). We also discovered a significantly greater proportion of 
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AAs positive for β-catenin compared with EAs among QNBC patients. Wnt/β-catenin signaling is 
highly upregulated in TNBC and associated with increased risk for metastasis(39). β-catenin has 
been found to positively correlate with stromal lymphocytic infiltration in BC, suggesting that 
Wnt/β-catenin signaling may be playing a critical role in BC anti-tumoral immunity(31). 
Furthermore, β-catenin overexpression was recently reported to underlie an aggressive disease 
course among AA QNBC patients. Thus, differential expression of this marker between AA and 
EA QNBCs may be playing a role in the racial disparate burden in QNBC.   
We discovered that the percentage of stromal TILs were significantly higher among AA 
compared with EA among early-stage QNBC patients as well as among early-stage QNBC patients 
treated with radiotherapy. Thus, a higher TIL count may be reflective of increased antitumoral 
immune response among AAs compared with EAs in early-stage QNBC disease. We speculate 
that increased inflammatory activity among AA tumors, despite their poorer clinical outcomes 
compared to EAs, might be reflective of an enhanced immune response as a result of their more 
aggressive disease. Among AA QNBC patients, both stromal and peripheral TILs were associated 
with younger age at diagnosis, which corroborates previous reports of increased tumor 
lymphocytic infiltration among TNBC patients diagnosed at a younger age. Furthermore, 
peripheral TILs were associated with increased lymph node involvement among early-stage AA 
QNBC patients as well as chemotherapy-treated early-stage AA QNBC patents, which is also 
similar to previous reports of increased tumor lymphocytic infiltration associated with greater 
lymph node involvement in TNBC. In regards to clinical biomarkers, both stromal and peripheral 
TILs were associated with increased PD1 expression among early-stage AA QNBC patients as 
well as among chemotherapy- and radiation- treated early-stage AA QNBC patients suggesting 
elevated levels of PD1-expressing TILs and immunosuppression among this patient population in 
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early-stage disease irrespective of treatment. Stromal TILs were also associated with increased 
PD-L1 expression among chemotherapy- and radiation- treated early-stage AA QNBC patients, 
further indicating increased TIL immunosuppression among AA QNBC patients in the early stages 
of their disease. Among EA QNBC patients, high stromal and peripheral TIL levels were also 
associated with younger age at diagnosis as well as increased lymph node involvement and 
lymphovascular invasion. Stromal TILs positively correlated with BAP1 among radiation-treated 
early-stage EA patients suggesting TILs may be associated with increased DNA damage response 
among these patients.   
We observed that high peripheral TIL levels predicted significantly better 10-year OS 
among all and early-stage AA QNBC patients in both Kaplan-Meier and multivariate analyses. 
Furthermore, high peripheral TIL levels predicted significantly better 10-year OS among all and 
early-stage radiation treated AA QNBC patients in Kaplan-Meier analyses and among all radiation 
treated AA QNBC patients in multivariate analyses. Thus, these findings indicate that peripheral 
TIL levels may be able to risk-stratify early-stage QNBC patients of African descent for better or 
worse survival and that peripheral TILs may be able to predict response to radiotherapy among 
AA QNBC patients. Furthermore, our results suggest therapies that induce antitumoral immunity 
such as adoptive T cell therapy may be selectively beneficial for QNBC patients of African 
descent.  
Our gene expression analyses revealed significantly more upregulation of pro-
inflammatory genes, biological pathways, and gene ontologies among AA compared with EA AR-
low expressing TNBC patients in the TCGA breast dataset. Particularly, we observed significantly 
more enrichment of the leukocyte transendothelial migration biological pathway among AA 
compared with EA AR-low expressing TNBCs suggesting AA QNBC patients may exhibit more 
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recruitment of pro-inflammatory mediators. Furthermore, gene ontologies reflecting increased T 
cell and NK cell antitumoral immunity were significantly more upregulated among AA compared 
with EA AR-low expressing TNBCs. Moreover, genes encoding chemokines and cytokines as well 
as other key mediators in the T- and NK- cell-mediated antitumoral immune response were 
significantly more upregulated in AA compared with EA among AR-low expressing TNBC 
samples. In addition, the innate immune response gene ontology was significantly more 
upregulated among AA compared with EA AR-low expressing TNBC samples suggesting 
increased innate immunity among QNBC patients of African compared with European descent.  
Our study uncovers previously unrecognized racial differences in the tumor immune 
microenvironment among QNBCs, reveals a novel, alternative risk-prognostic biomarker and 
suggests early-stage AA QNBC patients harboring lower levels of TILs may be ideal candidates 
for TIL immunotherapy, particularly among those undergoing radiotherapy. However, robust 
validation of our results in additional non-NAC and NAC patient cohorts as well as 
characterization of TIL immune subsets in early-stage QNBC patients of African ancestry will be 
critical to successfully achieving this aim.      
8.5 Methods 
8.5.1 Study Cohort 
We analyzed a cohort of 75 TNBC patients negative for AR expression (AR Nh-score) 
among 121 TNBC patients treated at Emory University Hospital (EH) in Atlanta, GA from 2002 
(initial day of diagnosis) to 2016 (last day of contact). We obtained approval and permission from 
the institutional review board at EH to gain access to patient information and samples used in this 
study. The percentage of stromal and peripheral TILs was assessed in hematoxylin- and eosin- 
stained patient specimens as described by Krishnamurti and colleagues (22). TILs were evaluated 
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according to the International TILs working group 2014 in which the percentage of stromal tissues 
occupied by infiltrating lymphocytes and plasma cells were estimated(33). Intratumoral 
lymphocytes, or lymphocytes in direct contact with tumor cells, were excluded from the evaluation 
and only stromal lymphocytes were counted. Peripheral TILs were evaluated as the percentage of 
stromal lymphocytes occupying the entire circumference of the invasive tumor front with a width 
of roughly one dozen tumor cells(22). The percentage of stromal and peripheral TILs were 
estimated in intervals including <5%, 5-10%, 11-50% and >50%. Patient demographic 
characteristics, clinico-pathological variables, and breast cancer (BC) biomarker status were 
evaluated and recorded for each patient. Demographic characteristics include self-reported race 
and age at the time of diagnosis. This article referred to the 7th edition of the American Joint 
Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM Classification 
and Stage groupings for BC (34). Information on patient treatment was also recorded including 
adjuvant chemotherapy and radiation therapy. No patients in this study underwent NAC. 
8.5.2 Immunohistochemistry and scoring 
Expression of all BC biomarkers investigated in this study was determined through 
immunohistochemical (IHC) staining and scored as H-score (percentage x intensity), Nper 
(nuclear percentage) and Nh-score (nuclear percentage x intensity). Intensity of staining were 
scored as 0=none, 1=low, 2=moderate, and 3=high. Negativity was determined as <1% expression 
and positivity was determined as ≥1% expression for all biomarkers. Antibody details and 
concentrations can be found in Table 1. The maximum score for any given H-score is 300. 
Negativity was determined as <1% expression and positivity was determined as ≥1% expression 
for all biomarkers. Patient samples were stained, scored, and reviewed at EH. Scoring was 




8.5.3 Follow Up 
Initial diagnosis of patients occurred between 2002 and 2016. Median duration of follow-
up for EH was approximately 6 years. Initial dates of diagnoses, treatment start and completion 
dates, and last dates of contact were recorded for each patient. Survival status (alive/dead) was 
also recorded for each patient in addition to survival time. The date of last follow-up for the last 
patient seen is March 3, 2016.  
8.5.4 Differential Gene Expression Determination  
We queried the publically available The Cancer Genome Atlas (TCGA) breast dataset from 
the TCGA portal for all TNBC patients(35). Publically-available ER/PR/HER2/AR IHC data was 
used to determine TNBC and QNBC status. We performed a log-rank test to identify the optimal 
cut-off to stratify the TNBC patients into high- (³160.43) and low- (<160.43) AR expressing 
patients. According to the race data, we selected AA and EA samples out of the AR-low expressing 
TNBC samples. We performed differential gene expression analysis for 15,942 genes between the 
ethnic groups using the DESeq2 software tool(36). Differential expression analyses of Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontologies between the ethnic 
groups were predicted by GAGE and Pathview packages, respectively(37, 38).  
8.5.5 Statistical Analysis 
The significance level for all analyses was p<0.05 with 95% confidence intervals (CIs). 
Chi-square tests were performed to analyze differences in demographic characteristics, breast 
clinico-pathological variables and biomarkers, and treatment information between AA and EA 
QNBC patients. SAS 9.4 program was used to generate test statistics and 2-tailed univariate p-
values were reported. Wilcoxon rank-sum tests were performed to determine differences in the 
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means of stromal and peripheral TILs between AA and EA patient populations. Pearson correlation 
coefficients (ρ) were computed to determine associations between stromal and peripheral TILs 
with demographic and breast clinico-pathological variables and biomarkers among AA and EA 
QNBC patients. Spearman’s rank correlation coefficients (ρ) were computed for categorical 
covariates. Unadjusted and adjusted multivariate Cox proportional hazard regression models were 
computed to assess the impact of TILs on 10-year OS before and after controlling for age, 
Nottingham grade, and stage. The Kaplan-Meier analysis was conducted using SAS 9.4 program 
to estimate survival function for AA and EA QNBC patients over a 5- or 10- year period based on 
high and low TIL levels. A log-rank test was used to stratify stromal and peripheral TILs into high 
and low groups to evaluate associations of a high and low presence of TILs with better or worse 
survival among racially-distinct QNBC patients. The Wald test was used to test for significance 
among differentially expressed genes between the racial-distinct patient populations using the 
DESeq2 software tool. 
8.6 Tables and Figures 











Table 8.2 Clinico-pathological and treatment characteristics of AA and EA QNBC patients 
observed at EH.  
Table 8.1 Antibodies and dilutions used for immunohistochemical biomarker staining at EH.  
Biomarker 
Subcellular 
location Clone  Source Species Dilution 
FOXM1 
(NPER) Nuclear G-5 Santa Cruz 
monoclonal 
mouse 1:200 









AB1287 Abcam polyclonal Rabbit 1:20 
SURVIVIN 
(NPER) Nuclear 71G4b7 Cell Signaling polyclonal Rabbit 1:400 
BAP1 












SCORE) Membrane E1L3N Cell Signaling polyclonal rabbit 1:200 
RARa (H-
SCORE) Nuclear C-20 Santa Cruz polyclonal rabbit 1:20 
EGFR (H-










SCORE) Cytoplasmic HFR-1 Abcam 
monoclonal 
mouse 3:1 
Abbreviations; FOXM1, Forkhead box 1 protein; AR, androgen receptor; PRC1, protein 
regulator of cytokinesis 1; RARα, Retinoic acid receptor α; BAP1, BRCA1 associated protein 
1; PD1, Programmed cell death protein 1; PD-L1, Programmed cell death ligand 1, H-score, 
percentage x intensity; Nper, nuclear percentage; Nh-score, nuclear percentage x intensity; 






Table 8.3 Breast cancer biomarker expression among AA and EA QNBC patients observed at 
EH. 
Table 8.2. Clinico-pathological and treatment characteristics of AA and EA QNBC 
patients observed at EH 
  AA (n=55) EA (n=20)   
Clinical 
characteristic n % n % p value 
Age 	       
0.635 
20-40 5 6.67 2 2.67 
41-60 34 45.33 10 13.33 
61-80 16 21.33 8 10.67 
Nuclear grade         
0.278 
1 0 0 0 0 
2 2 2.67 2 2.67 
3 53 70.67 18 24 
Tubule 
formation         
0.306 1 0 0 0 0 
2 6 8 4 5.33 
3 49 65.33 16 21.33 
Mitotic Index         
0.012 
1 4 5.33 4 5.33 
2 5 6.67 6 8 
3 46 61.33 10 13.33 
Nottingham 
grade         
0.007 1 0 0 0 0 
2 5 6.67 7 9.33 
3 50 66.67 13 17.33 
Stage         
0.204 
I 15 20 10 13.33 
II 29 38.67 9 12 
III 9 12 1 1.33 
IIIC 2 2.67 0 0 
Nodal status         
0.352 Negative 38 50.67 16 21.33 




        
0.191 0 2 2.67 0 0 
5-Jan 24 32 9 12 





Table 8.3 Breast cancer biomarker expression among AA and EA QNBC patients observed 
at EH 
  AA (n=87) EA (n=34)   
Biomarker n % N % p value 
FOXM1 (Nper)         
0.279 Negative 1 1.33 2 2.67 
Positive 45 60 15 20 
Missing/Unknown 9 12 3 4 
PRC1 (Nper)         
0.278 Negative 23 30.67 12 16 
Positive 19 25.33 6 8 
Missing/Unknown 13 17.33 2 2.67 
RARα (Nper)         
0.182 Negative 20 26.67 5 6.67 
Positive 30 66.67 15 33.33 
Missing/Unknown 5 6.67 0 0 
Aurora A (Nh-
score)         
0.424 Negative 27 36 11 14.67 
Positive 26 34.67 7 9.33 
Missing/Unknown 2 2.67 2 2.67 
Survivin (Nh-
score)         
0.410 Negative 2 2.67 1 1.33 
Positive 48 64 15 20 
Missing/Unknown 5 6.67 4 5.33 
BAP1 (Nper)         
0.491 Negative 1 1.33 0 0 
Positive 46 61.33 15 20 
Missing/Unknown 8 10.67 5 6.67 
β-catenin (H-
score)         
0.049 Negative 6 8 5 6.67 
Positive 47 62.67 12 16 
Missing/Unknown 2 2.67 3 4 
PD-1 (H-score)         0.858 
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Table 8.4 Correlation of stromal TILs with clinico-pathological variables and biomarkers 





Table 8.4. Correlation of stromal TILs with clinico-pathological variables and biomarkers 
among early-stage AA nd EA QNBC patients 
  Clinico-pathological variables and biomarkers 








ρ -0.272 0.112 0.595 0.250 0.070 0.205 
p 
value 0.044 0.414 <.0001 0.066 0.648 0.167 




ρ -0.216 0.164 0.460 0.239 0.129 0.186 
p 
value 0.117 0.235 0.001 0.081 0.389 0.226 





ρ -0.248 0.238 0.662 0.513 -0.037 0.185 
p 
value 0.186 0.205 <.0001 0.004 0.862 0.375 




ρ -0.158 0.213 0.725 0.545 0.027 0.252 
p 
value 0.462 0.318 <.0001 0.006 0.907 0.283 
n 24 24 24 24 21 20 
Overall 
EA 
ρ -0.174 0.461 0.749 0.365 0.749 0.433 
p 
value 0.477 0.041 <.001 0.113 <.001 0.107 




ρ -0.844 0.547 0.520 0.330 0.867 0.463 
p 
value 0.004 0.128 0.152 0.386 0.012 0.248 





ρ 0.369 0.452 0.586 0.586 0.836 0.478 
p 
value 0.215 0.079 0.017 0.017 <.001 0.116 




ρ 0.153 0.526 0.658 0.351 0.840 0.661 
p 
value 0.403 0.053 0.011 0.219 <.001 0.038 
n 32 14 14 14 13 10 
aPearson correlation test (ρ) 
bSpearman’s rank correlation test (ρ) 




Table 8.5 Correlation of peripheral TILs with clinico-pathological variables and biomarkers 





Table 8.5. Correlation of peripheral TILs wit  li ico-pathol gical variables and 
biomarkers among early-stage AA and EA QNBC patients 
  Clinico-pathological variables and biomarkers 















ρ -0.289 0.140 0.109 -0.157 0.033 0.047 0.044 
p 
value 0.032 0.307 0.426 0.251 0.831 0.734 0.771 




ρ -0.247 0.066 0.440 
-
0.098 0.007 0.289 0.105 
p 
value 0.072 0.633 0.015 0.480 0.961 0.034 0.496 





ρ -0.231 -0.071 0.381 
-
0.153 -0.054 0.390 0.036 
p 
value 0.219 0.711 0.038 0.421 0.797 0.033 0.865 




ρ -0.141 -0.022 0.285 -0.303 -0.156 0.476 0.088 
p 
value 0.510 0.918 0.178 0.150 0.500 0.019 0.712 
n 2 24 24 24 21 24 20 
Overall 
EA 
ρ -0.213 0.383 0.481 0.457 0.173 0.311 0.401 
p 
value 0.367 0.096 0.032 0.043 0.493 0.182 0.138 




ρ -0.784 0.646 0.629 0.475 0.867 0.540 0.428 
p 
value 0.012 0.060 0.070 0.196 0.012 0.134 0.291 





ρ -0.454 0.435 0.582 0.570 0.607 0.321 0.442 
p 
value 0.077 0.092 0.018 0.021 0.021 0.226 0.150 




ρ 0.135 0.534 0.584 0.611 0.592 0.439 0.717 
p 
value 0.463 0.049 0.028 0.020 0.033 0.116 0.020 
n 32 14 14 14 13 14 10 
aPearson correlation test (ρ) 
bSpearman’s rank correlation test (ρ) 
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; LN, lymph node; LVI, 




Table 8.6 Correlation of stromal TILs with clinico-pathological variables and biomarkers 






















Table 8.6. Correlation of stromal TIL  it i t ological variables and 
biomarkers among early-stage QNBC patients 
  Clinico-pathological variables and biomarkers 








ρ -0.289 0.256 0.196 0.455 0.270 
p 
value 0.012 0.026 0.092 <.0001 0.019 
n 75.000 75 75 75 75 
Early 
ρ -0.274 0.230 0.228 0.452 0.246 
p 
value 0.030 0.069 0.072 <0.001 0.052 
n 63.000 63 63 63 63 
Chemo 
ρ -0.264 0.215 0.260 0.468 0.448 
p 
value 0.077 0.151 0.081 0.001 0.002 
n 46.000 46 46.000 46 46 
Rad 
ρ -0.229 0.321 0.235 0.574 0.510 
p 
value 0.167 0.050 0.156 <0.001 0.001 
n 38.000 38 38 38 38 
aPearson correlation test (ρ) 
bSpearman’s rank correlation test (ρ) 




Table 8.7 Correlation of peripheral TILs with clinico-pathological variables and biomarkers 






















Table 8.7. Correlation of peripheral TILs with clinico-pathological 
variables and biomarkers among early-stage QNBC patients 
  Clinico-pathological variables and biomarkers 




ρ -0.276 0.200 0.322 0.213 
p 
value 0.016 0.085 0.005 0.067 
n 75 75 75 75 
Early 
ρ -0.289 0.338 0.301 0.199 
p 
value 0.021 0.007 0.017 0.118 
n 63 63 63 63 
Chemo 
ρ -0.275 0.392 0.265 0.365 
p 
value 0.064 0.007 0.076 0.013 
n 46 46 46 46 
Rad 
ρ -0.225 0.310 0.370 0.423 
p 
value 0.175 0.058 0.022 0.008 
n 38 38 38 38 
aPearson correlation test (ρ) 
bSpearman’s rank correlation test (ρ) 
Abbreviations: Early, early-stage (I-II); Chemo, adjuvant chemotherapy; Rad, 


































Table .8. Prediction of peripheral TI  f r 10-year OS among A  QNBC 
patients.  
AR-Negative 
patients p value; HR (95% CI) p value; HR (95% CI) 
  Unadjusted model Adjusted model  
Early and late 
stage       
Overall 0.020; 0.290 (0.102, 0.290) 0.027; 0.272 (0.086,0.864) 
Chemotherapy 0.153; 0.377 (0.099,1.438) 0.162; 0.338 (0.074,1.547) 
Radiation 0.074; 0.231 (0.046, 1.155) 0.042; 0.025 (0.001,0.879) 
Early-stage     
Overall 0.023; 0.208 (0.054, 0.804) 0.015; 0.155 (0.034, 0.694) 
Chemotherapy 0.761 ;0.71 (0.078, 6.455) 0.0617; 0.548 (0.052,5.815) 
Radiation 0.079; 0.081 (0.005,1.339) 0.997;  0.000 (0,000,0.000) 
Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional 
hazard model adjusted for age, Nottingham grade, and stage. Peripheral TILs 





Table 8.9 Immune response related-pathways significantly upregulated in AAs compared to 





























Table 8.9. Immune response related-pathways 
significantly more upregulated in AAs compared to EAs 
among AR-low TNBC patients in TCGA dataset. 
Pathway Statistical mean 
p 
value q value 
hsa04512 ECM-
receptor interaction   2.554 0.006 0.933 
hsa04510 Focal 





1.97 0.027 0.933 
hsa04720 Long-term 




migration      





Table 8.10 Immune response-related gene ontologies more upregulated among AA compared 






Table 8.10. Immune response-related gene ontologies more 
upr gulated among AA comp r  to EA AR-low samples in TCGA 
database. 
Gene ontology p-value 
GO:0045087 innate immune response                                                                                                                                               0.004
GO:0071347 cellular response to 
interleukin-1                                                                                                                                                 0.010 
GO:0034341 response to interferon-
gamma                                                                                                                                                     0.010 
GO:0060333 interferon-gamma-
mediated signaling pathway                                                                                                                                         0.013
GO:0071346 cellular response to 
interferon-gamma                                                                                                                                              0.014
GO:0034340 response to type I 
interferon                                                                                                                                                      0.019
GO:0070555 response to interleukin-1                                                                                                                                                          0.020
GO:0060337 type I interferon-mediated 
signaling pathway                                                                                                                                       0.021
GO:0071357 cellular response to type I 
interferon                                                                                                                                              0.021
GO:0050701 interleukin-1 secretion                                                                                                                                                             0.023 
GO:0050704 regulation of interleukin-1 
secretion                                                                                                                                               0.028
GO:0042311 vasodilation                                                                                                                                                                        0.030
GO:0032088 negative regulation of NF-
kappaB transcription factor activity                                                                                                                     0.033 
GO:0001779 natural killer cell 
differentiation                                                                                                                                               0.035
GO:0002526 acute inflammatory 
response                                                                                                                                                        0.036 
GO:0042089 cytokine biosynthetic 
process                                                                                                                                                     0.038
GO:0032732 positive regulation of 
interleukin-1 production                                                                                                                                     0.041
GO:0050716 positive regulation of 
interleukin-1 secretion                                                                                                                                      0.041
GO:0031331 positive regulation of 
cellular catabolic process                                                                                                                                   0.042
GO:0032649 regulation of interferon-
gamma production                                                                                                                                          0.044 
GO:0030101 natural killer cell activation                                                                                                                                                    0.046
GO:0042035 regulation of cytokine 




Table 8.11 Immune-related genes significantly upregulated in AAs compared to EAs among 
AR-low TNBC patients in the TCGA database.  
 
Table 8.11. Immune-related genes significantly more upregulated in AAs compared to 
EAs among AR-low TNBC patients in the TCGA database.  






C3b/C4b receptor 1 
(Knops blood group) 
32.382 1.529 <0.001 
ENSG00000152672 CLEC4F 
C-type lectin domain 
family 4 member F 





2758.089 1.322 <0.001 
ENSG00000189377 CXCL17 
C-X-C motif 
chemokine ligand 17 
260.445 1.649 0.001 
ENSG00000276409 CCL14 
C-C motif 
chemokine ligand 14 
86.378 1.51 0.002 
ENSG00000150630 VEGFC 
vascular endothelial 
growth factor C 










435.675 1.317 0.003 
ENSG00000164330 EBF1 early B-cell factor 1 94.082 1.063 0.003 
ENSG00000112936 C7 complement C7 42.535 1.424 0.004 
ENSG00000066056 TIE1 
tyrosine kinase with 
immunoglobulin like 
and EGF like 
domains 1 




C-type lectin domain 
family 14 member A 
240.377 0.904 0.006 
ENSG00000138795 LEF1 
lymphoid enhancer 
binding factor 1 





5.205 1.004 0.012 
ENSG00000006016 CRLF1 
cytokine receptor 
like factor 1 
346.321 1.192 0.012 
ENSG00000173757 STAT5B 
signal transducer 
and activator of 
transcription 5B 
1414.081 0.553 0.012 
ENSG00000072736 NFATC3 
nuclear factor of 
activated T-cells 3 




natural killer cell 
cytotoxicity receptor 
3 ligand 1 





Figure 8.1 Comparison of stromal and peripheral TILs among racially-distinct QNBC 
patients.  
Comparison of stromal and peripheral TILs between all (overall), early-stage (I-II) (early), early-
stage chemotherapy- and radiation- treated AA and EA QNBC patients. Abbreviations: Chemo 










Figure 8.2 Peripheral TILs associated with overall survival among early-stage AA QNBC 
patients.    
Peripheral TILs were stratified into high (≥10) and low (<10) subgroups using a log-rank test. 
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on 
overall survival over a 10-year period among AA QNBC patients. Prediction of high and low 
peripherals TILs on 10-year OS among all (A), chemotherapy-treated (B), radiation-treated (C), 
early-stage (I-II) (D), chemotherapy treated early-stage (E) and radiation treated early-stage (F) 
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9 LACK OF HER4 SIGNALING PREDICTS POOR PROGNOSIS AMONG 
BIOGEOGRAPHICALLY-DISTINCT TRIPLE NEGATIVE BREAST CANCER 
PATIENTS: A MULTI-INSTITUTIONAL STUDY 
9.1 Abstract 
Triple negative breast cancer (TNBC) disproportionately afflicts African-American (AA) 
women compared to European-American (EA) women. West African (WA) women exhibit 
higher TNBC incidence and mortality rates than AA women. Identification of biomarkers 
underlying this global burden are urgently needed. We analyzed differences in expression of 
breast cancer (BC)-related immunohistochemical biomarkers between self-reported European, 
EA, AA, and WA TNBC patients treated at Nottingham University in Nottingham, UK, Emory 
University in Atlanta, GA, and Olabisi Onabanjo University Teaching Hospital in Sagamu, 
Nigeria, respectively. We discovered differences in expression of the human epidermal growth 
factor receptor (HER) family; HER1/EGFR, HER3 and HER4 between the racial groups 
(p<0.0001). HER4 cytoplasmic H-score and a summation of EGFR membrane and HER4 
cytoplasmic H-scores (EGFR-HER4) decreased with increasing self-reported African ancestry. 
Differential gene expression analysis revealed that EGFR (ERBB1) and HER4 (ERBB4) genes 
were expressed lower among AA compared to EA TNBC samples (p<0.05). A lack of HER4 
expression was associated with higher Nottingham grade (p=0.03) and mitotic index (p=0.03) 
among AA patients and higher Ki67 (p=0.04) among early-stage AA patients. In multivariate 
models, low EGFR-HER4 score predicted shorter 10-year overall (p=0.03; HR: 33.33) and 
disease-free (p=0.04; HR: 33.33) survival among non-chemotherapy treated AA patients. 
Furthermore, peroxisome proliferator-activated receptor (PPAR) signaling was downregulated 
more among TNBC patients with low compared to high EGFR-HER4 scores (p=0.04). These 
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results suggest that HER4 signaling differs among biogeographically-distinct TNBC patients and 
that lack of HER4 and EGFR-HER4 expression may predict more aggressive disease among AA 
and indigenous African TNBC patient populations. Our findings also suggest that the PPAR 
signaling pathway has potential therapeutic implications among patients with low HER4 and 
EGFR-HER4 scores.  
9.2 Introduction 
Triple negative breast cancer (TNBC) comprises a fifth of breast cancer (BC) cases 
worldwide but remains the most fatal subgroup of BC owing to its more aggressive clinical 
disease course. TNBC is defined by a lack of estrogen receptor (ER) and progesterone receptor 
(PR) expression, and human epidermal growth factor receptor 2 (HER2) amplification 
underscoring the urgent need for identification of treatment targets for this patient populatiGon. 
Studies suggest that biogeographic ancestry may be a critical driver of aggressive TNBC. 
African-American (AA) women are disproportionately afflicted with TNBC 1, tend to be 
diagnosed at a younger age and show more aggressive clinicopathological features at 
presentation than European-American TNBC patients. Furthermore, West African (WA) women 
experience significantly higher TNBC incidence and mortality rates than AA women2-7. WAs 
also present with TNBC at a younger age and with higher grade compared to AAs among TNBC 
patients. Moreover, TNBC is more prevalent among WA women compared to women residing in 
Europe and other parts of the world.  
The human epidermal growth factor receptor (EGFR) family consists of four tyrosine 
kinase receptors (EGFR/HER1, HER2, HER3, and HER4) that stimulate growth signaling 
pathways involved in cell proliferation, growth, survival, and differentiation. EGFR is 
overexpressed in at least 50% of TNBCs, which is notably higher than in other BC subtypes8. 
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High EGFR copy number, immunoreactivity and membrane expression have been shown to be 
independent prognostic indicators of poorer overall survival (OS) and disease-free survival 
(DFS) in TNBC, suggesting EGFR to be a potentially targetable and risk-predictive biomarker in 
TNBC9-12. HER3 is the only receptor in the family that is catalytically inactive and requires 
dimerization with other members in order to be actived13. HER3 overexpression has been 
reported in approximately 20-30% of invasive breast carcinomas14. Reports on the prognostic 
role of HER3 in BC remain conflicted however, it has been associated with poorer overall 
survival (OS) and DFS in TNBC13,15.  
HER4 is reported to be downregulated in 18-75% of BCs and upregulated in 7-29% of 
cases16. In comparison to non-TNBCs, its expression has been reported to be significantly lower 
among TNBCs17. It can exist in four isoforms due to alternative mRNA splicing and one of these 
isoforms can be cleaved and released into the cytoplasm as a soluble HER4 intracellular domain 
(4ICD) that can translocate to the nucleus18-20. 4ICD displays a diverse range of roles including 
modulating cell proliferation and pro-apoptotic pathways21,22.  4ICD has been reported to impede 
breast tumor progression by activating genes that promote cellular differentiation and inhibit 
proliferation23. Thus, 4ICD is often associated with a favorable prognosis such as longer DFS in 
BC and TNBCs13,24-26.  4ICD has also been associated with luminal and well-differentiated 
histology, ER and PR positivity, low histological grade, and low Ki6727. However, reports on the 
prognostic value of HER4 in TNBC remain conflicted 17,28.    
We conducted a multi-institutional study in which we screened European, US (EA and 
AA), and Nigerian for differences in immunohistochemical (IHC) expression of BC-related 
biomarkers. Interestingly, we only observed significant differences in EGFR, HER3, and HER4 
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expression between all four ethnic groups. We also investigated the prognostic role of these 
markers among these ethnically-distinct patient populations.  
9.3 Results 
9.3.1 Distinctions in clinico-pathological characteristics and survival among 
biogeographically-distinct TNBC patient populations 
We assessed differences in associations with demographic characteristics, clinico-
pathological variables and treatment information between UK, EA, AA and Nigerian TNBC 
patients (Table 1). The Nigerian cohort had the highest percentage of patients diagnosed with 
TNBC before 40 and the lowest percentage of postmenopausal patients. The Nigerian cohort had 
the largest percentage of patients with tubule formation score of 3 and the AA cohort had the 
highest percentage of patients with a mitotic score of 3, nuclear grade of 3, clinical stage of 3, 
and highest Ki-67 scores. Stage information was unavailable for the Nigerian cohort.  We also 
compared associations with IHC expression of 11 BC-related markers between all four cohorts 
(Table 2).  
We compared OS in Kaplan-Meier analyses between all four cohorts (Figure 1). We 
observed significant differences in OS between all 4 cohorts (p<0.0001). Nigerian patients 
exhibited shorter 5-year OS than UK patients and AA patients exhibited shorter 5-year OS than 
EA patients (Fig 1A). Nigerian patients also exhibited shorter 10-year OS than UK patients and 
AA patients exhibited shorter 10-year OS than EA patients (Fig 1B).  
9.3.2 TNBC patients of African descent show low HER4 expression  
We screened all four ethnic groups for differences in expression of 11 common BC-
related IHC biomarkers in Table S2 (data not shown). We discovered significant differences in 
only the EGFR family (EGFR, HER3 and HER4) between all four patient populations suggesting 
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a role for this family in driving distinct tumor biology among the biogeographically-distinct 
cohorts (p<0.0001) (Figure 2). Interestingly, HER4 expression directly decreased with 
increasing presumed African ancestry as expression was highest among European and EA 
patients but lowest among Nigerian and AA patients (p<0.0001) (Fig 2C). Since, the receptors 
often heterodimerize to initiative signaling activity, we assessed differences in the combined 
scores of EGFR and HER3 (Fig 2D), EGFR and HER4 (Fig 2E) and HER3 and HER4 (Fig 2F) 
between the study cohorts. Interestingly, we also observed that EGFR-HER4 score was highest 
among European and EA patients but lowest among Nigerian and AA patients (p<0.0001) (Fig 
2D-E). Mean values of EGFR family expression levels among each racial group can be found in 
Table 3. Owing to a different HER4 antibody used among the Nigerian cohort, we excluded 
Nigerian patients from our comparison analyses involving HER4 and EGFR-HER4 scores and 
yielded similar results (Figure 3). Representative images of membrane EGFR and cytoplasmic 
HER4 staining can be found in Fig 3Ai and ii, respectively. HER4 (Fig 3B) and EGFR-HER4 
(Fig 3C) scores directly decreased with increasing presumed African ancestry (p<0.0001).      
9.3.3 Low EGFR-HER4 expression is associated with more aggressive disease features 
among patients of African descent 
Since HER4 and EGFR-HER4 scores decreased with increasing presumed African 
ancestry, we determined associations of HER4 and EGFR-HER4 scores with clinicopathological 
parameters among all (Table 4) and early-stage (I-II) (Table 5) TNBC patients for each ethnic 
group. HER4 expression negatively correlated with Ki67 percentage among EA patients 
(p=0.04). Furthermore, EGFR-HER4 negatively correlated with pT of TNM staging (p=0.04) 
among the UK cohort. Among early-stage UK patients, EGFR-HER4 negatively correlated with 
tubule formation (p=0.03). Among AA patients, HER4 negatively correlated with Nottingham 
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grade (p=0.03) and mitotic index (p=0.03). Furthermore, among early-stage AA patients, HER4 
expression negatively correlated with Ki67 percentage (p=0.04).  
We also analyzed correlations of HER4 and EGFR-HER4 scores with IHC biomarkers 
associated with BC tumorigenesis/progression among all (Table 6) and early-stage (Table 7) 
TNBC patients from the UK and US (AA and EA) cohorts. The biomarkers mentioned in this 
section were not assessed among Nigerian patients. We observed that cytoplasmic HER4 
expression correlated positively with nuclear AR (p=0.02) and RARα (p=0.02) expression 
among European patients. Furthermore, EGFR-HER4 correlated positively with stromal tumor 
infiltrating lymphocytes (TILs) among EA patients (p=0.04). We observed similar results among 
early-stage European and EA patients. Among AA patients, EGFR-HER4 also correlated 
positively with nuclear AR expression (p=0.03). However, in contrast to European patients, 
HER4 correlated negatively with nuclear RARα (p=0.03) expression among AA TNBC. 
Furthermore, HER4 expression correlated negatively with PD1 expression among AA patients 
(p=0.03). We also observed similar results among early-stage AA patents with the exception of 
PD1.  
9.3.4 Low HER4 and EGFR-HER4 expression predict worse prognosis among TNBC 
patients of African ancestry 
We also assessed the prognostic role of cytoplasmic HER4 and EGFR-HER4 among 
ethnically-distinct TNBC patients by investigating the impact of their expression on survival. 
The IHC expression of cytoplasmic HER4 and EGFR-HER4 was stratified into high and low 
subgroups among each ethnic cohort and the impact of high and low expression of HER4 and 
EGFR-HER4 scores on 5- and 10- year survival was estimated through Kaplan-Meier analysis 
(Figure 4). Low HER4 and EGFR-HER4 predicted worse survival among patients of both 
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African and European descent. Low EGFR-HER4 predicted significantly shorter 10-year OS 
among non-chemotherapy-treated AA patients (p=0.040) (Fig 4A). Low HER4 (Fig 4B) and 
EGFR-HER4 (Fig 4C) predicted significantly shorter 5-year OS among UK patients (p=0.008 
and p=0.023, respectively). Furthermore, among early-stage UK patients, low HER4 (Fig 4D) 
and EGFR-HER4 (Fig 4E) predicted significantly shorter 5-year OS (p=0.001 and p=0.006, 
respectively). Moreover, among chemotherapy-treated early-stage UK patients, low HER4 was 
associated with significantly poorer survival (p=0.007) (Fig 4F). We also investigated the impact 
of HER4 and EGFR-HER4 on DFS among ethnically-distinct TNBC patients using Kaplan-
Meier analyses and yielded similar results (Figure 5).  
We also investigated the prognostic role of HER4 and EGFR-HER4 among the 
ethnically-distinct TNBC patient populations by computing Cox proportional hazard regression 
models adjusted for age, grade, and stage. Similar to Kaplan-Meier analyses, low HER4 and 
EGFR-HER4 predicted poorer survival among patients of European and African descent. Low 
HER4 expression predicted significantly shorter 5-year OS among all (p=0.04; HR: 1.59) and 
early-stage (p=0.004; HR: 2.00) UK patients (Table 8). Low EGFR-HER4 also predicted shorter 
5-year OS among early-stage (p=0.011; HR: 2.08) and early-stage radiation treated UK patients 
(p=0.006; HR: 2.78) in adjusted models (Table 9). Furthermore, we observed that low HER4 
(Table 10) and EGFR-HER4 (Table 11) predicted shorter 5-year DFS among all radiation 
treated and early-stage radiation treated UK patients. Low EGFR-HER4 predicted significantly 
shorter 5-year OS in adjusted model among non-radiation treated AA patients (p=0.036; HR: 20) 
(Table 4). Low EGFR-HER4 also predicted shorter 10-year OS in multivariate analyses among 
non-chemotherapy and non-radiation treated AA patients as well as among early-stage non-
radiation treated AA patients (Table 12). Similar to OS results, low EGFR-HER4 was associated 
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with shorter 5-year (Table 4) and 10-year DFS among non-radiation treated AA patients as well 
as shorter 10-year DFS among non-chemotherapy treated AA patients (Table 13).  
9.3.5 EGFR and EGFR signaling-related genes are underexpressed among AA TNBC 
patients compared to EA TNBC patients 
We also investigated differential expression of EGFR and EGFR signaling-related genes 
between AA (n=41) and EA (n=87) TNBC patients in the TCGA RNA sequenced dataset to 
confirm our protein expression results. Utilizing the DESeq2 software tool, we analyzed 
differences in expression of 15,942 genes between AA and EA TNBC patients in TCGA breast 
dataset. Log2fold changes can be found in Table 14. In line with our protein expression findings, 
the genes encoding EGFR (ERBB1) and HER4 (ERBB4) were significantly more downregulated 
in AA compared to EA samples (p<0.05). We also observed significant underexpression of the 
EGFR pathway receptor substrate 8 (EPS8) and 15 (EPS15) genes in AA compared to EA 
patients (p<0.05). Furthermore, we observed significant underexpression of genes encoding the 
ligands for EGFR and HER4 such as neuregulin 3 (NRG3), neuregulin 4 (NRG4), and heparin 
binding EGF like growth factor (HBEGF) (p<0.05) in AA compared to EA patients. Moreover, 
we also discovered underexpression of genes encoding key molecules in downstream pathways 
of EGFR and HER4 in AA compared to EA samples (p<0.05).        
9.3.6 Peroxisome proliferator-activated receptor signaling more upregulated among high 
compared to low EGFR-HER4 gene-expressing TNBC patients 
We also identified differentially-expressed biological pathways (Table 15) and gene 
ontologies (Table 16) between high (n=85) and low (n=58) EGFR-HER4 gene-expressing 
subgroups among TNBC patients in TCGA dataset. Interestingly, we discovered significant 
upregulation of the peroxisome proliferator-activated receptor (PPAR) signaling pathway among 
210 
 
high compared to low EGFR-HER4 expressing patients (p=0.036). We also observed significant 
upregulation of pathways regulated by PPAR signaling among high compared to low EGFR-HER4 
(p<0.05). We also discovered significant upregulation of gene ontologies reflecting metabolic and 
catabolic processes regulated by PPAR signaling (p<0.05) as well as other gene ontologies 
indicative PPAR signaling (p<0.05). Furthermore, we found significant upregulation of gene 
ontologies reflecting inflammatory activity, which is modulated by PPAR signaling (p<0.05).  
 
9.4 Discussion 
The absence of conventional BC markers, ER, PR, and HER2, in triple negative breast 
tumors has prompted the investigation into alternative actionable targets. We screened all four 
ethnic groups (Europeans, EAs, AAs, and West Africans) for differences in expression levels of 
11 common BC biomarkers. TNBC patients in the UK cohort are comprised of predominantly 
Europeans who harbor low levels of African ancestry. EAs have been reported to harbor 
anywhere between 1-2% African ancestry depending on the region of the US they reside32. AAs 
represent a highly admixed population with a reported average of 24% of European ancestry, 
which also varies according to the region of the US they reside32. AAs harbor a reported average 
of 73.2% of African ancestry, most of which can be traced back to western Africa according to 
genetic studies. Genetic ancestry typing was not performed in our study.  
Interestingly, the EGFR family members were the only biomarkers that exhibited 
significant differences in expression levels between all four biogeographically-distinct patient 
populations. Furthermore, expression of HER4 and EGFR-HER4 showed lowest expression in 
Nigerian patients and highest expression in UK patients. Our gene expression analyses 
corroborated our protein expression findings as we observed significant downregulation of 
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ERBB1 and ERBB4 among AA compared to EA TNBC samples. As consistent with the 
literature mentioned earlier, cytoplasmic HER4 and EGFR-HER4 was associated with more 
favorable disease features among TNBC patients of both European and African descent. Our 
findings of low HER4 expression and EGFR-HER4 score among AA and Nigerian patients 
compared to their European counterparts may rationalize their increased presentation of poor 
prognostic disease features among TNBC patients of African compared to European descent. We 
discovered cytoplasmic HER4 and EGFR-HER4 expression was prognostic among 
biogeographically-distinct patients in both Kaplan-Meier and multivariate analyses as high 
expression of these markers predicted better survival.  
PPAR signaling was the key pathway that was discovered to be significantly upregulated 
among high compared to low EGFR-HER4 score patients. PPAR signaling has been reported to 
regulate glucose homeostasis, steroid hormone biosynthesis, lipid metabolism, hydrogen 
peroxide metabolism, insulin signaling, inflammation, and cell cycle regulation33-37. The role of 
PPAR signaling in cancer remains controversial, however the pathway has been reported to 
exhibit an antitumor effect in BC by reducing cell growth and proliferation and inducing 
differentiation and apoptosis. Hence, a lack of EGFR-HER4 signaling may be associated with a 
poorer prognosis among TNBC patients of African descent owing to a deficiency in PPAR 
signaling. PPAR agonists may be promising therapeutic strategies for TNBC patients of African 
descent lacking EGFR-HER4 signaling.  
Our study further corroborates previous findings revealing that patients of African 
ancestry tend to lack expression of common BC targets such as ER, PR, HER2, AR and now 
HER4 expression. Our findings present additional biomarkers that can risk-stratify patients of 




9.5.1 Patient Cohorts   
We procured TNBC patient datasets from 3 different institutions: (1) Nottingham 
University Hospital (NH) in Nottingham, UK, (2) Emory University Hospital (EH) in Atlanta, 
GA, and (3) Olabisi Onabanjo University Teaching Hospital (OOTH) in Sagamu, Nigeria. NH, 
EH and OOTH cohorts were comprised of 322, 121 and 307 TNBC patients, respectively. NH 
patients were diagnosed between 2007-2013, EH patients were diagnosed between 2002-2016 
and the OOTH patients were diagnosed between 2011-2016. We obtained consent and 
permission from the institutional review boards at each institution to obtain access to deidentified 
patient information used in this study. None of the patients treated at EH received neoadjuvant 
chemotherapy.  
9.5.2 Immunohistochemistry and scoring  
Biomarker expression was determined through standard IHC staining and scored as H-
score (percentage x intensity), Nper (nuclear percentage) and NH-score (nuclear percentage x 
intensity). Intensity of staining were scored as 0=none, 1=low, 2=moderate, and 3=high. 
Negativity was determined as <1% expression and positivity was determined as ≥1% expression 
for all biomarkers. Antibody details and concentrations can be found in Table 17. The maximum 
score for any given H-score is 300 and for combined (summed) H-scores is 600. Combined 
biomarker scores were determined by summing the scores for each biomarker to yield a single 
score. NH and OOTH patient samples were centrally stained, scored, and reviewed at NH. EH 
patient samples were stained, scored, and reviewed at EH. Scoring was performed by two 




Median duration of follow-up for each cohort was approximately 6 years for EH, 5 years 
for NH, and 1 year for OOTH patients. Survival status (alive/dead) was recorded for each patient 
at last follow-up in addition to survival time.  
9.5.4 Statistical Analyses 
The significance level for all analyses was set to p<0.05 with 95% confidence intervals 
(CIs). Chi-square tests were performed to analyze differences in frequency of demographic 
characteristics, breast clinicopathological variables and biomarkers, as well as treatment 
information between UK, AA, EA, and Nigerian TNBC patients. SAS 9.4 program was used to 
generate test statistics and 2-tailed univariate p-values were reported. One-way ANOVA tests were 
performed to determine differences in mean expression of BC biomarkers between all four patient 
groups. Associations between HER4 H-score and combined EGFR and HER4 H-scores (EGFR-
HER4) with demographic and breast clinico-pathological variables and biomarkers among each 
ethnic group were determined by computing Spearman’s rank correlation coefficients (ρ) for 
categorical covariates and Pearson correlation coefficients for continuous covariates. Unadjusted 
and adjusted multivariate Cox proportional hazard regression models were computed to assess the 
impact of HER4 and EGFR-HER4 scores on 5- and 10-year OS and disease-free survival (DFS) 
before and after controlling for age, Nottingham grade and stage. The Kaplan-Meier analysis was 
conducted using SAS 9.4 program to estimate survival function for each patient group based on 
high and low expression levels of HER4 and EGFR-HER4 score. A log-rank test was used to 
stratify HER4 and EGFR-HER4 scores into high and low subgroups. 
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9.5.5 Differential Gene Expression Analysis 
We queried The Cancer Genome Atlas (TCGA) breast dataset for TNBC patients. 
Publically-available ER/PR/HER2 IHC data was used to determine TNBC status. We performed 
differential gene expression analysis between high and low EGFR-HER4 gene-expressing 
subgroups using the DESeq2 software tool29. EGFR-HER4 scores were determined by summing 
the normalized gene expression values for each biomarker. Differential expression analyses of 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontologies between 
high and low EGFR-HER4-expressing TNBC patients were predicted by GAGE and Pathview 
packages, respectively30,31. High and low EGFR-HER4-expressing TNBC patients were stratified 
according to the median.  
9.6 Tables and Figures 
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Table 9.3 Differences in HER family member expression between ethnically-distinct TNBC 





Table 9.4 Correlation of HER4 and EGFR-HER4 scores with clinicopathological variables 















Table 9.5 Correlation of HER4 and EGFR-HER4 scores with clinicopathological variables 





Table 9.6 Correlation of HER4 and EGFR-HER4 scores with clinical BC biomarkers among 







Table 9.7 Correlation of HER4 and EGFR-HER4 scores with clinical BC biomarkers among 



























Table 9.8 Impact of cytoplasmic HER4 on 5-year survival among biogeographically-distinct 








Table 9.9 Prediction of EGFR-HER4 scores on 5-year overall survival among 






Table 9.10 Prediction of HER4 with 5-year disease-free survival among biogeographically-




Table 9.11 Prediction of EGFR-HER4 score on 5-year disease-free survival among 





Table 9.12 Prediction of EGFR-HER4 score on 10-year overall survival among racially-






















Table 9.13 Prediction of EGFR-HER4 score on 10-year disease-free survival among racially-
























Table 9.14 Genes significantly upregulated among AA compared to EA TNBC patients in 













Table 9.15 Biological pathways upregulated or downregulated among high compared to low 





































Table 9.16 Gene ontologies upregulated or downregulated among high compared to low 

















GO:0006067 ethanol metabolic process            0.035
GO:0002702 positive regulation of production of molecular mediator of immune response                 0.035
GO:0002443 leukocyte mediated immunity                   0.036
GO:0002700 regulation of production of molecular mediator of immune response     0.038
GO:0002065 columnar/cuboidal epithelial cell differentiation          0.038
GO:0002697 regulation of immune effector process                  0.038
GO:0009404 toxin metabolic process      0.038
GO:0010565 regulation of cellular ketone metabolic process                 0.039
GO:0006979 response to oxidative stress                      0.04
GO:0009636 response to toxin           0.04
GO:0010560 positive regulation of glycoprotein biosynthetic process          0.041
GO:0019400 alditol metabolic process                       0.042
GO:0006694 steroid biosynthetic process            0.043
GO:0097237 cellular response to toxin       0.044
GO:0002377 immunoglobulin production                    0.044
GO:0035725 sodium ion transmembrane transport       0.045
GO:0006921 cellular component disassembly involved in execution phase of apoptosis      0.046
GO:0042102 positive regulation of T cell proliferation        0.046
GO:0002021 response to dietary excess                            0.046
GO:0010884 positive regulation of lipid storage            0.046
GO:0032615 interleukin-12 production       0.047
GO:0032655 regulation of interleukin-12 production     0.047
GO:0002250 adaptive immune response              0.048
GO:0032609 interferon-gamma production       0.049
GO:0060081 membrane hyperpolarization                      0.049
GO:0045664 regulation of neuron differentiation    <0.001
GO:0010975 regulation of neuron projection development    <0.001
GO:0051960 regulation of nervous system development     <0.001
GO:0050767 regulation of neurogenesis    <0.001
GO:0007409 axonogenesis                <0.001
GO:0048812 neuron projection morphogenesis     <0.001
GO:0045047 protein targeting to ER               <0.001
GO:0072599 establishment of protein localization to endoplasmic reticulum   <0.001
GO:0019080 viral genome expression        0.001
GO:0019083 viral transcription                 0.001
GO:0006613 cotranslational protein targeting to membrane        0.001
GO:0006614 SRP-dependent cotranslational protein targeting to membrane                0.001
GO:0006414 translational elongation       0.001
GO:0006415 translational termination       0.001
GO:0048667 cell morphogenesis involved in neuron differentiation    0.001
GO:0019058 viral infectious cycle                      0.001
GO:0050770 regulation of axonogenesis                  0.001
GO:0070972 protein localization to endoplasmic reticulum      0.001
GO:0031344 regulation of cell projection organization               0.001
GO:0060284 regulation of cell development              0.002
GO:0022604 regulation of cell morphogenesis  0.002
GO:0006612 protein targeting to membrane 0.002



















































Figure 9.1 Overall survival among ethnically-distinct TNBC patients.  
Comparison of 5-year (A) and 10-year (B) overall survival between UK, EA, AA and Nigerian 
TNBC patient cohorts treated at NH, EH and OOTH respectively, using Kaplan-Meier survival 
analyses. A log-rank test was used to determine statistical differences in survival between the 







Figure 9.2 Comparison of EGFR family members between ethnically-distinct TNBC patients.  
Box and whisker plots comparing IHC expression of EGFR (p<0.0001) (A), HER3 (p<0.0001) 
(B), HER4 (p<0.0001) (C), combined EGFR-HER3 (p<0.0001) (D), combined EGFR-HER4 
(p<0.0001) (E) and combined HER3-HER4 (p<0.0001) (F) scores between European (UK), EA, 
AA, and Nigerian TNBC patients. One-way ANOVA test was performed to determine 







Figure 9.3 Comparison of HER4 and combined EGFR-HER4 scores between 
biogeographically-distinct TNBC patients.  
Representative microscopic images of membrane EGFR (Ai) and cytoplasmic HER4 (Aii) IHC 
staining. Box and whisker plots comparing IHC expression of cytoplasmic HER4 (B) and 
combined EGFR-HER4 (C) scores between European (UK), EA, and AA TNBC patients. One-
way ANOVA test was performed to determine significant differences in expression of the 
markers between the biogeographically-distinct patient populations. Images acquired at 200x 







Figure 9.4 HER4 and combined EGFR-HER4 score predict overall survival among 
biogeographically-distinct TNBC patients.  
HER4 and combined EGFR-HER4 scores were stratified into high (≥4 for HER4; ≥5 for EGFR-
HER4) and low (<4 for HER4; <5 for EGFR-HER4) subgroups using a log-rank test. The impact 
of high and low expression of HER4 and combined EGFR-HER4 score on 5- and 10-year 
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survival among treated TNBC patients of African and European descent was estimated through 
Kaplan-Meier analyses. Survival curves (10-year OS) of non-chemotherapy-treated AA patients 
stratified based on high vs. low expression of EGFR-HER4 (A), survival curves (5-year OS) of 
UK TNBC patients stratified based on high vs. low HER4 score (B), survival curves (5-year OS) 
of UK TNBC patients stratified based on high vs. low EGFR-HER4 score (C), survival curves 
(5-year OS) of early-stage UK TNBC patients stratified based on high vs. low HER4 expression 
(D), survival curves (5-year OS) of early-stage UK TNBC patients stratified based on high vs. 
low EGFR-HER4 expression (E), and survival curves (5-year OS) of chemotherapy-treated 
early-stage UK TNBC patients stratified based on high vs. low HER4 expression (F). p<0.05 






Figure 9.5 HER4 and combined EGFR-HER4 score predict disease-free survival among 
biogeographically-distinct TNBC patients.  
HER4 and combined EGFR-HER4 scores were stratified into high (≥4 for HER4 and ≥5 for 
EGFR-HER4) and low (<4 for HER4 and <5 for EGFR-HER4) subgroups using a log-rank test. 
The impact of high and low expression of HER4 and combined EGFR-HER4 score on 5- and 10-
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year disease-free survival (DFS) among treated TNBC patients of African and European descent 
estimated through Kaplan-Meier analyses. Survival curves (10-year DFS) of non-chemotherapy-
treated AA patients stratified based on high vs. low expression of EGFR-HER4 (A), survival 
curves (5-year DFS) of radiation-treated UK patients stratified based on high vs. low expression 
of HER4 (B) and EGFR-HER4 (C), survival curves (5-year DFS) of radiation-treated early-stage 
UK patients stratified based on high vs. low expression HER4 (D) and combined EGFR-HER4 
scores (E), and survival curves (5-year DFS) of chemotherapy-treated early-stage UK patients 
stratified based on high vs. low expression of HER4 (F). p<0.05 was considered significant.  
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10 LACK OF COMBINED IMMUNOHISTOCHEMICAL HER3-HER4 SCORE 
PREDICTS POOR PROGNOSIS AMONG EARLY-STAGE AFRICAN-AMERICAN 
QUADRUPLE NEGATIVE BREAST CANCER PATIENTS 
10.1 Abstract 
Quadruple negative breast cancer (QNBC) has recently emerged as a subgroup of triple 
negative breast cancer (TNBC) and is defined by the absence of androgen receptor (AR), which 
differentiates them from TNBC. Although controversial, a lack of AR expression in TNBC has 
been reported to confer an aggressive disease course. Recent evidence suggest that QNBC 
disproportionately affects women of African descent. The role of the other three members of the 
epidermal growth factor receptor (EGFR) family (EGFR/HER1, HER3, HER4) in AA QNBC 
remains underexplored. We compared individual and combined immunohistochemical (IHC) 
expression scores of these EGFR family members between formalin-fixed, paraffin-embedded 
resection AR-negative and AR-positive AA TNBC patient samples from Emory Hospital in 
Atlanta, GA. We performed differential gene expression analyses to determine differences in 
mRNA expression of the EGFR family members and downstream signaling between AR-low 
and AR-high expressing AA TNBC patients in a publically-available dataset. Combined IHC 
HER3 and HER4 expression (HER3-HER4 score) was significantly lower among QNBC (n=48) 
compared to TNBC (n=14) early-stage (I-II) AA patients (p=0.04). Gene expression analyses 
revealed lower HER4 expression and downstream signaling among AR-low compared to AR-
high expressing AA TNBC patients. Lack of HER3-HER4 score was associated with high Ki-67 
percentage (p=0.03) and Nottingham score (p=0.04) among early-stage AA QNBC patients. 
Moreover, low HER3-HER4 score predicted shorter 10-year overall survival among early-stage 
AA QNBC patients in Kaplan-Meier analysis (p=0.047). In silico analyses revealed more 
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downregulation of pro-apoptotic genes as well as gene ontologies reflecting cell death, loss of 
cell-cell contact, and pro-inflammatory pathways among AR-low compared to AR-high AA 
TNBC samples (p<0.05). However, we observed more upregulation of biological pathways and 
gene ontologies reflecting cell cycle progression, cell proliferation, and DNA damage repair 
response among AR-low compared to AR-high AA TNBC patients (p<0.05). Our findings 
suggest that a low HER3-HER4 score may be associated with early-stage QNBC disease among 
AAs and may serve as a valuable risk-prognostic biomarker for this patient population. Our 
results also indicate that early-stage AA QNBC patients lacking HER3-HER4 expression may 
exhibit sensitivity to therapies targeting cell cycle progression and DNA damage response.    
10.2 Introduction 
Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer that 
continues to confound researchers and clinicians today. TNBC is characterized by a lack of 
expression of the pharmacologically-targetable biomarkers, estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) expression rendering 
this subgroup of breast cancer patients refractory to traditional endocrine and HER2-targeted 
systemic therapies (1). Anthracycline- and taxane- based chemotherapy remain the cornerstone 
of TNBC treatment however, about 30-40% of TNBC patients achieve pCR and experience 
improved disease-free survival (DFS)(2, 3). The disease is further typified by more aggressive 
tumor characteristics such as higher grade, clinical stage, and proliferation, a more aggressive 
clinical course characterized by increased lymph node, cerebral, and visceral metastasis, and a 
poorer prognosis defined by higher mortality rates compared to non-TNBCs(4-9). Furthermore, 
TNBC disproportionately afflicts younger and African-American (AA) women(10). Moreover, 
within the inherently aggressive subtype, AAs exhibit more aggressive disease features, acquire 
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more aggressive TNBC subtypes, and suffer poorer clinical outcomes compared to European-
Americans (EAs) patients (11-17). Androgen receptor (AR) has recently emerged as a promising 
therapeutic target for TNBC patients, however AAs have been reported to lack expression of AR 
or harbor quadruple negative breast cancer (QNBC) disease significantly more than EAs among 
TNBC patients rendering them more refractory to AR-targeted therapies(17). Furthermore, 
although the prognostic role of AR in TNBC remains controversial, a lack of AR expression has 
been reported to be associated with poor differentiation, high clinical stage, high Ki-67, high 
mitotic index, increased lymphovascular invasion, increased risk of recurrence and distant 
metastasis, and worse 5-year disease-free survival (DFS) and overall survival (OS) suggesting 
the high absence of AR expression among AAs may be contributing to the racial disparate 
burden in TNBC (18-22). Furthermore, our group recently reported that AA’s exhibit poorer 
survival than EAs among QNBC patients. Thus, novel alternative risk-prognostic biomarkers and 
therapeutic strategies are urgently needed to target QNBC disease in AA women.   
The human epidermal growth factor receptor (EGFR) family plays a critical role in cell 
proliferation, growth, survival, and differentiation through stimulating key growth signaling 
pathways such as PI3 kinase, Ras-Raf-MAPK, JNK, and PLCg(23-25). The family is comprised 
of four structurally related tyrosine kinase receptors ((EGFR/HER1, HER2, HER3, and HER4) 
that are activated upon ligand binding, hetero- or homo- dimerization of these receptors, and 
subsequent phosphorylation of tyrosine residues on the intracellular tyrosine kinase domain(26). 
Aberrant expression of these receptors can stimulate carcinogenesis by promoting loss of cell 
adhesion, polarity, and initiating invasion and angiogenesis(27, 28). EGFR is overexpressed in 
approximately 50% of TNBCs, which is significantly higher compared to other BC subtypes(17, 
24). High EGFR copy number, immunoreactivity, and expression have been reported to 
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independently predict poorer overall survival (OS) and disease-free survival (DFS) in TNBC 
providing evidence for EGFR as a potentially targetable and risk-predictive biomarker in 
TNBC(29-32). HER3 is the only receptor in the family that is catalytically inactive and can only 
be activated if it dimerizes with other members in the family(33). The receptor has been reported 
to be overexpressed in roughly 20-30% of invasive breast carcinomas. Evidence on the 
prognostic role of HER3 in breast cancer are conflicted however, the receptor has been linked to 
poorer OS and DFS in TNBC. HER4 is the only family member to exist in four isoforms as a 
result of alternative mRNA splicing(34). One of these isoforms can be cleaved as a soluble 
HER4 intracellular (4ICD) in the cytoplasm and translocate to the nucleus(35-37). HER4 has 
been consistently reported to modulate cell proliferation and pro-apoptotic pathways and thus has 
been linked to a favorable prognosis in BC and specifically among TNBCs33, (33, 38-41). 
Furthermore, elevated HER4 gene expression levels during chemotherapy has been shown to 
predict response to neoadjuvant chemotherapy in breast cancer(42).  
It may be worthy to investigate the role of the other three EGFR family members as 
alternative risk-predictive and/or therapeutic targets in QNBC owing to its inherent lack of ER, 
PR, HER2, and AR expression. The role of the EGFR growth factor receptor family in QNBC 
and in the racial disparate burden remains elusive, however recent evidence suggests that the 
EGFR family members may be critical drivers in QNBC disease etiology and progression. AR 
has been reported to regulate expression of members of the EGFR family and vice versa in 
multiple cancer types(43-51). Researchers at Caris Research Institute recently observed 
significantly higher EGFR expression among AR-negative compared to AR-positive TNBCs. In 
contrast, HER4 mRNA expression levels have been reported to be significantly lower among 
AR-negative compared to AR-positive TNBC patients(17). Thus, a lack of HER4 expression 
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may be associated with QNBC disease and serve as a novel prognostic biomarker for QNBC 
patients. Hence, we examined the prognostic and predictive role of the EGFR family members in 
AA QNBC disease to explore the potential of these receptors to improve risk-prognostication 
and/or be exploited for therapeutic intervention among this patient population. We 
immunostained specimens from AA TNBC patients observed at Emory University Hospital (EH) 
for AR and the EGFR family receptors and examined differences in their immunohistochemistry 
(IHC) expression levels between AR-negative and AR-positive patients, as well as investigated 
the prognostic role of this receptor family in AA QNBC.  
10.3 Results 
10.3.1 Clinico-pathological characteristics and biomarker expression among AR-negative and 
AR-positive AA TNBC patients  
We analyzed differences in associations with demographic and clinico-pathological 
characteristics as well as treatment status between AR-negative (n=61) and AR-positive (n=16) 
AA TNBC patients observed at EH (Table 1) We did not observe significant differences in 
associations with demographic and clinico-pathological characteristics between AA QNBC and 
TNBC patients. However, we did observe moderate significant differences associations with 
nuclear grade, Nottingham grade, and lymph node status between the groups. A higher 
percentage of AA QNBCs (76.6%) presented with a nuclear grade of 3 compared to AA TNBCs 
(18.2%) (p=0.139). A higher proportion of AA QNBCs (72.7%) also presented with a 
Nottingham grade of 3 compared to AA TNBC patients (15.6%) (p=0.062). Furthermore, a 
greater percentage of AA QNBC patients (26%) exhibited lymph node involvement compared to 
AA TNBC patients (2.6%) (p=0.110).    
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10.3.2 AR-negatives exhibit lower combined immunohistochemical HER3-HER4 score than 
AR-positives among AA TNBC patients  
We examined differences in the IHC expression of the EGFR family members [EGFR 
(membranous), HER3 (membranous), and HER4 (cytoplasmic)] between AR-negative and AR-
positive AA TNBC patients. We also compared combinations of the scores between the groups 
to determine differences in dimerization and cooperative signaling. We only observed significant 
differences in combined IHC HER3 and HER4 expression (HER3-HER4 score) between QNBC 
and TNBC AA patients, in which HER3-HER4 score was significantly lower in AR-negative 
(n=61) compared to AR-positive (n=16) TNBC patients (p=0.014) (Figure 1). We further 
investigated differences in HER3-HER4 score between the groups by comparing the scores 
between chemotherapy treated and non-treated AA QNBC and TNBC patients, as well as among 
early-stage treated patients (Figure 2). Representative microscopic images of HER3 
(membranous) and HER4 (cytoplasmic) IHC staining can be found in Fig 2A. Interestingly, we 
also observed significantly lower HER3-HER4 score among all (p=0.014) and chemotherapy-
treated (p=0.014) AR-negative (n=42) and AR-positive (n=12) AA TNBC patients (Fig 2B). 
Furthermore, HER3-HER4 score was significantly lower among QNBCs (n=48) compared to 
TNBCs (n=14) among early-stage AA patients (p=0.04) as well as among early-stage AA 
patients treated with chemotherapy (p=0.03) (Fig 2C).      
10.3.3 Lack of HER3-HER4 score is associated with more aggressive disease features among 
early-stage AA QNBC patients 
We investigated associations of HER3-HER4 score with clinico-pathological variables 
(Table 2) and biomarkers (Table 3) among AA QNBC patients. Regarding clinico-pathological 
characteristics, HER3-HER4 score negatively correlated with aggressive tumor features among 
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AA patients. Among all AA patients, HER3-HER4 score negatively correlated with Ki67 
percentage (ρ=-0.294; p=0.023) and Nottingham score (ρ=-0.275; p=0.033). Moreover, HER3-
HER4 score negatively correlated with Ki67 percentage among early-stage AA patients (ρ=-
0.307; p=0.034) and negatively correlated with Nottingham score among early-stage AA patients 
administered chemotherapy (ρ=-0.366; p=0.040). However, among AA patients administered 
chemotherapy, HER3-HER4 score positively correlated with sentinel lymph node (SLN) 
involvement (ρ=0.325; p=0.036). Regarding clinical biomarkers, HER3-HER4 score also 
negatively correlated with biomarkers associated with aggressive disease among AA QNBC 
patients. Among all (ρ=-0.322; p=0.020) and early-stage (ρ=-0.315; p=0.040) AA patients, 
HER3-HER4 score negatively correlated with nuclear forkhead box protein M1 (FOXM1) 
expression. HER3-HER4 score also negatively correlated with nuclear retinoic acid receptor 
alpha (RARα) expression among all (ρ=-0.326; p=0.014) and early-stage (ρ=-0.361; p=0.014) 
AA patients. Furthermore, among early-stage AA patients, HER3-HER4 score negatively 
correlated with BRCA1-associated protein 1 (BAP1) expression (ρ=-0.294; p=0.043).       
10.3.4 Lack of combined IHC HER3-HER4 score predicts poorer survival among early-stage 
AA QNBC patients 
We investigated the prognostic and predictive power of HER3-HER4 score among AA 
QNBC patients. HER3-HER4 scores were stratified into high (³6) and low (<6) subgroups using 
a log-rank test among AA QNBC patients and Kaplan-Meier analyses were performed to 
estimate the impact of HER3-HER4 score on survival over a 5- and 10- year period (Figure 2). 
We observed that low HER3-HER4 score moderately predicted poorer 10-year (p=0.136) and 5-
year (p=0.0137) OS among all AA QNBC patients (Fig 2A-B). However, low HER3-HER4 
score significantly predicted poorer 10-year OS among early-stage AA QNBC patients (p=0.047) 
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(Fig 2C). Furthermore, low HER3-HER4 score weakly predicted poorer 10-year (p=0.108) OS 
among early-stage radiation treated AA patients (Fig 2D).  We also computed Cox proportional 
hazard regression models to assess unadjusted and adjusted associations of HER3-HER4 score 
with 5- and 10-year OS among AA QNBC patients (Table 4).  Low HER3-HER4 score 
moderately predicted shorter 10-year OS in adjusted analyses among all (p=0.057; HR: 0.310; 
95% CI: 0.093-1.035) and early-stage (p=0.054; HR: 0.251; 95% CI: 0.062-1.025) AA QNBC 
patients.      
Downregulation of genes, pathways, and gene ontologies involved in HER4 signaling 
among AA QNBC patients 
 
We investigated differential expression of genes, pathways, and gene ontologies between 
AR-low and AR-high AA patients isolated from TCGA breast dataset. We utilized the GAGE 
package to analyze differences in biological pathways or experimentally-derived differential 
expression sets between AR-low and AR-high AA TNBCs in TCGA breast dataset (Table 5). 
We observed significantly more upregulation of cell proliferation and DNA damage repair 
expression sets such as cell cycle, DNA replication, base-excision repair, mismatch repair, and 
nucleotide excision repair (p<0.05) and significantly more downregulation of downstream 
pathways of HER4 signaling such as MAPK, JAK/STAT, calcium signaling pathways, and 
adenylate cyclase-modulating G-protein coupled receptor signaling pathway (p<0.05) among 
AR-low compared to AR-high AA TNBCs. Furthermore, we discovered significantly more 
downregulation of pro-inflammatory expression sets such as leukocyte transendothelial 
migration and intestinal immune network for IgA production as well as chemokine, T cell, and B 
cell signaling pathways among AR-low compared to AR-high AA patients (p<0.05). Moreover, 
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we also found significantly more downregulation of cell-cell contact such as focal adhesion, cell 
adhesion molecules (CAMs), and gap junction among AR-low compared to AR-high AAs 
(p<0.05).   
We utilized the Pathview package to analyze differences in gene ontologies between AR-
low and AR-high AA TNBCs in TCGA breast dataset (Table 6). We also observed significantly 
more upregulation of gene ontologies associated with cell cycle progression such as interphase, S 
phase, mitosis, DNA replication, cell cycle checkpoint, M/G1 transition of mitotic cell cycle, and 
G1/S transition of mitotic cell cycle as well as DNA damage response such as DNA repair, 
response to DNA damage stimulus, DNA integrity checkpoint, and DNA damage checkpoint 
(p<0.05). Gene ontologies associated with downstream signaling of HER4 such as MAPK 
cascade, ERK1 and ERK2 cascade, phospholipase C activity, cAMP metabolic process, 
phosphatidylinositol 3-kinase cascade, second-messenger-mediated signaling, and platelet 
derived growth factor receptor signaling pathway were significantly more downregulated in AR-
low compared to AR-high AA TNBC samples (p<0.05). Gene ontologies associated with 
regulation of cell death, differentiation, and proliferation such as cell type specific apoptotic 
processes, negative regulation of cell death, negative regulation of programmed cell death, 
negative regulation of cell proliferation, and negative regulation of cell differentiation were also 
significantly more downregulated among AR-low compared to AR-high AA samples (p<0.05). 
In addition, gene ontologies indicative of cell-cell contact and tissue homeostasis such as cell-
cell adhesion, actin cytoskeleton organization, extracellular matrix organization, cell-substrate 
adhesion, cell-matrix adhesion, cell adhesion mediated by integrin, positive regulation of cell 
migration, and positive regulation of cell motility were significantly more downregulated among 
AR-low compared to AR-high AA samples (p<0.05). Furthermore, gene ontologies reflective of 
253 
 
a pro-inflammatory response such as T cell activation, lymphocyte activation, lymphocyte 
differentiation, inflammatory response, B cell activation, leukocyte proliferation, leukocyte 
migration, adaptive immune response, and humor immune response were significantly more 
downregulated in AR-low compared to AR-high AA TNBC samples (p<0.05).      
Utilizing the DESeq2 software tool, we analyzed differences in expression of 15,942 
genes between AR-low and AR-high AA TNBC patients in the TCGA breast dataset. Log2 fold 
changes can found in (Table 7). We observed the gene encoding HER4, ERBB4, was 
significantly more downregulated among AR-low compared to AR-high AA TNBCs (p<0.05). 
Furthermore, we discovered that the gene encoding the HER4 ligand that induces its proteolytic 
cleavage, heparin-binding epidermal growth factor (HB-EGF), was significantly more 
downregulated in AR-low compared to AR-high AA TNBC samples (p<0.05).  We also 
observed significantly more downregulation of genes encoding key signaling molecules in the 
downstream pathways of HER4 signaling such as phosphodiesterase 1A (PTGER3), 
phosphatidylinositol-3,4,5-triphosphate dependent Rac exchange factor 2 (PREX2), inositol-3-
phosphate synthase 1 (ISYNA1), phospholipase C like 1 (PLCL1), Ras guanyl releasing protein 
2 (RASGRP2), mitogen-activated protein kinase binding protein 1 (MAPKBP1), Janus kinase 3 
(JAK3), and signal transducer and activator of transcription 5B (STAT5B) among AR-low 
compared to AR-high AA patients (p<0.05). We also observed significantly more 
downregulation of genes encoding G-protein signaling such as G-protein-coupled receptor 4 
(GPR4) and regulator of G-protein signaling 22 (p<0.05). Furthermore, we found that pro-
apoptotic caspases such as caspase 10 (CASP10) and 12 (CASP12) were significantly more 




TNBC patients of African descent suffer the most aggressive clinical disease course, the 
poorest prognosis, and have the least amount of targeted treatment options in comparison to 
TNBC patients of other ethnicities. Thus, novel risk-predictive biomarkers and therapeutic 
targets are urgently needed to circumvent a poor prognosis among this patient population. AR 
has recently emerged as a promising alternative therapeutic target for TNBC patients, however, 
AA TNBC patients have been reported to lack AR expression significantly more than EA TNBC 
patients, leaving AAs less susceptible to AR-targeted therapy than EAs among TNBC patients. 
Furthermore, a lack of AR expression has been associated with a poor prognosis among TNBC 
patients of African descent. Thus, alternative actionable targets are needed for AA TNBC 
patients lacking AR expression. The other EGFR family members (EGFR/HER1, HER3, and 
HER4) have also emerged as promising alternative prognostic and/or pharmacologically-
targetable biomarkers in TNBC. Hence, in this study we investigated the potential of these EGFR 
family members as novel, alternative biomarkers for AA TNBC patients absent of AR 
expression.   
 
We compared IHC expression of the three EGFR family members as well as combined 
variations of the receptors between AR-negative and AR-positive AA TNBC patients and 
observed that only HER3-HER4 score significantly differed between the patient groups. 
Specifically, HER3-HER4 score was significantly lower among all and early-stage QNBC 
compared to TNBC AA patients suggesting that a lack of HER3-HER4 signaling may be 
underlying more aggressive TNBC among patients of African ancestry. Furthermore, HER3-
HER4 score was significantly lower among all and early-stage chemotherapy-treated QNBC 
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compared to TNBC AA patients. As previously discussed, HER3 is catalytically inactive unless 
it dimerizes with another EGFR family member and HER4 expression is the only family member 
that is associated with a better prognosis in TNBC owing to its pro-apoptotic and 
antiproliferative activity. Hence, lower HER3-HER4 expression among AR-absent compared to 
AR-expressing AA TNBC patients may reflect reduced cell death and increased proliferation 
among AA QNBC patients. Furthermore, these findings suggest less dimerization of HER3 with 
HER4 and downstream signaling among AA QNBC compared to AA TNBC patients.   
We also discovered that a lack of HER3-HER4 expression was associated with more 
aggressive disease features among AA QNBC patients. Low IHC HER3-HER4 score was 
associated with high Ki-67 percentage and Nottingham score among all and early-stage AA 
QNBC patients. Low IHC HER3-HER4 score was also associated with high Ki-67 index among 
early-stage AA QNBC patients administered chemotherapy. Thus, our observation of low IHC 
HER3-HER4 score associated with high Ki-67 proliferation may be reflective of low HER4 
signaling and consequently reduced modulation of cell proliferation among AA QNBC patients. 
Furthermore, low HER3-HER4 score was associated with high FOXM1, RARα, and BAP1 
expression among all and early-stage AA QNBC patients. FOXM1 is a transcription factor that 
regulates cell cycle progression, particularly mitotic division, chromosome segregation and 
genomic stability(57, 58). It has been found to be overexpressed in approximately 85% of 
TNBCs and its upregulation has been suggested to play a critical role in carcinogenesis through 
stimulating cell proliferation and tumor metastasis(59). Thus, our observation of low HER3-
HER4 score associated with high FOXM1 expression may be indicative of increased 
deregulation of cell cycle progression, aberrant mitotic division, missegregation of 
chromosomes, and genomic instability and subsequently tumorigenesis and progression among 
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AA QNBC patients. Hence, FOXM1 may serve as a viable, alternative therapeutic target for AA 
QNBC patients lacking HER3-HER4 expression. RARα is known to stimulate growth inhibition 
of ER-positive but not, ER-negative BC cell lines as they tend to express RARα at lower 
levels(60). The role of RARα in TNBC remains elusive however, our finding of low HER3-
HER4 score associated with increased RARα expression suggest that AA QNBC patients with 
low HER3-HER4 signaling may also be sensitive to retinoid therapy. BAP1 acts a tumor 
suppressor and plays a key role in the DNA damage response pathway. Hence, upregulation of 
BAP1 among low HER3-HER4-expressing AA QNBC patients may be indicative of increased 
DNA damage among this patient population suggesting they may be susceptible to DNA repair 
targeted therapy.     
We also discovered that low HER3-HER4 score significantly predicted poorer 10-year 
OS among early-stage AA QNBC patients in Kaplan-Meier analysis. Furthermore, low HER3-
HER4 score predicted shorter 10-year OS among early-stage AA QNBC patients in multivariate 
analyses. Thus, these findings suggest that a lack of HER3-HER4 expression may be associated 
with more aggressive disease among early-stage AA TNBC patients lacking AR expression and 
that HER3-HER4 score may serve as an alternative risk-prognostic biomarker for this patient 
population.   
Our gene expression analyses revealed that HER4 gene expression was significantly 
more downregulated among AR-low compared to AR-high AA TNBC samples in TCGA 
dataset, which corroborates our protein expression results. Furthermore, we observed 
significantly more downregulation of signaling pathways and gene ontologies reflecting 
downstream signaling of HER4 as well as genes encoding key downstream signaling molecules 
in the HER4 pathway among AR-low compared to AR-high AA TNBC samples. We also 
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observed significantly more downregulation of gene ontologies and genes encoding key 
downstream proteins in processes modulated by HER4 signaling such as apoptosis, cell 
proliferation, and cell differentiation among AR-low compared to AR-high AA TNBC samples. 
This finding suggest that more downregulation of HER4 signaling may reflect less cell death as 
well as more aberrant cell proliferation and differentiation among AR-low compared to AR-high 
AA TNBC patients with low HER4 signaling. In addition, we observed significantly more 
downregulation of biological pathways and gene ontologies reflecting pro-inflammatory activity 
and cell-cell contact among AR-low compared to AR-high AA TNBC samples suggesting 
suppressed antitumoral immune response and increased metastatic potential among AR-low AA 
patients with low HER4 signaling. However, we discovered significantly more upregulation of 
biological pathways and gene ontologies indicating increased cell cycle progression, cell 
proliferation, and DNA damage response among AR-low compared to AR-high AA TNBC 
patients. This finding also reflects our protein expression correlation results indicating that lack 
of combined HER3-HER4 score was associated with high FOXM1 and BAP1 expression further 
emphasizing that therapies targeting cell cycle progression and DNA damage response may be 
selectively beneficial for AA QNBC patients with a low HER3-HER4 score.  
Our study uncovers a valuable risk-prognostic biomarker for AA QNBC patients in early-
stage disease. Our findings suggest that HER3-HER4 score should be assessed among AA 
TNBC patients lacking AR expression in the clinic to guide clinical decision-making and 
segment patients into optimal treatment paths. Furthermore, our results suggest alternative 
therapeutic strategies for AA QNBC patients with low HER4 signaling such as FOXM1 
inhibition, cytotoxic chemotherapy, and other cell-cycle progression-targeting therapies as well 
as DNA damage response inhibition such as platinum-based agents. Thus, stratifying AA QNBC 
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patients into high and low HER3-HER4 score may notably improve risk-prognostication and 
prognosis among this patient population and subsequently help reduce the racial disparate burden 
in TNBC.  However, robust validation of our findings in additional cohorts is necessary in order 
to successfully achieve these aims.     
10.5 Methods 
10.5.1 Study Cohort 
We analyzed a cohort of 121 TNBC patients observed at EH in Atlanta, GA from 2002 
(initial day of diagnosis) to 2016 (last day of contact). We isolated 77 AA TNBC patients from 
this cohort and stratified them into AR-negative and AR-positive subgroups based on IHC AR 
nuclear percentage. Negativity was determined as <1% expression and positivity was determined 
as ≥1% expression. We obtained approval and permission from the institutional review board at 
EH to gain access to patient information and samples used in this study. Patient demographic 
characteristics, clinico-pathological variables, and breast cancer biomarker status were recorded 
for each patient. This article referred to the 7th edition of the American Joint Committee on 
Cancer)/Union for International Cancer Control TNM Classification and Stage groupings for 
breast cancer (52). Demographic characteristics include self-reported race and age at the time of 
diagnosis. Adjuvant chemotherapy treatment was recorded. No patients in this study underwent 
neoadjuvant chemotherapy. Regarding adjuvant chemotherapy, 54 patients underwent treatment 
and 9 patients did not.  
10.5.2 Immunohistochemistry and scoring  
Biomarker expression was evaluated through standard IHC staining and scored as H-
score (percentage x intensity), NH-score (nuclear percentage x intensity), and Nper (nuclear 
percentage). Intensity of staining were scored as 0=none, 1=low, 2=moderate, and 3=high. 
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Negativity was determined as <1% expression and positivity was determined as ≥1% expression 
for all biomarkers. Antibody details and concentrations can be found in Table 8. The maximum 
score for any given H-score is 300 and for combined (summed) H-scores is 600. Combined 
biomarker scores were determined by summing the scores for each biomarker to yield a single 
score. EH patient samples were stained, scored, and reviewed at EH. Scoring was performed by 
two independent pathologists blinded to clinical annotation and individual scores were averaged. 
10.5.3 Follow Up 
Initial diagnosis and follow-up of patients occurred between 2002 and 2016. Initial dates 
of diagnoses, treatment start and completion dates, and last dates of contact were recorded for 
each patient. Survival status (alive/dead) was also recorded for each patient in addition to 
survival time. The date of last follow-up for the last patient seen is March 3, 2016. 
10.5.4 Gene Expression Dataset  
We queried the publically available The Cancer Genome Atlas (TCGA) breast dataset 
from the TCGA portal for all TNBC patients(53). Publically available ER/PR/HER2/AR IHC 
data was used to determine TNBC and QNBC status. According to the available race data, we 
selected AA patients out of the TNBC samples. We performed a log-rank test to identify the 
optimal cut-off to stratify the AA TNBC patients into high- and low- AR expressing subgroups. 
We performed differential gene expression analysis between AR-low and AR-high expressing 
AA TNBC samples using the DESeq2 software tool(54). Differentially expressed genes with a p 
value of <0.05 and log2fold change of above +1 and below -1 were selected in this study. 
Differential expression analyses of Kyoto Encyclopedia of Genes and Genomes pathways and 
gene ontologies between the patient groups were predicted by GAGE and Pathview packages, 
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respectively(55, 56). A heat map was generated to depict the differentially expressed genes 
among the patient groups of interest.   
10.5.5 Statistical Analysis 
The significance level for all analyses was p<0.05 with 95% confidence intervals (CIs). 
SAS 9.4 program was used to generate test statistics and 2-tailed univariate p-values were 
reported. Chi-square tests were performed to analyze differences in demographic characteristics, 
breast clinico-pathological variables and biomarkers, as well as treatment information between 
AR-negative and AR-positive AA TNBC patients. Wilcoxon rank-sum tests were performed to 
determine differences in the means in expression of the EGFR family members between AR-
negative and AR-positive AA TNBC patients. Spearman’s rank correlation coefficients (ρ) were 
computed to determine associations of the EGFR family members with demographic and clinico-
pathological variables as well as biomarker expression among AR-negative AA TNBC patients. 
Unadjusted and adjusted multivariate Cox proportional hazard models were computed to assess 
the impact of combined IHC HER3-HER4 score on 10-year OS before and after controlling for 
age, Nottingham grade, and stage. The Kaplan-Meier analysis was conducted using SAS 9.4 
program to estimate survival function for AR-negative AA TNBC patients over a 10- year period 
based on high and low combined IHC HER3-HER4 score. A log-rank test was used to stratify 
combined IHC HER3-HER4 expression with better or worse survival in Kaplan-Meier analyses. 
A log-rank test was also performed to identify the appropriate cut-off for low and high 
expression of AR among AA TNBC patients in the TCGA dataset. The Wald test was used to 
test for significance among differentially expressed genes between the patient groups using the 
DESeq2 software tool.  
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Table 10.2 Correlation of combined HER3-HER4 score with clinico-pathological variables 

















Table 10.3 Correlation of combined HER3-HER4 score with clinico-pathological biomarkers 






































Table 10.5 KEGG pathways upregulated and downregulated among AR-low compared to AR-

















Table 10.7 HER4 signaling-related differentially-expressed genes between AR-low and AR-











































Figure 10.1 IHC expression of the EGFR family members among AR-negative and AR-
positive AA TNBC patients.  
IHC expression of EGFR (membranous), HER3 (membranous), and HER4 (cytoplasmic) as well 
as combinations of the receptors combined were compared between AR-negative and AR-positive 

















Figure 10.2 Combined IHC HER3-HER4 scores among AA QNBC and TNBC patients.  
(A) Representative IHC staining of HER3 (membranous) and HER4 (cytoplasmic) images. (B) 
IHC expression of combined HER3-HER4 scores were compared between all (overall), 
chemotherapy treated (chemo), and non-chemotherapy treated (non-chemo) AR-negative and AR-
positive AA TNBC patients. (C) Combined HER3-HER4 scores were also compared between 
early-stage (I-II) (early overall) and early-stage chemotherapy-treated (early chemo) AR-negative 
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and AR-positive AA TNBC patients. Sample size was too small to analyze early-stage non-
chemotherapy treated patients. H-score represents expression percentage x intensity. *p<0.05. 











Figure 10.3 Combined IHC HER3-HER4 score predicts OS among early-stage AA QNBC 
patients.  
Combined IHC HER3-HER4 H-scores (percentage x intensity) were stratified into high (³6) and 
low (<6) subgroups based on log-rank test. Kaplan-Meier curves were generated to estimate the 
effect of high and low IHC HER3-HER4 score on survival over a 5- and 10- year period among 
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AA QNBC patients. Prediction of high and low combined IHC HER3-HER4 score on 10-year OS 
among (A) all, (B) early-stage, and (C) radiation treated early-stage AA QNBC patients. Prediction 
of high and low combined IHC HER3-HER4 score on 5-year OS among radiation treated early-
stage AA QNBC patients (D). p<0.05 was set as the level of significance.  
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11 RETINOIC ACID RECEPTOR ALPHA AS A POSITIVE PROGNOSTIC 
BIOMARKER IN TRIPLE NEGATIVE BREAST CANCER 
11.1 Abstract 
Triple negative breast cancers (TNBCs) lack conventional breast cancer targets, thus lack 
risk-predictive biomarkers and targeted treatment options. RARa stimulates antiproliferative 
activity in breast cancer by inhibiting cell growth, cell differentiation, and promoting apoptosis. 
However, the role of RARα signaling in TNBC remains underexplored. We analyzed differences 
in RARα gene expression between TNBC and non-TNBC patients in two independent publicly-
available breast datasets and investigated the prognostic role of nuclear RARα 
immunohistochemical (IHC) expression, which represents the transcriptionally active form of the 
biomarker, in TNBC patients treated at Nottingham Hospital (NH) (n=166) and Emory 
University Hospital (EH) (n=106). TNBCs expressed lower levels of RARα mRNA than non-
TNBCs in the METABRIC (n=1,975) and TCGA (n=1,098) breast datasets (p<0.0001). High 
nuclear RARα IHC expression was an independent predictor of good prognosis in multivariable 
models in NH (HR=0.501, p<0.05 for BCSS and HR=0.394, p<0.01 for DMFS) and EH 
(HR=0.223 for BCSS p<0.05) patients. Nuclear RARα IHC expression may provide valuable 
risk-prognostic information and guide clinical decision making, specifically revealing a subset of 
TNBC patients with good prognosis. Future studies are needed to evaluate whether this high 
nuclear RARα group could benefit from RARα agonists or alternative therapeutic strategies and 
be spared harsher chemotherapeutic regimens. 
11.2 Introduction 
Triple negative breast cancer (TNBC), a subtype of breast cancer (BC), remains a 
formidable disease fraught with many challenges that elude successful clinical intervention. The 
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disease accounts for approximately 20% of all reported BC cases and is defined by a lack of the 
actionable targets, estrogen receptor (ER), progesterone receptor (PR), and human epidermal 
growth factor receptor (HER2) 1. Thus, this subgroup of BCs is excluded from receiving 
traditional endocrine and HER2-targeted systemic therapies and lacks risk-predictive biomarkers. 
Furthermore, TNBC is characterized by a more aggressive disease course typified by higher 
nuclear grade, clinical stage, proliferation, and increased lymph node, cerebral, and visceral 
metastases that all collude to result in poorer clinical outcomes compared with non-TNBCs 1-6. 
Chemotherapy and radiation remain the standard of care for TNBC patients; however, TNBC 
patients often relapse within the first 5 years after diagnosis, underscoring an unmet need for 
alternative risk-predictive biomarkers and alternative therapeutic targets for this patient 
population 3. Younger women and women of West African descent are disproportionately 
diagnosed with TNBC and also exhibit more aggressive disease features, acquire more 
aggressive TNBC subtypes, and experience poorer clinical outcomes compared to women of 
European descent among TNBC patients 7-13,14-17.  
Steroid or nuclear hormone receptors constitute a superfamily of transcription regulators 
that play critical roles in embryonic development, cell growth, cell differentiation, and 
homeostasis. These unique receptors dimerize in the nuclei to modulate transcription of target 
genes upon ligand stimulation 18,19. They possess a C-terminal domain that binds to their ligand 
as well as a highly-conserved N-terminal zinc-finger that facilitates specificity in target DNA 
sequence or ligand-response element binding. The RAR and retinoic X receptor (RXR) families 
represent subgroups of the steroid/nuclear receptor superfamily that also comprises receptors that 
bind to steroid and thyroid hormones and harbor highly-conserved domains that mediate DNA 
and ligand-binding activities20. RAR isoforms have been identified including RARα, RARβ, and 
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RARγ as well as the RXR isoforms including RXRα, RXRβ, and RXRγ based on alternative 
mRNA splicing. Retinoids are natural and synthetic vitamin A analogues that modulate cell 
proliferation, differentiation, morphogenesis, metabolism, and apoptosis via RARs and RXRs21. 
In the presence of retinoids, RAR heterodimerizes with RXR and the RAR/RXR dimer binds to 
hormone response elements on DNA such as retinoic acid or retinoid X response elements 
(RAREs and RXREs) to regulate transcription of target genes 22,23.  
Retinoid signaling via RARs and RXRs have been shown to stimulate antiproliferative 
activity, unlike ER, by inhibiting cell growth, cell differentiation, and promoting apoptosis in 
mammary carcinoma cells24,25. Thus, loss of RARβ has been suggested to be an early event in 
breast carcinogenesis 21. High levels of RARα have been observed in ER-positive BC cells, as 
estrogens upregulate RARα, but not in ER-negative cells24,26. Retinoid signaling via RARα has 
been demonstrated to mediate growth inhibition of ER-positive BC cell lines but not in ER-
negative cell lines owing to low levels of RARα which are thus, considered to be retinoid 
resistant 25. However, Fitzerald et. al showed that ER-negative BC cells with RARα expression 
were sensitive to retinoid-stimulated growth inhibition suggesting that RARα expression 
correlates with retinoid-induced growth inhibition irrespective of ER status27. However, the role 
of RARα in TNBC remains elusive.  
Given its seeming role in suppressing breast tumorigenesis, RARα may serve as a 
positive prognostic biomarker in TNBC. While RARα levels are lower in TNBC than non-TNBC 
cells, it is possible that a subset of TNBC patients have higher levels and a more favorable 
prognosis, given how molecularly heterogeneous TNBCs are 28,29. Towards this end, we explored 
the effect of nuclear RARα levels on survival outcomes in TNBC patients. Nuclear levels were 
tested because they represent the transcriptionally active form of RARα 30. Ultimately, we found 
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that high mRNA and protein nuclear RARα levels are associated with better survival among 
TNBC patients in multivariate analyses. We also observed a racial disparity in nuclear RARα 
levels among BC and TNBC patients. Furthermore, we identified differentially-expressed genes, 
pathways, and gene ontologies between high and low nuclear RARα-expressing TNBC patients 
which may be exploited therapeutically. Thus, a subset of TNBC patients with high intratumoral 
RARα could potentially be spared harsher chemotherapy regimens and may benefit from RARα 
agonism, whereas TNBC patients with low intratumoral RARα may require more aggressive 
treatment. 
11.3 Results 
11.3.1 Nuclear RARα expression levels lower among TNBCs compared to non-TNBCs 
Accumulating studies consistently suggest that RARα expression levels are lower among 
hormone receptor (HR)-negative compared to HR-positive breast tumor phenotypes suggesting 
that low levels of the protein could be conferring a more aggressive disease course. Hence, we 
wanted to further explore differences in nuclear RARα expression levels between TNBC and 
non-TNBC patients. We analyzed the METABRIC (discovery) and TCGA (validation) BC 
datasets to compare normalized RARα expression levels between TNBC and non-TNBC 
patients. As consistent with the literature, we observed significantly lower RARα expression 
among TNBC compared to non-TNBC patients in both the discovery and validation cohorts 
(Figure 1). In both the METABRIC (Fig 1A) and TCGA (Fig 1B) datasets, RARα expression 
levels were approximately one third lower among TNBCs than non-TNBCs (p<0.0001 and 
p<0.0001, respectively). Thus, our findings confirm literature evidence supporting reduced 
RARα signaling among TNBCs compared to non-TNBCs in two independent breast cancer 
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datasets and warrant further exploration of the role of RARα signaling in conferring aggressive 
BC.  
11.3.2 Nuclear RARα expression levels are lower among TNBC patients of African compared 
to European descent  
As previously mentioned, AA BC patients are significantly more likely to present with 
TNBC compared to EA BC patients. Hence, we investigated whether racial disparities exist in 
RARα signaling among BC and TNBC patients. Race information was unavailable for the 
METABRIC dataset, so we compared RARα gene expression levels between AA and EA 
patients only in TCGA dataset. We discovered significant differences in RARα expression 
among AA compared to EA BC patients in the TCGA dataset (Figure 2). RARα gene expression 
was significantly lower among AA (n=192) compared to EA (n=770) BC patients (p=0.003) (Fig 
2A). Mean RARα gene expression was also lower in AAs (n=41) compared to EAs (n=87) 
among TNBC patients but did not reach statistical significance (p=0.620) (Fig 2B).  
We also compared nuclear RARα protein expression levels between racially distinct 
TNBC patients in clinical datasets. We screened three ethnically-distinct patient populations 
[European (n=166), EA (n=29), and AA (n=71)] from the NH and EH datasets, respectively, for 
differences in expression of nuclear RARα IHC expression by performing a one-way ANOVA 
test. We discovered significant differences in the marker between all three patient populations 
suggesting a significant role for this marker in the racially disparate burden in TNBC (Figure 3) 
(p<0.0001). Specifically, nuclear RARα IHC expression decreased with decreasing self-reported 
European ancestry from European to AA samples in which Europeans exhibited the highest and 
AA’s exhibited the lowest expression levels overall and among chemotherapy- and radiation- 
treated patients. Hence, our findings indicate that racial disparities in RARα signaling exists and 
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reduce RARα signaling among patients of African descent could be contributing to the racial 
disparate burden in BC and TNBC.   
11.3.3 High nuclear RARα expression levels predict better prognosis among TNBC patients 
Based on our observed significant differences in RARα gene and nuclear protein 
expression levels between TNBC and non-TNBC patients, we investigated the impact of nuclear 
RARα IHC expression on survival among TNBC patients in two independent clinical datasets 
from NH (n=166) and EH (n=106). We assessed the influence of categorical nuclear RARα (low 
vs. high) on overall survival 31, breast cancer specific survival (BCSS), disease-free survival 
(DFS) and distant metastasis-free survival (DMFS) using the Kaplan-Meier method and Cox 
proportional hazards regression in TNBC patients from both cohorts. High nuclear RARα H-
score was associated with significantly better OS (p<0.001) (Fig 4A), 5-, 10-, and 15- year BCSS 
(p=0.006, p<0.001, and p=0.005, respectively) (Fig 4B-D), DFS (p<0.001) (Fig 4E), and DMFS 
(p<0.0001) (Fig 4F) among TNBC patients treated at NH according to Kaplan-Meier analyses 
(Figure 4). Representative micrograph of nuclear IHC staining can be found in Fig 5A. High 
nuclear RARα percentage was also associated with better OS (p=0.040) (Fig 5B) and moderately 
longer BCSS (p=0.090) (Fig 5C) among TNBC patients treated at EH according to the Kaplan-
Meier method (Figure 5). We observed similar results using Cox proportional hazard regression 
models. Nuclear RARα H-score was found to be an independent predictor of better OS, BCSS, 
DFS, and DMFS among TNBC patients observed at NH in multivariable analysis, where the 
covariates adjusted for included age at diagnosis, tumor size, Nottingham grade, lymph node 
stage, and Ki67-labeling index (HR=0.483, p=0.001 for OS, HR=0.464, p=0.040 for 5-year 
BCSS, HR=0.501, p=0.043 for 10-year BCSS, HR=0.045, p=0.006 for DFS and HR=0.394, 
p=0.003 for DMFS) (Table 1). Furthermore, nuclear RARα H-score predicted better OS, DFS, 
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and DMFS irrespective of the same covariates in addition to receipt of adjuvant chemotherapy 
(HR=0.484, p=0.010 for OS, HR=0.457, p=0.008 for DFS and HR=0.412, p=0.005 for DMFS). 
Nuclear RARα percentage was also found to be an independent predictor of better OS among 
TNBC patients observed at EH in multivariate analysis, where the covariates adjusted for 
included age at diagnosis, Nottingham grade, and Ki67-labeling index (HR=0.223, p=0.0498) 
(Table 2). We also assessed associations of nuclear RARα expression levels with 
clinicopathological characteristics among both cohorts. Interestingly, we found that nuclear 
RARα H-score negatively correlated with lymphovascular invasion (r=-0.192; p=0.015) among 
TNBC patients observed at NH (Table 3).    
11.4 Methods 
Publicly-available datasets 
We queried the publicly available Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) (n=1975; patient characteristics described in 39) and The Cancer 
Genome Atlas (TCGA) (n=1098; patient characteristics described in 31) gene expression breast 
datasets from Oncomine for BC and TNBC patients40. Publicly-available ER/PR/HER2 IHC data 
was used to determine TNBC status. We selected 167 and 145 TNBC samples from the 
METABRIC and TCGA datasets, respectively.  
Clinical datasets 
We procured TNBC patient databases from Nottingham University Hospital (NH) in 
Nottingham, UK and Emory University Hospital (EH) in Atlanta, GA.  NH and EH cohorts were 
comprised of 166 and 106 TNBC patients, respectively. NH patients were observed from 2007-
2013 and EH patients were observed from 2002-2016. We obtained consent and permission from 
the institutional review boards at each institution to obtain access to patient information used in 
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this study. Patient demographic characteristics, clinicopathological variables, and treatment 
information were recorded for NH (Table 4) and EH (Table 5) patients. This article referred to 
the 7th edition of the American Joint Committee on Cancer/Union for International Cancer 
Control TNM Classification and Stage groupings for BC 41. However, only lymph node staging 
was available in the NH cohort and referred to in this study. Demographic characteristics include 
self-reported race and age at the time of diagnosis. No EH patients received neoadjuvant 
chemotherapy.  
Immunohistochemistry and scoring 
Nuclear RARα expression in TNBC patients observed at NH and EH was determined 
through standard immunohistochemistry (IHC) staining. We immunolabeled primary TNBC 
specimens for RARα and calculated H-scores as the product of the nuclear staining intensity (0-
3) and the percentage of cells with any nuclear staining. Antibody details and concentration can 
be found in Table 6. NH patient samples were stained, scored, and reviewed at NH. EH patient 
samples were stained, scored, and reviewed at EH. Scoring was performed by two independent 
pathologists blinded to clinical annotation and individual scores were averaged. 
Follow up 
Initial diagnosis occurred between 2002 and 2016 for EH patients and between 2007-
2013 for NH patients. Median duration of follow-up for each cohort was approximately 6 and 5 
years for EH and NH patients, respectively. Initial dates of diagnoses, treatment start and 
completion dates, and last dates of contact were recorded for each patient. Survival status 
(alive/dead) was also recorded for each patient in addition to survival time. The date of last 




The significance level for all analyses was set to p<0.05 with 95% confidence intervals 42. 
Chi-square tests were performed to analyze differences association of demographic 
characteristics, breast clinicopathological variables and treatment information with UK, EA, and 
AA TNBC patients in the NH and EH datasets, respectively. SAS 9.4 program was used to 
generate test statistics and 2-tailed univariate p-values were reported. Mann-Whitney U tests was 
performed to determine differences in nuclear RARa normalized gene expression levels between 
TNBC and non-TNBC patients in the METABRIC and TCGA dataset and between AA and EA 
BC patients in TCGA dataset. One-way ANOVA tests were performed to determine differences 
in mean IHC expression of nuclear RARa between UK, EA, and AA TNBC patients in the NH 
and EH datasets, respectively. Unadjusted and adjusted multivariate Cox proportional hazard 
regression models were also computed to assess the impact of nuclear RARα on survival among 
TNBC patients in the clinical datasets. The Kaplan-Meier analysis was also conducted using 
SAS 9.4 program to estimate survival function for TNBC patients observed at NH and EH based 
on high and low expression levels of nuclear RARα. A log-rank test was used to stratify RARα 
into high and low subgroups to evaluate associations of a high and low expression of nuclear 
RARα with better or worse survival among TNBC patients. In the NH dataset, the optimal, most-
significant cut point based on breast cancer specific survival (BCSS) was found using X-tile 43. 
The proportional hazards assumption was found to be satisfied because plots of partial residuals 
against rank time had nearly zero slope or y-intercept. Multivariable Cox models were fit using 
backward stepwise elimination of covariates with a p-value >0.10.  












Table 11.1 Prediction of nuclear RARα Hscore on clinical outcomes among NH TNBC 
patients.  
 




Table 11.3 Correlation of nuclear RARα with clinico-pathological variables among NH 










































Figure 11.1 Normalized gene expression levels of RARα differ between TNBCs and non-
TNBCs.  
Wilcoxon rank sum tests were performed to determine differences in normalized nuclear RARα 
gene expression levels between TNBC and non-TNBC patients in the (A) METABRIC and (B) 




Figure 11.2 Normalized gene expression levels of RARα differ between AA vs. EA BC 
patients.  
Wilcoxon rank sum tests were performed to determine differences in normalized RARα gene 
expression levels between AA and EA (A) BC and (B) TNBC patient in TCGA BC dataset, 











Figure 11.3 Nuclear RARα IHC expression differs between biogeographically-distinct TNBC 
patients.  
Box and whisker plot comparing nuclear RARα IHC expression among between AA, EA, and 
European patients treated at EH and NH, respectively. One-way Anova test was performed to 
determine significant differences between the racial groups. p<0.05 was the level of significance. 
















Figure 11.4 Nuclear RARα expression is associated with better prognosis among NH TNBC 
patients.  
Kaplan-Meier survival curves were generated to assess the impact of nuclear RARα Hscore on 
clinical outcomes among NH TNBC patients (n=166). Log-rank tests were performed to identify 
the optimal cutpoints to stratify patients into high and low nuclear RARα Hscore subgroups for 
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each clinical outcome. Impact of nuclear RARα Hscore on (A) overall survival (optimal 
cutpoint=180), 5-year breast cancer specific survival (BCSS) (optimal cutpoint=180), 10-year 
BCSS (optimal cutpoint=180), (D) 15-year BCSS (optimal cutpoint=200), (E) disease-free 








Kaplan-Meier survival curves were generated to assess the impact of nuclear RARα percentage on 
clinical outcomes among EH TNBC patients (n=106). Log-rank tests were performed to identify 
the optimal cutpoints to stratify patients into high and low nuclear RARα percentage subgroups 
for each clinical outcome. Representative micrographs of nuclear RARα IHC staining (A). Impact 
of nuclear RARα Hscore on (B) overall survival (optimal cutpoint=60) and (C) breast cancer 
specific survival (optimal cutpoint=80).    
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Women of African descent continue to disproportionately suffer from BC compared to 
women of other ethnic backgrounds worldwide. This global racially disparate burden in BC can 
be largely attributed to distinctions in inherent tumor biology between patients of African 
ancestry and other ethnicities. African and AA women are more likely to acquire aggressive 
breast tumor phenotypes such as TNBC and QNBC, which lack expression of 
pharmacologically-targetable biomarkers, leaving this patient population with no approved 
targeted therapeutic options. My work seeks to address inherent tumor biological differences 
between breast tumors of African and European descent to ascertain more aggressive tumor 
biology among African patients. This work may also proffer alternative risk-predictive 
biomarkers and therapeutic targets for this patient population to improve their clinical disease 
course.  My work proposes a three-pronged strategy to addressing inherent differences in breast 
tumor biology between ethnically-distinct patient populations.  
ITH has been widely reported to be the culprit of the acquisition of aggressive 
phenotypes and drug resistance and has been shown to be more prevalent among BC and TNBC 
patients of African descent. However, quantitating and therapeutically targeting ITH remains a 
challenge in the clinic. My first approach involves investigating racial disparities in key drivers 
of ITH, mitotic propensity and CA, among BC patients. Mitotic propensity captures the 
frequency of actively dividing cells among the proliferating cell population. Increased mitotic 
turnover can lead to increased erroneous mitosis and thus, the generation of diverse cellular 
phenotypes or ITH. Our laboratory recently proposed a novel metric termed, M:P ratio, that can 
potentially allow clinicians to quantitate mitotic propensity in a clinical setting. Hence, we 
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proposed analyzing differences in M:P ratio between breast tumors of African and European 
descent and the role of M:P ratio in a more aggressive disease course among AA BC patients. 
We discovered this metric to be higher among early-stage AA compared to EA BC patients and 
that among several confounding variables (i.e. race, grade, stage, receptor status), race was the 
only factor significantly associated with M:P ratio. CA is a hallmark of cancer cells and recently 
reported to be associated with more aggressive BC such as high grade, stage, Ki67, and a TNBC 
phenotype. CA has been suggested to be a key driver of ITH through inducing aberrant 
multipolar mitosis and subsequently increased aneuploidy. Measuring centrosomal aberrations is 
feasible in the clinic through non-invasive methods such as fine-needle aspirate cytology and 
IHC. Furthermore, amplified centrosomes can be targeted therapeutically through cancer cell-
selective agents such as putative centrosome declustering drugs (i.e. griseofulvin and noscapine), 
commercially available HSET inhibitors (i.e. CW069 and AZ82), and poly-ADP ribose 
polymerase inhibitors (i.e. GF-15). Hence, we also compared centrosomal profiles between 
breast tumors of African and European descent and investigated the role of CA in a more 
aggressive disease course among AA patients. Our findings collectively suggest that women of 
African descent may exhibit enhanced mitotic propensity and greater centrosomal aberrations 
compared to women of European descent, which may underlie the acquisition of more aggressive 
phenotypes among AA BC patients. Our work also demonstrated that QNBCs, more prevalent 
among women of African descent, may exhibit greater centrosomal aberrations than TNBCs and 
underlie a more aggressive disease course in this group of TNBCs. This work suggests that BC 
patients of African descent may be selectively susceptible to CA-targeting agents and both CA 
and M:P ratio may be able to improve risk-stratification of this patient population in the clinic for 
optimal treatment paths.  
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The tumor immune microenvironment has been implicated in disease progression and 
drug resistance. Emerging evidence suggest that disparities in the presence of inflammatory 
mediators exists among breast tumors of African and European descent and may be implicated in 
the stark racial disparity in survival. Cancer immunotherapy has emerged as one of the leading 
therapeutic strategies for cancer. TILs (i.e. T, B, and NK cells) are key mediators in the 
antitumoral inflammatory response and have been harnessed for therapeutic purposes. The 
presence of TILs have been associated with better clinical outcomes and pCR post neoadjuvant 
chemotherapy but more aggressive disease, such as TNBC. Hence, we investigated differences in 
the presence of lymphocytic infiltration among AA and EA TNBC patients. Our findings suggest 
patients of African descent may exhibit a greater presence of TILs compared to patients of 
European descent and that high TIL levels were associated with longer OS and DFS among AA 
patients irrespective of confounding variables. This racial disparity and survival trend persisted 
among QNBC patients. TIL levels were also discovered to be higher among AR-negative 
compared AR-positive TNBCs and a greater presence of TILs were associated with more 
favorable clinical outcomes among QNBCs patients. Thus, my work has uncovered a previously 
unrecognized racial disparity in the breast tumor immune microenvironment that may be 
exploited therapeutically to help reduce the racially disparate burden in breast cancer. Adoptive 
T Cell therapy has emerged as a promising immunotherapeutic strategy to augment TIL levels to 
improve patient outcomes. Thus, this work suggest patients of African descent with low TIL 
levels may be selectively susceptible to TIL immunotherapy. Furthermore, TIL levels, which can 
be easily assessed in the clinic via H&E staining and quantitated according to the International 
TILs Working Group 2014 recommendations, may help risk-stratify TNBC patients of African 
ancestry for ideal treatment paths.  
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As previously mentioned, the greater incidence of triple and quadruple negative receptor 
statuses among breast cancer patients of African descent has left this patient population with no 
approved targeted therapies, underlying their more aggressive disease course and poorer 
prognosis. This lack has increased my interest in investigating alternative growth receptors that 
can be therapeutically targeted and potentially adapted for enhanced risk-prognostication among 
this patient population. As TNBCs and QNBCs are characterized by a lack of HER2 expression, 
I wanted to investigate racial disparities in the expression of the other three members in the HER 
family including, EGFR, HER3, and HER4 and their potential as alternative risk-prognostic and 
therapeutic targets among TNBC patients. Interestingly, in addition to HER2, the other three 
HER family members, also showed lower expression among TNBC patients of African 
compared to TNBC patients of European descent. Particularly, HER4, which has been 
demonstrated to elicit  antiproliferative activity, and EGFR-HER4 expression directly decreased 
with increasing presumed African ancestry with Nigerian TNBC patients exhibiting the lowest 
expression. EGFR and HER4 mRNA expression was also found to be expressed lower among 
TNBC patients of African compared to European descent. Furthermore, lack of HER4 and 
EGFR-HER4 expression was associated with a poor prognosis among TNBC patients of both 
African and European ancestry suggesting that lack of HER4 signaling among Africans may be 
underlying their more aggressive disease course compared to Europeans. Thus, in addition to ER, 
PR, and HER2, lack of HER4 among TNBC patients may predict a poor prognosis suggesting it 
may be useful to also assess HER4 expression among TNBC patients, particularly of African 
descent, to guide clinical decision-making. Moreover, we discovered through gene expression 
analysis, that PPAR signaling was more upregulated among TNBC patients low in EGFR-HER4 
mRNA expression suggesting the PPAR pathway could be exploited for alternative therapeutic 
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purposes among TNBC patients lacking HER4 signaling. We also investigated the role of an 
additional receptor in the nuclear retinoid family, RARa, as another potential alternative 
therapeutic target or prognostic biomarker among TNBC patients of African descent. As opposed 
to most of the HER family members, RARa signaling has been reported to suppress tumor 
growth and proliferation. Hence, we also observed significantly lower IHC expression of RARa 
among TNBC patients of African compared to European descent suggesting lack of tumor 
growth suppression via RARa signaling may also be contributing to disproportionately higher 
mortality rates observed among African TNBCs. Furthermore, lack of nuclear RARa IHC 
expression was able to predict poor prognosis among TNBC patients in two independent cohorts. 
Thus, my findings also suggest that it may be beneficial to assess nuclear RARa expression 
among TNBC patients, particularly of African descent, in the clinic to improve risk-
prognostication.  
BC in Africans continues to be characterized by what it lacks making it challenging for 
clinicians to manage this patient population. My work proposes a three-pronged approach in 
identifying novel actionable biomarkers associated with African ancestry that can improve risk-
prognostication and treatment for this population. In addition to the lack of ER, PR, HER2, and 
AR expression being disproportionately higher among BC patients of West African compared to 
European descent, we discovered an additional biomarker, HER4, to previously unrecognized to 
be expressed lower among Nigerian and AA TNBCs compared to European and EA TNBCs and 
its lack of IHC expression associated with a poorer prognosis. Hence, we discovered another 
novel biomarker disproportionately lacking in expression among TNBC patients of African 
ancestry. However, owing to its antiproliferative activity as opposed to the other biomarkers, 
HER4 may be exploited therapeutically among patients of African descent lacking HER4 
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expression to improve their clinical outcomes. Future studies delineating mechanisms and 
pathways upregulated among low HER4-expressing patients may also be exploited 
therapeutically to improve outcomes in this TNBC patient population. Our multi-pronged 
approach also uncovered a previously unrecognized racial disparity in levels of lymphocytic 
infiltration between ethnically-distinct TNBC patients and revealed that TILs may also improve 
risk-prognostication for TNBC of African descent in the clinic. Moreover, this work has 
suggested a novel, cancer immunotherapeutic approach to treating TNBC in AA patients, such as 
adoptive T cell therapy, which is currently being tested in clinical trials for BC. With ITH being 
a major interference in the clinic in regards to treatment and being reported to be more prevalent 
among BC patients of African compared to European descent, targeting ITH may be critical to 
reducing disproportionate mortality rates among this patient population. However, measuring 
and counteracting ITH in the clinic presents with many obstacles and challenges. Lastly, my 
work has also revealed potential racial disparities in key drivers of ITH, mitotic propensity and 
CA, that can more easily assess levels of ITH and be therapeutically targeted in a clinical setting, 
suggesting a more clinically-facile strategy to reducing ITH and subsequently an aggressive 
disease course among BC patients of African descent. Collectively, my findings proffer 
alternative, actionable biomarkers that may circumvent obstacles in bridging the gap in survival 
rates between BC patients of 4African and European descent and allow patients of West African 
descent, disproportionately lacking in conventional actionable BC biomarkers, with alternative 
treatment options. However, validation of our findings in additional cohorts and further 
investigation into the mechanisms causing disparities in these novel biomarkers will be necessary 





This work primarily seeks to augment clinical management and risk-prognostication of 
breast cancer patients of African descent, however it has broader clinical implications. Discovery 
of previously unrecognized racial distinctions in breast tumor biology may lead to the 
identification of novel therapeutic strategies for aggressive breast cancer patients irrespective of 
ethnicity, which may attenuate global breast cancer mortality. Furthermore, this work inspires 
investigation into alternative avenues of addressing the global racially disparate burden in breast 
cancer through -omic approaches such as metabolomics, proteomics, and epigenomics. These 
novel technologies may uncover unique distinctions in breast tumor biology between racially-
distinct patients and spur the development of novel therapeutic strategies for disadvantaged 
populations. Additionally, this work sparks interest into the investigation of the role of non-
genetic risk factors in the global racial divide in mortality, such as lifestyle and environment, as 
well as the interplay between these risk factors and alterations in the genetic landscape of 
racially-distinct populations. Ultimately, our findings as well as other breakthroughs in cancer 
health disparity research provide an incentive to increase personalization of patient care 
according to each individual’s unique tumor genetic, epigenetic, and metabolic profiles to more 
efficaciously reduce the global breast cancer burden.  
   
 
 
 
